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Summary
The National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, and CDC have
developed guidelines for treatment of opportunistic infections (OIs) among adults and adolescents infected with human immuno-
deficiency virus (HIV). These guidelines are intended for clinicians and other health-care providers who care for HIV-infected
adults and adolescents, including pregnant women; they complement companion guidelines for treatment of OIs among HIV-
infected children and previously published guidelines for prevention of OIs in these populations. They include evidence-based
guidelines for treatment of 28 OIs caused by protozoa, bacteria, fungi, and viruses, including certain OIs endemic in other parts
of the world but that might be observed in patients in the United States. Each OI section includes information on epidemiology,
clinical manifestations, diagnosis, treatment recommendations, monitoring and adverse events, management of treatment fail-
ure, prevention of recurrence, and special considerations in pregnancy. Tables address drugs and doses, drug toxicities, drug
interactions, adjustment of drug doses in persons with reduced renal function, and data about use of drugs in pregnant women.
Introduction
Opportunistic infections (OIs) continue to cause morbidity
and mortality in patients with human immunodeficiency virus
(HIV)-1 infection throughout the world. Potent combination
antiretroviral therapy (ART) has reduced the incidence of OIs
for certain patients with access to care. However, certain
patients in the developed and developing world do not have
access to care and have OIs. Other patients do not have a
sustained response to antiretroviral agents for multiple reasons,
including poor adherence, drug toxicities, drug interactions,
or initial acquisition of a drug-resistant strain of HIV-1.
Therefore, OIs will continue to cause substantial morbidity
and mortality in patients with HIV-1 infection.
The therapy of OIs has changed substantially during the
AIDS epidemic. As more information about efficacy, toxicity,
and interactions of the drugs to treat and prevent OIs has
emerged, management strategies have evolved. New drugs have
also become available that occupy important roles in our
therapeutic armamentarium.
These guidelines and the accompanying guidelines, Treating
Opportunistic Infections Among HIV-Exposed and Infected
Children, join two previous guidelines, The United States Public
Health Service-Infectious Diseases Society of America Guidelines
for the Prevention of Opportunistic Infections in Persons Infected
with the Human Immunodeficiency Virus and The Department
of Health and Human Services (DHHS) Guidelines for the Use
of Antiretroviral Agents in HIV-Infected Adults and Adolescents.
The current guidelines share key features with their companion
guidelines:
• They are labeled as guidelines, indicating that the recom-
mendations should be considered in the context of the
individual patient situation and the community where
the patient is being managed.
• They are evidence based. For each therapeutic recommen-
dation, the strength and quality of the evidence supporting
it are indicated using the rating system of the IDSA.
• They have been developed by a broadly based panel that
included representatives from academic medical centers,
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federal governmental agencies, community-based
practices, and consumer advocates. Representatives from
Europe, Latin America, Africa, and Asia also took part in
the process.
• They are available in print media and on the Internet.
• They are written for physicians and other health-care
providers who care for HIV-1–infected persons in the
United States and Western Europe where access is available
to a full range of up-to-date medical services; however,
these recommended strategies might not be feasible or
appropriate in all settings where the spectrum of
HIV-1–related complications and diagnostic capacity
differ from those observed in the United States and
Western Europe.
• The guidelines were reviewed by respective members of
each panel to ensure the recommendations were complete
and in agreement, where possible and appropriate.
• They are endorsed by CDC, the National Institutes of
Health, the HIV Medicine Association of the Infectious
Diseases Society of America, the Swiss Society for
Infectious Diseases, and the European AIDS Clinical
Society.
• They are intended to complement more comprehensive
textbooks, journals, and other relevant informational
materials.
• They will require periodic updating; this will be done
primarily on the Internet-based version.
• Information is summarized in 10 tables (Tables 1–10).
How To Use the Information
in This Report
For each of the diseases covered in this report, specific
recommendations are provided. Recommendations are rated
by the IDSA rating system. In this system, the letters A through
E signify the strength of the recommendation for or against a
treatment measure, and Roman numerals I through III indicate
the quality of evidence supporting the recommendation (Box).
Effect of Antiretroviral
Therapy on the Incidence
and Management of OIs
Data from both randomized controlled trials and
observational cohort studies document that antiretroviral
therapy (ART) reduces the incidence of OIs and improves
survival, independent of the use of antimicrobial prophylaxis,
and reduces overall mortality among persons with HIV-1
infection (1–7). Potent ART does not replace the need for
antimicrobial prophylaxis among patients with severe immune
suppression. However, ART is the cornerstone of the overall
strategy to reduce morbidity attributed to HIV-1–related
infections and other HIV-1–related processes.
The clinical benefit of ART in reducing the risk for OIs over
the short term has been best demonstrated for those with a
CD4+ T lymphocyte count <200 cells/µL. Studies also support
benefit in patients with CD4+ T lymphocyte counts >200 cells/
µL, although the overall benefit of starting ART in this
population is uncertain. Improvements in specific measures of
immune function, including pathogen-specific immunity, have
been well documented among patients who initiated ART at
BOX. Rating Scheme for Treatment Recommendations
Category Definition
A Both strong evidence for efficacy and sub-
stantial clinical benefit support recommen-
dation for use. Should always be offered.
B Moderate evidence for efficacy – or strong
evidence for efficacy but only limited clinical
benefit – support recommendation for use.
Should generally be offered.
C Evidence for efficacy is insufficient to sup-
port a recommendation for or against use.
Or evidence for efficacy might not outweigh
adverse consequences (e.g. drug toxicity, drug
interactions) or cost of the treatment under
consideration. Optional.
D Moderate evidence for lack of efficacy or for
adverse outcome supports a recommendation
against use. Should generally not be offered.
E Good evidence for lack of efficacy or for ad-
verse outcome supports a recommendation
against use. Should never be offered.
Quality of evidence supporting the recommendation
I Evidence from at least one properly designed
randomized, controlled trial.
II Evidence from at least one well-designed clini-
cal trial without randomization, from cohort
or case-controlled analytic studies (preferably
from more than one center), or from mul-
tiple time-series studies. Or dramatic results
from uncontrolled experiments.
III Evidence from opinions of respected authori-
ties based on clinical experience, descriptive
studies, or reports of expert committees.
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CD4+ T lymphocyte counts >200 cells/µL (8–10). Whether
such measures correlate with clinical protection against infection
or other HIV-1-related complications remains to be determined.
In addition to preventing OIs, ART can lead to resolution
or improvement of certain OIs, most notably for those where
specific treatment is not available. Treatment of patients with
ART in the setting of an OI also can result in an exuberant
inflammatory reaction that might require the use of anti-
inflammatory agents for clinical management. Finally, patients
who receive potent ART can have atypical presentations of
OIs either early after the initiation of ART or after prolonged
treatment.
Specific guidelines for the management of ART in the
presence of acute OIs have not previously been developed.
Two principal circumstances to consider include the initiation
of ART in the setting of an acute OI, and the management of
ART when an acute OI occurs in a patient who is already
receiving ART. The management in each circumstance will
vary depending on the degree of virologic and immunologic
disease progression before initiation of ART and the virologic
and immunologic benefit resulting from ART, the duration
of HIV-1 disease before and since starting ART, and the
potential for drug-drug interactions between the ART regimen
and the treatment needed for the OI.
Initiation of ART
in the Setting of an Acute
OI (Treatment-Naïve Patients)
The benefits of ART in the setting of an acute OI include
the improvement in immune function that would potentially
contribute to faster resolution of the OI. The beneficial effect
of initiating ART during an acute OI has been best
demonstrated for OIs for which limited or no effective
therapies are available. Reports detailing the resolution of
cryptosporidiosis, microsporidiosis, progressive multifocal
leukoencephalopathy (PML), and Kaposi sarcoma after the
initiation of potent ART provide evidence that improving
immune function can lead to improved outcome in the setting
of an acute OI (11–14). Another benefit of immediate
initiation of potent ART during an acute OI is the reduction
in risk for a second OI.
Arguments against the immediate initiation of ART
concurrent with the diagnosis of an OI include drug toxicities
including additive toxicities, distinguishing toxicities caused
by antiretrovirals (ARVs) from toxicities related to drugs used
to manage OIs, the potential for drug interactions between
OI therapies and ART, and the potential for inflammatory
immune reconstitution syndromes to complicate the
management of the OI in this setting. Much simpler ART
regimens are available for the treatment of HIV-1 disease,
diminishing the argument to delay therapy for reasons of
complexity. However, overlapping toxicities exist between OI
treatments and ART regimens that can complicate the ability
to identify drug specific toxicity. Drug interactions pose the
biggest problem for the treatment of patients with tuberculosis
(TB), but ART regimens compatible with TB treatment are
available.
Immune reconstitution syndromes have been described for
mycobacterial infections (including disease caused by
Mycobacterium avium complex [MAC] and Mycobacterium
tuberculosis, Pneumocystis jiroveci pneumonia (PCP),
toxoplasmosis, hepatitis B and hepatitis C viruses,
cytomegalovirus (CMV) infection, varicella-zoster virus (VZV)
infection, cryptococcal infection and PML (12,15–25).
Immune reconstitution syndromes are characterized by fever
and worsening of the clinical manifestations of the OI or new
manifestations weeks after the initiation of ART. Determining
the absence of recrudescence of the underlying OI and new
drug toxicity or a new OI is important. If the syndrome does
represent an immune reactivation syndrome, adding
nonsteroidal anti-inflammatory agents or corticosteroids to
alleviate the inflammatory reaction is appropriate. The
inflammation might take weeks or months to subside.
The largest number of published reports of immune recon-
stitution syndromes is among patients with TB disease.
Patients can experience high fevers, worsening lympha-
denopathy or transient-to-severe worsening of pulmonary
infiltrates, and expanding central nervous system lesions
(19,26,27). Such “paradoxical reactions” might be more com-
mon among HIV-1–infected patients with TB disease who
were started on potent ART compared with those not started
on ART and among patients with TB disease who were not
HIV-1-infected (19). Reduction of HIV-1 RNA levels and
marked increases in CD4+ T lymphocyte counts have been
associated with the occurrence of paradoxical reactions in
patients with TB disease or MAC (15,17,19, 26). Although
the majority of reactions occur within the first few weeks after
initiation of ART, some have occurred up to several months
after the initiation of TB therapy or ART.
No randomized controlled trials exist that demonstrate that
initiating ART improves outcome for patients being treated
with specific therapy for their acute OI. In addition, no data
demonstrate that initiation of ART in the setting of an acute
OI worsens the prognosis or treatment for that OI. Trials are
underway to evaluate the most appropriate timing for initiation
of ART in this context.
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Management of Acute
OIs in the Setting of ART
OIs that develop after patients have been started on potent
ART can be categorized into three groups. The first group
includes OIs that occur shortly after initiating ART (within 12
weeks). These cases are thought to be subclinical infections that
have been unmasked by early immune reconstitution and are
not considered to be early failure of ART (10,15,17,28–31).
The second group includes reports of OIs occurring >12 weeks
after initiation of ART among patients with suppressed HIV-1
RNA levels and sustained CD4+ T lymphocyte counts >200
cells/µL (32,33). Two cases of spinal MAC among patients with
nadir CD4+ T lymphocyte counts <50 cells/µL who had
sustained CD4+ T lymphocyte count increases to >200 cells/µL
are examples. Determining whether these represent a form of
immune reconstitution syndrome as opposed to incomplete
immunity with the occurrence of a new OI is difficult. The
presence of organisms by stain and culture suggests that, in either
situation, specific therapy is indicated.
The third group includes OIs that develop among patients
who are experiencing virologic and immunologic failure while
on potent ART. These represent clinical failure of ART.
When To Initiate ART
in the Setting of an OI
No consensus has been reached about the optimal time to
start ART in the presence of a recently diagnosed OI. The
decision to start potent ART should take into consideration
the availability of effective therapy for the OI, the risk for
drug interactions, overlapping drug toxicities, the risk for and
consequences of the development of an inflammatory immune
reconstitution syndrome, and the willingness and ability of
patients to take and adhere to their regimens.
In cases of cryptosporidiosis, microsporidiosis, PML, and
Kaposi sarcoma, the early benefits of potent ART outweigh
any increased risk, and potent ART should be started as soon
as possible (AIII). In the setting of TB disease, MAC, PCP,
and cryptococcal meningitis, awaiting a response to OI therapy
is usually warranted before initiating ART (CIII). When an
OI occurs within 12 weeks of starting ART, treatment for the
OI should be started, and ART should be continued (AIII).
When an OI occurs despite complete virologic suppression
(i.e., late OI), therapy for the OI should be initiated, potent
ART should be continued, and if the CD4+ T cell response to
ART has been suboptimal, modification of the ART regimen
may be considered (CIII). When an OI occurs in the setting
of virologic failure, OI therapy should be started, antiretroviral
resistance testing should be performed, and the ART regimen




No large studies have been conducted on the epidemiology or
manifestations of HIV-1–associated OIs among pregnant women.
No data demonstrate that the spectrum differs from that among
nonpregnant women with comparable CD4+ T lymphocyte
counts. CD4+ T lymphocyte counts characteristically drop during
pregnancy, probably because of dilutional effects of the increased
plasma volume. CD4+ T lymphocyte percentages are generally
more stable and should be used for determining degree of immune
suppression during pregnancy (34–36).
Physiologic changes occur during pregnancy that might
impact the presentation of acute OIs and the considerations
for implementing OI treatment or antiretroviral therapies.
These changes include (37):
• Increased cardiac output by 30%–50% with concomitant
increase in glomerular filtration rate, and renal clearance.
• Increased plasma volume by 45%–50% while red cell mass
increases only by 20%–30%, leading to dilutional anemia.
• Increased tidal volume and pulmonary blood flow, possibly
leading to increased absorption of aerosolized medications.
Changes in late pregnancy might affect distribution of
aerosolized medication. The tidal volume increase of 30%–
40% should be considered if ventilatory assistance is
required.
• Placental transfer of drugs, increased renal clearance,
altered gastrointestinal absorption, and metabolism by the
fetus might affect maternal drug levels.
• Limited pharmacokinetic data are available about the
effects of pregnancy on levels of OI therapy drugs. Use
usual adult doses based on current weight, monitor levels
if available, and consider the possible need to increase
doses if the patient is not responding as expected.
Pregnancy also impacts decisions about diagnostic testing.
Fetal risk is not increased with cumulative radiation doses
below 5 rads. Teratogenesis is observed in animals at doses of
100–200 rads. In humans, the primary risk associated with
high dose radiation exposure is growth restriction,
microcephaly, and developmental disabilities. The most
vulnerable period is 8–15 menstrual weeks of gestation with
minimal risk before 8 weeks and after 25 weeks. The apparent
threshold for development of mental retardation is 20–40 rads,
with risk increasing linearly with increasing exposures above
this level. Among children, risk for carcinogenesis might be
increased approximately one per 1,000 or less per rad of in
utero radiation exposure (38).
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The majority of radiographic and nuclear medicine studies
result in radiation exposure to the fetus that is much lower
than the 5 rad recommended limit; therefore, pregnancy should
not preclude usual diagnostic evaluation when an OI is
suspected (Table 1) (38–40). Abdominal shielding should be
used when feasible to further limit radiation exposure to the
fetus. Experience with use of magnetic resonance imaging
(MRI) in pregnancy is limited. Although no adverse fetal effects
have been reported, the National Radiological Protection
Board advises against use of MRI in the first trimester (38).
Other procedures necessary for diagnosis of suspected OIs
should be performed in pregnancy as indicated for nonpregnant
patients. Pregnant women who are >20 weeks of gestation should
not lie flat on their backs but should have the left hip elevated
with a wedge to displace the uterus off of the great vessels and
prevent supine hypotension. Adequate oxygenation should be
maintained.
Because of the serious nature of OIs among HIV-1–infected
persons, diagnostic procedures and indicated therapy should
not be withheld during pregnancy; the therapy with the least
potential toxicity should be selected (Table 2). The predictive
value of animal data for effects in humans is unclear. In
addition, reproductive studies among animals usually include
only one drug at a time, and HIV-1–infected pregnant women
might be using multiple antiretroviral, OI, and other drugs
concurrently. The potential for enhanced toxicity of
combinations of drugs has not been evaluated.
For pregnant women who have had an OI diagnosed and
are not on ART, immediate initiation of ART with OI therapy
should be encouraged (AIII) (41). Decisions about immediate
versus delayed initiation of ART in pregnancy should take
into account gestational age, maternal HIV-1 RNA levels and
clinical condition, and potential toxicities and interactions
between ART and OI drugs.
Pregnant women with active OIs who receive drugs for which
information about their use in pregnancy is limited should
have additional evaluation of fetal growth and well-being. After
first trimester exposure to agents of uncertain teratogenic
potential, a detailed ultrasound examination at 18–20 weeks
should be conducted to detect major anomalies, although the
ultrasound will not detect all anomalies. For women who
receive drugs throughout pregnancy or in the third trimester
for which information about their use in pregnancy is limited,
an ultrasound should be conducted every 4–6 weeks to assess
fetal growth and fluid volume. Pregnant women in the third
trimester should be instructed in daily fetal movement
counting to detect decreased activity that might indicate fetal
compromise. Weekly fetal nonstress testing should be initiated
at 32 weeks of gestation unless indicated sooner based on




Pneumocystis jiroveci pneumonia (PCP) is caused by
Pneumocystis jiroveci, a ubiquitous organism classified as a
fungus but that shares biologic characteristics with protozoa.
The taxonomy of the organism has been changed; Pneumocystis
carinii now refers only to the pneumocystis that infects rodents,
and Pneumocystis jiroveci refers to the distinct species that
infects humans. The abbreviation PCP is still used to designate
Pneumocystis pneumonia. Initial infection with P. jiroveci
usually occurs in early childhood; two thirds of healthy children
have antibody to P. jiroveci by age 2–4 years (43). PCP is a
result either of reactivation of latent infection or new exposure
to the organism. Rodent studies and case clusters among
immunosuppressed patients indicate that spread among
persons can occur by the airborne route. Disease probably
occurs by new acquisition and by reactivation (44,45).
Before the widespread use of primary PCP prophylaxis and
effective ART, PCP occurred in 70%–80% of patients with
AIDS (46). The course of treated PCP was associated with a
mortality of 20%–40% in persons with profound
immunosuppression. Approximately 90% of cases occurred
among patients with CD4+ T lymphocyte counts of <200/µL.
Other factors associated with a higher risk of PCP included
CD4+ T lymphocyte percentage <15%, previous episodes of
PCP, oral thrush, recurrent bacterial pneumonia, unintentional
weight loss, and higher plasma HIV-1 RNA (47,48).
Incidence of PCP has declined substantially with widespread
use of prophylaxis and effective ART; recent incidence rates
among patients with AIDS in Western Europe and the U.S.
are 2–3 cases per 100 person-years (49). The majority of cases
occur among patients who are unaware of their HIV-1
infection or are not receiving ongoing HIV care (50) or among
those with advanced immunosuppression (CD4+ T
lymphocyte counts <100 cells/µL) (51).
Clinical Manifestations
The most common manifestations of PCP among
HIV-1–infected persons are the subacute onset of progressive
exertional dyspnea, fever, nonproductive cough, and chest
discomfort that worsens over a period of days to weeks. The
fulminant pneumonia observed among non-HIV-1–infected
patients is less common (52,53).
In mild cases, pulmonary examination is usually normal at
rest. With exertion, tachypnea, tachycardia, and diffuse dry
(“cellophane”) rales might be observed (53). Oral thrush is a
common co-infection. Fever is apparent in the majority of
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cases and might be the predominant symptom among some
patients. Extrapulmonary disease is rare but can present in
any organ and has been associated with use of aerosolized
pentamidine prophylaxis.
Hypoxemia, the most characteristic laboratory abnormality,
might range from mild-to-moderate (room air arterial oxygen
[pO2] of >70 mm/Hg or alveolar-arterial O2 difference, [A-a]
DO2 <35 mm/Hg) to moderate-to-severe levels (pO2
<70 mm/Hg or [A-a] DO2 >35 mm/Hg). Oxygen desaturation
with exercise is indicative of an abnormal A-a gradient but is
nonspecific (54). Elevation of lactate dehydrogenase levels to
>500 mg/dL is common but nonspecific (55).
The chest radiograph typically demonstrates diffuse, bilateral,
symmetrical interstitial infiltrates emanating from the hiLa in a
butterfly pattern (53); however, patients with early disease might
have a normal chest radiograph (56). In addition, atypical
presentations with nodules, asymmetric disease, blebs and cysts,
upper lobe localization, and pneumothorax occur. Cavitation
or pleural effusion is uncommon in the absence of other
pulmonary pathogens or malignancy, and the presence of a
pleural effusion might indicate an alternative diagnosis.
Approximately 13%–18% of patients with documented PCP
have another concurrent cause of pulmonary dysfunction (e.g.,
TB, Kaposi sarcoma, or bacterial pneumonia) (57,58).
Pneumothorax in a patient with HIV-1 infection should raise
the suspicion of PCP (59,60).
Thin-section computerized tomography (CT)
demonstrating patchy ground-glass attenuation (61) or a
gallium scan showing increased pulmonary uptake (62)
increases the likelihood that a diagnostic study such as
bronchoscopy would demonstrate PCP in patients with mild-
to-moderate symptoms and a normal chest radiograph and
might be useful in adjunctive studies. However, a negative
thin-section CT scan does not rule out PCP.
Diagnosis
Because the clinical presentation, blood tests, or chest
radiographs are not pathognomonic for PCP and the organism
cannot be routinely cultivated, histopathologic demonstration
of organisms in tissue, bronchoalveolar lavage fluid, or induced
sputum (57,58,63,64) samples is required for a definitive
diagnosis. Spontaneously expectorated sputum has low
sensitivity and should not be submitted to the laboratory to
diagnose PCP. Cresyl violet, Giemsa, Diff-Quik, and Wright
stains detect both the cyst and trophozoite forms but do not
stain the cyst wall; Gomori Methenamine Silver, Gram-Weigert
and toluidine blue stain the cyst wall. Certain laboratories
prefer direct immunofluorescent staining. Nucleic acid tests
are being developed, but their use remains experimental
(65,66).
Previous studies of stained respiratory tract samples obtained
by various methods indicate the following relative diagnostic
sensitivities: induced sputum <50 to >90% (the sensitivity
and specificity depends heavily on the quality of the specimens
and the experience of the microbiologist or pathologist),
bronchoscopy with bronchoalveolar lavage 90%–99%,
transbronchial biopsy 95%–100%, and open lung biopsy
95%–100%.
Because of the potential for certain processes to have similar
clinical manifestations, a specific diagnosis of PCP should be
sought rather than relying on a presumptive diagnosis.
Treatment can be initiated before making a definitive diagnosis
because organisms persist in clinical specimens for days or
weeks after effective therapy is initiated (64).
Treatment Recommendations
Trimethoprim-sulfamethoxazole (TMP-SMX) is the
treatment of choice (67,68) (AI). The dose must be adjusted
for abnormal renal function. Multiple randomized clinical
trials indicate that TMP-SMX is as effective as parenteral
pentamidine and more effective than other regimens. Adding
leucovorin to prevent myelosuppression during acute treatment
is not recommended because of questionable efficacy and some
evidence for a higher failure rate (69) (DII). Oral outpatient
therapy of TMP-SMX is highly effective among patients with
mild-to-moderate disease (68) (AI).
Mutations associated with resistance to sulfa drugs have been
documented, but their effect on clinical outcome is uncertain
(70). Patients who have PCP despite TMP-SMX prophylaxis
are usually effectively treated with standard doses of TMP-SMX
(BIII).
Patients with documented PCP and moderate-to-severe
disease, as defined by room air pO2 <70 mm/Hg or arterial-
alveolar O2 gradient >35 mm/Hg, should receive
corticosteroids as early as possible, and certainly within 72
hours after starting specific PCP therapy (71–75) (AI). If
steroids are started at a later time, their benefits are unclear,
although the majority of clinicians would use them in such
circumstances for patients with severe disease (BIII). The
preferred corticosteroid dose and regimen is prednisone 40
mg by mouth twice a day for days 1–5, 40 mg daily for days
6–10, and 20 mg daily for days 11–21 (72,73) (AI).
Methylprednisolone at 75% of the respective prednisone dose
can be used if parenteral administration is necessary.
Alternative therapeutic regimens include 1) dapsone and
TMP for mild-to-moderate disease (69,76) (BI) (this regimen
may have similar efficacy and fewer side effects than
TMP-SMX but is less convenient because of the number of
pills); 2) primaquine plus clindamycin (77–79) (BI) (this
regimen is also effective in mild-to-moderate disease, and the
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clindamycin component can be administered intravenously
for more severe cases; however, primaquine is only available
orally; 3) intravenous pentamidine (80–82) (AI) (generally
the drug of second choice for severe disease); 4) atovaquone
suspension (67,83) (BI) (this is less effective than TMP-SMX
for mild-to-moderate disease but has fewer side effects); and
5) trimetrexate with leucovorin (84) (BI) (this is less effective
than TMP-SMX but can be used if the latter is not tolerated
and an intravenous regimen is needed). Leucovorin must be
continued 3 days after the last trimetrexate dose. The addition
of dapsone, sulfamethoxazole, or sulfadiazine to trimetrexate
might improve efficacy on the basis of the sequential enzyme
blockade of folate metabolism, although no study data exist
to confirm this (CIII). Aerosolized pentamidine should not
be used for the treatment of PCP because of limited efficacy
and more frequent relapse (82,85,86) (DI).
The recommended duration of therapy for PCP is 21 days
(52) (AII). The probability and rate of response to therapy
depends on the agent used, number of previous episodes,
severity of illness, degree of immunodeficiency, and timing of
initiation of therapy.
Although the overall prognosis of patients whose degree of
hypoxemia requires intensive care unit (ICU) admission or
mechanical ventilation remains poor, survival in up to 40%
of patients requiring ventilatory support has been reported in
recent years (87–89). Because long-term survival is possible
for patients in whom ART is effective, certain patients with
AIDS and severe PCP should be offered ICU admission or
mechanical ventilation when appropriate (e.g., when they have
reasonable functional status) (AII).
Because of the potential for additive or synergistic toxicities
associated with anti-PCP and antiretroviral therapies, certain
health-care providers delay initiation of ART until after the
completion of anti-PCP therapy, despite some suggestion of
potential benefit for early ART (88) (CIII). An immune
recovery inflammatory syndrome has been described for PCP
(90) and might complicate the concurrent administration of
anti-PCP treatment and ART.
Monitoring and Adverse Events
Careful monitoring during therapy is important to evaluate
response to treatment and to detect toxicity as soon as possible.
Follow-up after therapy includes assessment for early relapse,
especially when therapy has been with an agent other than
TMP-SMX or was shortened for toxicity. PCP prophylaxis
should be initiated promptly and maintained until the CD4+
T lymphocyte count is >200 cells/µL. If PCP occurred at a
CD4+ T lymphocyte count >200 cells/µL, maintaining PCP
prophylaxis for life regardless of the CD4+ T cell response
might be prudent; however, data about the most appropriate
approach in this setting are limited.
Adverse reaction rates among patients with AIDS are high
for TMP-SMX (20%–85%) (67,68,76,78,80,81,84,91–93).
Common adverse effects are rash (30%–55%) (including
Stevens-Johnson syndrome), fever (30%–40%), leukopenia
(30%–40%), thrombocytopenia (15%), azotemia (1%–5%),
hepatitis (20%), and hyperkalemia. Supportive care for
common adverse effects should be attempted before
discontinuing TMP-SMX (AIII). Rashes can often be “treated
through” with antihistamines, nausea can be controlled with
antiemetics, and fever can be managed with antipyretics.
The most common adverse effects of alternative therapies
include methemoglobinemia and hemolysis with dapsone or
primaquine (especially in those with G-6-PD deficiency), rash,
and fever with dapsone (68,76); azotemia, pancreatitis, hypo-
or hyperglycemia, leukopenia, fever, electrolyte abnormalities,
and cardiac dysrhythmia with pentamidine (80–83); anemia,
rash, fever, diarrhea, and methemoglobinemia with primaquine
and clindamycin (68,77,78); headache, nausea, diarrhea, rash,
fever, and transaminase elevations with atovaquone (67,91);
and bone marrow suppression, fever, rash, and hepatitis with
trimetrexate (84).
Management of Treatment Failure
Clinical failure is defined by the lack of improvement or
worsening of respiratory function documented by arterial
blood gases after at least 4–8 days of anti-PCP treatment.
Treatment failure attributed to treatment-limiting toxicities
occurs in up to one third of patients (69). Failure attributed
to lack of drug efficacy occurs in approximately 10% of those
with mild-to-moderate disease. Adding or switching to another
regimen is the appropriate management for treatment-related
toxicity (BII). No convincing clinical trials exist to base
recommendations for the management of treatment failure
attributed to lack of drug efficacy. It is important to wait at
least 4–8 days before switching therapy for lack of clinical
improvement (BIII). In the absence of corticosteroid therapy,
early and reversible deterioration within the first 3–5 days of
therapy is typical, probably because of the inflammatory
response caused by antibiotic-induced lysis of organisms in
the lung. Other concomitant infections must be excluded as a
cause for such deterioration (57,58). Bronchoscopy with
bronchoalveolar lavage should be strongly considered even if
it was conducted before initiating therapy.
If TMP-SMX has failed or must be avoided for toxicity in
moderate-to-severe disease, the common practice is to use
parenteral pentamidine, primaquine combined with
clindamycin, or trimetrexate (with or without oral dapsone)
plus leucovorin (78,80,84) (BII). For mild disease, atovaquone
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is a reasonable alternative (BII). Although one meta-analysis
concluded that the combination of clindamycin and primaquine
might be the most effective regimen for salvage therapy (79),
no prospective clinical trials have evaluated the optimal approach
to patients who fail therapy with TMP-SMX.
Prevention of Recurrence
Patients who have a history of PCP should be administered
secondary prophylaxis (chronic maintenance therapy) for life
with TMP-SMX unless immune reconstitution occurs as a
result of ART (94) (AI). For patients who are intolerant of
TMP-SMX, alternatives are dapsone, dapsone combined with
pyrimethamine, atovaquone, or aerosolized pentamidine.
Secondary prophylaxis should be discontinued for adult and
adolescent patients whose CD4+ T lymphocyte cell count has
increased from <200 cells/µL to >200 cells/µL for at least 3
months as a result of ART (94–97) (AI). Secondary prophylaxis
should be re-introduced if the CD4+ T lymphocyte count
decreases to <200 cells/µL (AIII) or if PCP recurs at a CD4+
T lymphocyte count of >200 cells/µL (CIII).
Special Considerations During Pregnancy
Diagnostic considerations during pregnancy are the same
as for nonpregnant women. Indications for therapy are the
same as for nonpregnant women. The preferred initial therapy
during pregnancy is TMP-SMX, although alternate therapies
can be used if patients are unable to tolerate or are unresponsive
to TMP-SMX (98) (AI). Neonatal care providers should be
informed of maternal sulfa or dapsone therapy if used near
delivery because of the theoretical increased risk for
hyperbilirubinemia and kernicterus (99).
Pentamidine is embryotoxic but not teratogenic among rats
and rabbits (100). Trimetrexate should not be used because of
teratogenicity at low doses in multiple animal studies, fetopathy
in humans associated with use of the biochemically similar
agents methotrexate and aminopterin, and the potential
negative effects on placental and fetal growth (101) (EIII).
Adjunctive corticosteroid therapy should be used as indicated
in nonpregnant adults (102–105) (AIII). Maternal fasting and
postprandial glucose levels should be monitored closely when
corticosteroids are used in the third trimester because the risk
for glucose intolerance is increased.
Rates of preterm labor and preterm delivery are increased
with pneumonia during pregnancy. Pregnant women with
pneumonia after 20 weeks of gestation should be monitored
for evidence of contractions (BII).
Toxoplasma gondii Encephalitis
Toxoplasmic encephalitis (TE) is caused by the protozoan
Toxoplasma gondii. Disease occurs almost exclusively because
of reactivation of latent tissue cysts (106–109). Primary
infection occasionally is associated with acute cerebral or
disseminated disease. Seroprevalence varies substantially among
different communities (e.g., approximately 15% in the United
States and 50%–75% in certain European countries)
(109,110). In the pre-ART era, for patients with advanced
immunosuppression who were seropositive for T. gondii and
not receiving prophylaxis with drugs active against T. gondii,
the 12-month incidence of TE was approximately 33%. The
incidence and associated mortality in Europe and the United
States has decreased substantially with the initiation of ART
and the broad use of prophylaxis regimens active against
T. gondii (111–113).
Clinical disease is rare among patients with CD4+ T
lymphocyte counts >200 cells/µL. The greatest risk is among
patients with a CD4+ T lymphocyte count <50 cells/µL
(106–108). Primary infection occurs after eating undercooked
meat containing tissue cysts or ingestion of oocysts that have
been shed in cat feces and have sporulated in the environment
(which requires at least 24 hours). No transmission of the
organism occurs by person-to-person contact.
Clinical Manifestations
The most common clinical presentation of T. gondii infection
among patients with AIDS is a focal encephalitis with
headache, confusion, or motor weakness and fever (106–108).
Physical examination might demonstrate focal neurological
abnormalities, and in the absence of treatment, disease
progression results in seizures, stupor, and coma.
Retinochoroiditis, pneumonia, and evidence of other
multifocal organ system involvement can be seen after
dissemination of infection but are rare manifestations in this
patient population.
CT scan or MRI of the brain will typically show multiple
contrast-enhancing lesions, often with associated edema
(106,107,114–116). Positron emission tomography (PET)
(115) or single-photon emission computed tomography
(SPECT) scanning (116) might be helpful for distinguishing
between TE and primary central nervous system (CNS)
lymphoma, but no imaging technique is completely specific.
Diagnosis
HIV-1–infected patients with TE are almost uniformly
seropositive for anti-toxoplasma IgG antibodies (106–108,
117). The absence of IgG antibody makes a diagnosis of
toxoplasmosis unlikely but not impossible. Anti-toxoplasma
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IgM antibodies are usually absent. Quantitative antibody titers
are not diagnostically useful.
Definitive diagnosis of TE requires a compatible clinical
syndrome; identification of one or more mass lesions by CT,
MRI, or other radiographic testing; and detection of the
organism in a clinical sample. For TE, this requires a brain
biopsy, which is most commonly performed by a stereotactic
CT-guided needle biopsy. Organisms are demonstrable with
hematoxylin and eosin stains, though immunoperoxidase
staining by experienced laboratories might increase sensitivity
(118). Detection of T. gondii by polymerase chain reaction
(PCR) in cerebrospinal fluid has produced disappointing
results; although specificity is high (96%–100%), sensitivity
is low (50%) and the results usually are negative once specific
anti-toxoplasma therapy has been started (119,120).
In the presence of neurologic disease, the differential
diagnosis (121) includes CNS lymphoma, mycobacterial
infection (especially TB), fungal infection (e.g. cryptococcosis),
Chagas disease, bacterial abscess, and rarely PML, which can
be distinguished on the basis of imaging studies (PML lesions
typically involve white matter rather than gray matter, are
noncontrast enhancing, and indicate no mass effect).
Certain clinicians rely initially on an empiric diagnosis,
which can be established as an objective response, on the basis
of clinical and radiographic improvement, to specific
anti-T. gondii therapy in the absence of a likely alternative
diagnosis. Brain biopsy is reserved for patients failing to
respond to specific therapy.
Treatment Recommendations
The initial therapy of choice consists of the combination of
pyrimethamine plus sulfadiazine plus leucovorin (122–125)
(AI). Pyrimethamine penetrates the brain parenchyma
efficiently even in the absence of inflammation (126). Use of
leucovorin prevents the hematologic toxicities associated with
pyrimethamine therapy (127,128). The preferred alternative
regimen for patients unable to tolerate or who fail to respond
to first-line therapy is pyrimethamine plus clindamycin plus
leucovorin (122,123) (AI).
TMP-SMX was reported in a small (77 patient) randomized
trial to be effective and better tolerated than pyrimethamine-
sulfadiazine (129). On the basis of less in vitro activity and
less experience with this regimen, pyrimethamine plus
sulfadiazine with leucovorin is the preferred therapy (BI). For
patients who cannot take an oral regimen, no well-studied
options exist. No parenteral formulation of pyrimethamine
exists; the only widely available parenteral sulfonamide is the
sulfamethoxazole component of TMP-SMX. Therefore,
certain specialists will treat severely ill patients requiring
parenteral therapy initially with oral pyrimethamine plus
parenteral TMP-SMX or parenteral clindamycin (CIII).
At least three regimens have activity in the treatment of TE
in at least two, nonrandomized, uncontrolled trials, although
their relative efficacy compared with the previous regimens is
unknown: 1) atovaquone (with meals or oral nutritional
supplements) plus pyrimethamine plus leucovorin (130) (BII);
2) atovaquone combined with sulfadiazine or, for patients
intolerant of both pyrimethamine and sulfadiazine, as a single
agent (130) (BII) (if atovaquone is used alone, measuring
plasma levels might be helpful given the high variability of
absorption of the drug among different patients; plasma levels
of >18.5 µg/mL are associated with an improved response rate)
(131–133); and 3) azithromycin plus pyrimethamine plus
leucovorin daily (134,135) (BII).
The following regimens have been reported to have activity
in the treatment of TE in small cohorts of patients or in case
reports of one or a few patients: clarithromycin plus
pyrimethamine (136) (CIII); 5-fluoro-uracil plus clindamycin
(137) (CIII), dapsone plus pyrimethamine plus leucovorin
(138) (CIII); and minocycline or doxycycline combined with
either pyrimethamine plus leucovorin, sulfadiazine, or
clarithromycin (139,140) (CIII). Although the clarithromycin
dose used in the only published study was 1 g twice a day,
doses >500 mg have been associated with increased mortality
in HIV-1–infected patients treated for disseminated MAC.
Doses >500 mg twice a day should not be used (DIII).
Acute therapy should be continued for at least 6 weeks, if
there is clinical and radiologic improvement (106–109) (BII).
Longer courses might be appropriate if clinical or radiologic
disease is extensive or response is incomplete at 6 weeks.
Adjunctive corticosteroids (e.g. dexamethasone) should be
administered when clinically indicated only for treatment of
a mass effect associated with focal lesions or associated edema
(BIII). Because of the potential immunosuppressive effects of
corticosteroids, they should be discontinued as soon as
clinically feasible. Patients receiving corticosteroids should be
closely monitored for the development of other OIs, including
cytomegalovirus retinitis and TB disease.
Anticonvulsants should be administered to patients with a
history of seizures (AIII), but should not be administered
prophylactically to all patients (DIII). Anticonvulsants, if
administered, should be continued at least through the period
of acute therapy.
Monitoring and Adverse Events
Changes in antibody titers are not useful for monitoring
responses to therapy. Patients should be routinely monitored
for adverse events and clinical and radiologic improvement
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(AIII). Common pyrimethamine toxicities include rash,
nausea, and bone-marrow suppression (neutropenia, anemia,
and thrombocytopenia) that can often be reversed by increasing
the dose of leucovorin to 50–100 mg/day administered in
divided doses (CIII).
Common sulfadiazine toxicities include rash, fever,
leukopenia, hepatitis, nausea, vomiting, diarrhea, and
crystalluria. Common clindamycin toxicities include fever,
rash, nausea, diarrhea (including pseudomembranous colitis
or diarrhea related to Clostridium difficile toxin), and
hepatotoxicity. Common TMP-SMX toxicities include rash,
fever, leukopenia, thrombocytopenia, and hepatotoxicity. Drug
interactions between anticonvulsants and antiretroviral agents
should be carefully evaluated and doses adjusted according to
established guidelines.
Management of Treatment Failure
A brain biopsy, if not previously performed, should be
strongly considered for patients who fail to respond to initial
therapy (BII) as defined by clinical or radiologic deterioration
during the first week despite adequate therapy or lack of clinical
improvement within 2 weeks. For those who undergo brain
biopsy and have confirmed histopathologic evidence of TE, a
switch to an alternative regimen as previously described should
be considered (BIII). Recurrence of disease during secondary
maintenance therapy following an initial clinical and
radiographic response is unusual if patients adhere to their
regimen.
Prevention of Recurrence
Patients who have successfully completed a 6-week course
of initial therapy for TE should be administered lifelong
secondary prophylaxis (i.e., chronic maintenance therapy)
(141–143) unless immune reconstitution occurs because of
ART (AI). Adult and adolescent patients appear to be at low
risk for recurrence of TE when they have successfully
completed initial therapy for TE, remain asymptomatic with
respect to signs and symptoms of TE, and have a sustained
(i.e., >6 months) increase in their CD4+ T lymphocyte counts
to >200 cells/µL on ART (144,145). The numbers of such
patients who have been evaluated remain limited. On the basis
of these observations and inference from more extensive data
about safety of discontinuing secondary prophylaxis for other
OIs during advanced HIV-1 disease, discontinuing chronic
maintenance therapy among such patients is a reasonable
consideration (CIII). Certain health-care providers would
obtain an MRI of the brain as part of their evaluation to
determine whether discontinuation of therapy is appropriate
and might be reluctant to stop therapy if any mass lesion or
contrast enhancement persists (CIII). Secondary prophylaxis
should be started again if the CD4+ T lymphocyte count
decreases to <200 cells/µL (AIII).
Special Considerations During Pregnancy
Documentation of maternal T. gondii serologic status should
be obtained during pregnancy. Indications for treatment of
T. gondii during pregnancy should be based on confirmed or
suspected symptomatic disease in the mother. Pediatric care
providers should be informed if the HIV-1–infected mother
is seropositive for T. gondii infection to allow evaluation of
the neonate for evidence of congenital infection. Pregnant
HIV-1–infected women with suspected or confirmed primary
T. gondii infection during pregnancy should be managed in
consultation with a maternal-fetal medicine or other
appropriate specialist (146) (BIII).
Treatment should be the same as in nonpregnant adults
(BIII). Although pyrimethamine has been associated with birth
defects in animals, limited human data have not suggested an
increased risk for defects and, therefore, it can be administered
to pregnant women (147,148). Pediatric providers should be
notified if sulfadiazine is continued until delivery because its
use might increase the risk for neonatal hyperbilirubinemia
and kernicterus (148).
Although perinatal transmission of T. gondii normally occurs
only with acute infection in the immunocompetent host, case
reports have documented occurrences of transmission with
reactivation of chronic infection in HIV-1–infected women
with severe immunosuppression (147,149). Because the risk
for transmission with chronic infection appears low, routine
evaluation of the fetus for infection with amniocentesis or
cordocentesis is not indicated. Detailed ultrasound
examination of the fetus specifically evaluating for
hydrocephalus, cerebral calcifications, and growth restriction
should be done for HIV-1–infected women with suspected




Cryptosporidiosis is caused by Cryptosporidium species, a
group of protozoan parasites that infect the small bowel
mucosa, and in immunosuppressed persons, the large bowel
and extraintestinal sites. Those at greatest risk for disease are
patients with advanced immunosuppression (i.e., CD4+ T
lymphocyte counts generally <100 cells/µL) (150). The three
most common species infecting humans are C. hominis
(formerly C. parvum genotype 1 or human genotype),
C. parvum (formerly C. parvum genotype 2 or bovine
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genotype), and C. meleagridis. In addition, infections with
C. canis, C. felis, C. muris, and Cryptosporidium pig genotype
have been reported in immunocompromised patients.
Preliminary analyses indicate that some zoonotic species might
have a stronger association with chronic diarrhea than
C. hominis. However, whether the different Cryptosporidium
species are associated with differences in severity of disease or
response to therapy is unknown.
In developed countries with low rates of environmental
contamination where potent ART is widely available,
cryptosporidiosis occurs at an incidence rate of <1 per 100
person-years among persons with AIDS. Transmission occurs
through ingestion of Cryptosporidium oocysts. C. hominis
infects only humans, and C. parvum infects humans and other
large mammals (e.g., cows and sheep). C. meleagridis infects
avians (e.g., turkeys and chickens) and humans. Feces from
infected animals, including humans, can contaminate water
supplies and recreational water with viable oocysts despite
standard chlorination (90). Person-to-person transmission,
primarily among men who engage in oral-anal sex, also has
been observed. Young children with cryptosporidial diarrhea
also might infect adults, especially during diapering.
Scrupulous handwashing, use of barriers during anal sex, and
other hygiene measures might help prevent person-to-person
transmission.
Clinical Manifestations
The most common presentation of cryptosporidiosis is the
acute or subacute onset of profuse, nonbloody watery diarrhea,
frequently accompanied by nausea, vomiting, and lower
abdominal cramping (151). Fever is present in approximately
one third of patients. Malabsorption is often present. The
epithelium of both the biliary tract and the pancreatic duct can
be infected with Cryptosporidium. Cholangitis and pancreatitis
occur among patients with prolonged disease (152).
Diagnosis
Cryptosporidium species cannot be cultivated in vitro. Diag-
nosis of cryptosporidiosis is primarily based on microscopic
identification of the oocysts in stool or tissue. Oocysts stain
red with varying intensities with a modified acid-fast tech-
nique; this technique allows for differentiation of the
Cryptosporidium oocysts from yeasts that are similar in size
and shape but are not acid fast. Oocysts also can be detected
by direct immunofluorescent or enzyme-linked immuno-
sorbent assays (153).
No consensus exists on the optimal oocyst detection method
in fecal samples. The modified acid-fast stain and a fluorescein
labeled monoclonal antibody technique indicate comparability
for diarrheal samples, but the immunofluorescent method is
probably preferable for formed stool specimens.
Cryptosporidium species and genotype identification requires
molecular methods (e.g., PCR followed by sequencing).
Cryptosporidial enteritis can be diagnosed on small intestinal
biopsy sections by identification of developmental stages of
Cryptosporidium organisms, found individually or in clusters,
on the brush border of the mucosal epithelial surfaces.
Organisms project into the lumen because of their intracellar
but extracytoplasmic characteristics and appear basophilic with
hematoxylin and eosin staining. Electron microscopy allows
resolution of cellular detail.
Among persons with profuse diarrheal illness, a single stool
specimen is usually adequate for diagnosis. Among persons
with less severe disease, repeat stool sampling is recommended,
although no controlled studies have demonstrated the utility
of three consecutive stool samples as is the case in Giardia
duodenalis infection.
Treatment Recommendations
ART with immune restoration (an increase of CD4+ T
lymphocyte count to >100 cells/µL) is associated with complete
resolution of cryptosporidiosis (154,155), and all patients with
cryptosporidiosis should be offered ART as part of the initial
management of their infection (AII). No consistently effective
pharmacologic or immunologic therapy directed specifically
against C. parvum exists. Approximately 95 interventional
agents have been tried for the treatment of cryptosporidiosis
with no consistent success.
Paromomycin, a nonabsorbable aminoglycoside that is
indicated for the treatment of intestinal amebiasis, is effective
in high doses for the treatment of cryptosporidiosis in animal
models (156). A meta-analysis of 11 published paromomycin
studies in humans reported a response rate of 67%. However,
relapse was common in certain studies, with long-term success
rates of only 33%. Two randomized controlled trials have
compared paromomycin with placebo among patients with
AIDS and cryptosporidiosis; modest, but statistically
significant improvement in symptoms and oocyst shedding
was demonstrated in one, but no difference from placebo was
observed in the other (157,158). A small open-label study
suggested a substantial benefit of paromomycin when used in
combination with azithromycin, but few cures were noted
(159). Therefore, efficacy data do not support a
recommendation for the use of paromomycin for therapy,
although the drug appears to be safe (CIII).
Nitazoxanide, an orally administered nitrothiazole
benzamide, has in vivo activity against a broad range of
helminths, bacteria, and protozoa, including cryptosporidia
(160–162). A short-term study among patients with HIV-1
infection documented increased cure rates compared with
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controls (based on clearance of organisms from stool and
reduced rates of diarrhea) among patients with CD4+ T
lymphocyte counts >50 cells/µL, but not in those with CD4+
T lymphocyte counts <50 cells/µL (161). Available data do
not warrant a definite recommendation for use of this agent
in this setting, but the drug has been approved by the U.S.
Food and Drug Administration (FDA) for use in children and
is expected to be approved for use in adults (CIII).
Treatment of persons with cryptosporidiosis should include
symptomatic treatment of diarrhea (AIII). Rehydration and
repletion of electrolyte losses by either the oral or intravenous
route is important. Severe diarrhea, which might be >10 L/day
among patients with AIDS, often requires intensive support.
Aggressive efforts at oral rehydration should be made with
oral rehydration solutions that contain glucose, sodium
bicarbonate, potassium, magnesium, and phosphorus (AIII).
Treatment with antimotility agents can play an important
adjunctive role in therapy, but these agents are not consistently
effective (BIII). Loperamide or tincture of opium will often
palliate symptoms. Octreotide, a synthetic octapeptide analog
of naturally occurring somatostatin that is approved for the
treatment of secreting tumor induced diarrhea, is no more
effective than other oral antidiarrheal agents, and is generally
not recommended (162) (DII).
Monitoring and Adverse Events
Patients should be closely monitored for signs and symptoms
of volume depletion, electrolyte and weight loss, and
malnutrition and should receive supportive treatment. Total
parenteral nutrition might be indicated in certain patients (CIII).
Management of Treatment Failure
Supportive treatment and optimizing ART to achieve full
virologic suppression are the only feasible approaches to the
management of treatment failure (CIII).
Prevention of Recurrence
No drug regimens are proven to be effective in preventing
the recurrence of cryptosporidiosis.
Special Considerations During Pregnancy
As with nonpregnant woman, initial treatment efforts should
rely on rehydration and initiation of ART. Pregnancy should
not preclude the use of ART.
Microsporidiosis
Epidemiology
Microsporidia organisms are protists related to fungi, defined
by the presence of a unique invasive organelle consisting of a
single polar tube that coils around the interior of the spore
(163,164). They are ubiquitous organisms and are likely
zoonotic and/or waterborne in origin (165). The microsporidia
reported as pathogens in humans include Encephalitozoon
cuniculi, Encephalitozoon hellem, Encephalitozoon (Septata)
intestinalis, Enterocytozoon bieneusi, Trachipleistophora hominis,
Trachipleistophora anthropopthera, Pleistophora species,
P. ronneeafyi, Vittaforma (Nosema) corneae, Microsporidium sp.,
Nosema ocularum, Brachiola (Nosema) connori, Brachiola
vesiculatum, and Brachiola (Nosema) algerae (163–169).
In the pre-ART era, reported prevalence rates of micro-
sporidiosis varied between 2% and 70% among HIV-1–infected
patients with diarrhea, depending on the diagnostic techniques
employed and the patient population described (163–166).
The incidence of microsporidiosis has declined dramatically
with the widespread use of effective ART. In the immunosup-
pressed host, microsporidiosis is most commonly observed
when the CD4+ T lymphocyte count is <100 cells/µL
(163–166).
Clinical Manifestations
The most common manifestation of microsporidiosis is
gastrointestinal tract infection with diarrhea; however,
encephalitis, ocular infection, sinusitis, myositis, and
disseminated infection are also described (163–166).
Clinical syndromes might vary by infecting species.
Enterocytozoon bieneusi is associated with malabsorption,
diarrhea, and cholangitis. Encephalitozoon cuniculi is associated
with hepatitis, encephalitis, and disseminated disease.
Encephalitozoon (Septata) intestinalis is associated with diarrhea,
disseminated infection, and superficial keratoconjuctivitis.
Encephalitozoon hellem is associated with superficial
keratoconjunctivitis, sinusitis, respiratory disease, prostatic
abscesses, and disseminated infection. Nosema, Vittaforma, and
Microsporidium are associated with stromal keratitis following
trauma in immunocompetent hosts. Pleistophora, Brachiola,
and Trachipleistophora  are associated with myositis.
Trachipleistophora is associated with encephalitis and
disseminated disease.
Diagnosis
Although microsporidia belonging to the genera
Encephalitozoon, Brachiola (B. algerae), Vittaforma (V. corneae),
and Trachipleistophora have been cultivated in vitro, E. bieneusi
has not been successfully cultivated in vitro. Effective
morphologic demonstration of microsporidia by light
microscopy can be accomplished by staining methods that
produce differential contrast between the spores of the
microsporidia and the cells and debris in clinical samples (e.g.,
stool). In addition, because of the small size of the spores
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(1–5 mm), adequate magnification (e.g., 1,000X) is required
for visualization. Chromotrope 2R, calcofluor white
(fluorescent brightener), and Uvitex 2B (fluorescent
brightener) are useful as selective stains for microsporidia in
stool and other body fluids (167–169).
In biopsy specimens, microsporidia can be visualized with
Giemsa, Brown-Hopps Gram stain, acid-fast staining,
Warthin-Starry silver staining, hematoxylin and eosin, or
Chromotrope 2A (169). In gastrointestinal disease,
examination of three stools with chromotrope and
chemofluorescent stains is often sufficient for diagnosis. If stool
examination is negative and microsporidiosis is suspected, a
small bowel biopsy should be performed. If the etiologic agent
is encephalitozoonidae or Trachipleistophora, examination of
urine often reveals the organism. Determination of the species
of microsporidia causing disease can be made by the
morphology of the organism demonstrated by transmission
electron microscopy or by PCR using species or genus specific
primers (169).
Treatment Recommendations
ART with immune restoration (an increase of CD4+ T
lymphocyte count to >100 cells/µL) is associated with
resolution of symptoms of enteric microsporidiosis, including
that caused by E. bieneusi (170–172). All patients should be
offered ART as part of the initial management of their infection
(AII). Nevertheless, data indicate that microsporidia are
suppressed but not eliminated (171).
No specific therapeutic agent is active against E. bieneusi
infection. A controlled clinical trial suggests that E. bieneusi
might respond to oral fumagillin (60 mg/day), a water
insoluble antibiotic made by Aspergillus fumigatus (173,174)
(BII). However, fumagillin is not available for systemic use in
the United States (173,174). One report indicates that 60 days
of nitazoxanide might resolve chronic diarrhea caused by
E. bieneusi in the absence of ART (175). However, the effect
might be minimal among patients with low CD4+ T cell
counts. Nitazoxanide is approved for use among children and
is expected to be approved by the FDA for use among adults.
Albendazole and fumagillin have demonstrated consistent
activity against other microsporidia in vitro and in vivo
(176–181). Albendazole, a benzimidazole that binds to
b-tubulin, has activity against many species of microsporidia,
but it is not effective for Enterocytozoon infections, although
fumagillin has activity in vitro and in vivo.
Albendazole is recommended for initial therapy of intestinal
and disseminated (not ocular) microsporidiosis caused by
microsporidia other than E. bieneusi (178,181) (AII).
Itraconazole also might be useful in disseminated disease when
combined with albendazole especially in infections caused by
Trachipleistophora or Brachiola (CIII).
Ocular infections caused by microsporidia should be treated
with topical Fumidil B (fumagillin bicylohexylammonium) in
saline (to achieve a concentration of 70 mg/mL of fumagillin)
(180) (BII). Topical fumagillin is the only formulation available
for treatment in the United States and is investigational.
Although clearance of microsporidia from the eye can be
demonstrated, the organism often is still present systemically
and can be detected in the urine or in nasal smears. In such
cases, the use of albendazole as a companion systemic agent is
recommended (BIII).
Metronidazole and atovaquone are not active in vitro or in
animal models and should not be used to treat microsporidiosis
(DII). Fluid support should be offered if diarrhea has resulted
in dehydration (AIII). Malnutrition and wasting should be
treated with nutritional supplementation (AIII).
Monitoring and Adverse Events
Albendazole side effects are rare but hypersensitivity (rash,
pruritis, fever), neutropenia (reversible), CNS effects (dizziness,
headache), gastrointestinal disturbances (abdominal pain,
diarrhea, nausea, vomiting), hair loss (reversible), and elevated
hepatic enzymes (reversible) have been reported. Albendazole
is not carcinogenic or mutagenic. Topical fumagillin has not
been associated with substantial side effects. Oral fumagillin
has been associated with thrombocytopenia, which is reversible
on stopping the drug.
Management of Treatment Failure
Supportive treatment and optimizing ART to attempt to
achieve full virologic suppression are the only feasible
approaches to the management of treatment failure (CIII).
Prevention of Recurrence
Treatment for ocular microsporidiosis should be continued
indefinitely because recurrence or relapse might follow
treatment discontinuation (BIII). Whether treatment can be
safely discontinued after immune restoration with ART is
unknown, although it is reasonable, on the basis of the
experience with discontinuation of secondary prophylaxis
(chronic maintenance therapy) for other opportunistic
infections during advanced HIV-1 disease, to discontinue
chronic maintenance therapy if patients remain asymptomatic
with regard to signs and symptoms of microsporidiosis and
have a sustained (e.g. >6 months) increase in their CD4+ T
lymphocyte counts to levels >200 cells/µL after ART (CIII).
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Special Considerations During Pregnancy
Among animals (i.e., rats and rabbits), albendazole is
embryotoxic and teratogenic at dosages of 30 mg/kg body
weight. Therefore, albendazole is not recommended for use
among pregnant women (DIII). However, well-controlled
studies in human pregnancy have not been performed.
Systemic fumagillin has been associated with increased
resorption and growth retardation in rats. No data on use in
human pregnancy are available. However, because of the
antiangiogenic effect of fumagillin, this drug should not be
used among pregnant women (EIII). Topical fumagillin has
not been associated with embryotoxic or teratogenic effects
among pregnant women and might be considered when
therapy with this agent is appropriate (CIII).
Mycobacterium tuberculosis Disease
Epidemiology
In the United States, overall case rates of TB disease are
declining with approximately 15,000 new cases reported in
2002 (182). HIV testing is recommended for suspected or
confirmed cases of TB, but this is not uniformly practiced.
Therefore, the percentage of TB patients with HIV-1 infection
in the United States can only be estimated. In 1999,
approximately 10% of all TB cases in the United States were
known to be HIV-1 infected.
The World Health Organization (WHO) estimates that TB
is the cause of death for 11% of all AIDS patients (183). The
percentage and absolute number of patients with TB disease
who are HIV-1 infected is declining in the United States
because of improved infection-control practices and better
diagnosis and treatment of both HIV-1 infection and TB. With
increased voluntary counseling and testing and the increasing
use of treatment for latent TB infection, TB disease will
probably continue to decrease among HIV-1–infected persons
in the United States and Western Europe (184).
Persons at high risk for TB in the United States include
injection-drug users, persons from high prevalence countries,
and those who live or work in congregate settings. TB disease
occurs among HIV-1–infected persons at all CD4+ T
lymphocyte counts. The clinical manifestations might be
altered depending on the degree of immunosuppression. Those
with more advanced immunosuppression (CD4+ T
lymphocyte count <200 cells/µL) are more likely to have
extrapulmonary or disseminated disease. In areas where TB is
endemic, certain patients have higher CD4+ T lymphocyte
counts at the time HIV-1–related TB disease develops; in
countries with low rates of TB disease (e.g., United States and
countries in Western Europe), more patients have advanced
HIV-1 disease at the time TB develops.
TB disease in persons with HIV-1 infection can develop
immediately after exposure (i.e., primary disease) or as a result
of progression after establishment of latent TB infection (i.e.,
reactivation disease). Primary TB has been reported in certain
group outbreaks, particularly in persons with advanced
immune suppression, and might account for one third or more
of cases of TB disease in the HIV-infected population (185).
Progression to disease among those with latent TB infection
is more likely among HIV-1–infected than in HIV-uninfected
persons (186). HIV-uninfected persons with a positive
tuberculin skin test (TST) result have a 5%–10% lifetime risk
for developing TB, compared with a 7%–10% annual risk in
the HIV-1–infected person with a positive TST result. Patients
with TB disease have higher HIV-1 viral loads and a more
rapid progression of their HIV-1 illness than comparable
HIV-1–infected patients without TB (187).
Clinical Manifestations
 The clinical, radiographic, and histopathologic presentation
of HIV-1–related TB disease is heavily influenced by the degree
of immunodeficiency (188,189). With CD4+ T lymphocyte
counts >350 cells/µL, HIV-1–related TB appears like TB
among HIV-uninfected persons. The majority of patients have
disease limited to the lungs, and common chest radiographic
manifestations include upper lobe fibronodular infiltrates with
or without cavitation (190). However, extrapulmonary disease
is more common in HIV-1–infected persons than in non-
HIV–infected persons. When extrapulmonary disease occurs
in HIV-1–infected persons, clinical manifestations are not
substantially different from those described in HIV-uninfected
patients.
With increasing degrees of immunodeficiency,
extrapulmonary TB, with or without pulmonary involvement,
becomes more common. At CD4+ T lymphocyte counts <50
cells/µL, extrapulmonary TB (pleuritis, pericarditis, and
meningitis) is common.
Among severely immunocompromised patients, TB can be
a severe systemic disease with high fevers, rapid progression,
and sepsis syndrome. The chest radiographic findings of TB
disease in advanced AIDS are markedly different compared
with those among patients with less severe HIV-1 infection;
lower lobe, middle lobe, and miliary infiltrates are common
and cavitation is less common. Patients with HIV-1 infection
and pulmonary TB can have sputum smears and culture results
positive for acid-fast bacilli (AFB) or M. tuberculosis, respectively,
even with a normal chest radiograph.
Histopathological findings are also affected by the degree of
immunodeficiency. Patients with relatively intact immune
function have typical granulomatous inflammation associated
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with TB disease. With progressive immunodeficiency, granulomas
become poorly formed or can be completely absent (189).
Diagnosis
 Suspicion of TB, and assiduous efforts to obtain appropriate
diagnostic specimens are important in diagnosing
HIV-1–related TB disease. The evaluation of suspected
HIV-1-related TB should always include a chest radiograph.
Sputum samples for AFB smear and culture should be obtained
from patients with pulmonary symptoms, cervical adenopathy,
or chest radiographic abnormalities. Sputum samples from a
substantial fraction of cases of pulmonary TB are negative by
direct smear microscopy.
Nucleic-acid amplification (NAA) tests are useful in
providing rapid identification of M. tuberculosis from sputum
smear-positive specimens, but false-negative results can occur
among patients with TB disease. The positive predictive value
of NAA tests are decreased in persons who have sputum smear-
negative results.
Among patients with signs of extrapulmonary TB, needle
aspiration of skin lesions, nodes, pleural, or pericardial fluid
might allow for rapid diagnosis, culture, and susceptibility
testing. Tissue biopsy is helpful among patients with negative
fine-needle aspirates. Among patients with signs of
disseminated disease, mycobacterial blood culture might allow
a definitive diagnosis. Mycobacterial blood culture is more
sensitive for diagnosis of TB among severely immunodeficient
patients.
Among patients with relatively intact immune function, the
yield of sputum smear and culture examinations is similar to
that of HIV-uninfected adults, with positive smear results being
more common among patients with cavitary pulmonary
involvement (191). TST is positive in the majority of patients
with pulmonary disease and CD4+ T lymphocyte counts
>200 cells/µL. Among patients with more severe immuno-
deficiency, sputum smear and culture examinations become
somewhat less sensitive, and TST has limited diagnostic value
because it is often negative (192). However, the yield of
mycobacterial stain and culture of specimens from
extrapulmonary sites (node aspirates and pleural and pericar-
dial fluid) is higher among patients with advanced immuno-
deficiency compared with HIV-uninfected adults (193–195).
Smear-positive specimens from these sites probably represent
a high burden of organisms resulting from lack of effective
immune response to mycobacteria and inability to limit
mycobacterial replication and kill the organisms.
A positive smear result in any of these specimens (sputum,
needle aspirate, tissue biopsy) represents some form of
mycobacterial disease but does not always represent TB.
However, because TB is the most virulent mycobacterial
pathogen and can be spread from person to person if
pulmonary involvement is present, patients with smear-positive
results should be treated for TB disease until definitive
mycobacterial species identification is made.
Drug susceptibility testing and adjustment of the treatment
regimen based on the results are critical to the successful
treatment of TB and to prevention of transmission of drug-
resistant M. tuberculosis in the community. Therefore, for all
patients with TB disease, testing for susceptibility to first line
agents (isoniazid [INH], rifampin [RIF], and ethambutol
[EMB]) should be performed, regardless of the source of the
specimen. Pyrazinamide (PZA) susceptibility testing should be
performed on an initial isolate if there is a sufficiently high
prevalence of PZA resistance in the community. Second-line
drug susceptibility testing should be performed only in reference
laboratories and should be limited to specimens from patients
who have had previous therapy, who are contacts of patients
with drug-resistant TB disease, who have demonstrated
resistance to rifampin or to other first-line drugs, or who have
positive cultures after >3 months of treatment (185).
Treatment Recommendations
Treatment of HIV–1-related TB disease should follow the
general principles developed for TB treatment among non-
HIV–infected persons (AI). Early diagnosis and treatment are
critical. Because of the severity of TB disease among
immunocompromised patients, directly observed therapy
(DOT) is strongly recommended for patients with
HIV-1–related TB (AI). Multiple drugs and DOT are used to
provide effective therapy, to prevent acquired drug resistance
during treatment, and to allow cure with a relatively short
course of treatment (6–9 months).
HIV-1–infected patients have other social and medical needs
and treatment success is enhanced by a case-management
approach, which incorporates assistance with all of these needs
(enhanced DOT) in addition to providing DOT.
Multiple concerns should be considered in the treatment of
HIV-1–associated TB disease. First, treatment is effective, but
the optimal duration of treatment is uncertain. Second,
acquired drug resistance is unusual with the use of DOT, but
does occur among HIV-1–infected persons. Third, the risk
for acquired rifamycin resistance has led to specific
recommendations about dosing frequency. Finally, the use of
potent ART among patients being treated for TB is
complicated by overlapping drug toxicity profiles, drug-drug
interactions, and an increase in TB manifestations during
immune reconstitution (paradoxical reactions). Recent studies
indicate that, with careful attention to these complicating
factors, the prognosis of HIV-1–associated TB disease can be
substantially improved with the provision of potent ART (AII),
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although the optimal relative timing between anti-TB and
HIV therapy is uncertain.
Treatment of drug susceptible TB disease in HIV-1–infected
adults should include the use of a 6-month regimen consisting
of an initial phase of INH, RIF or rifabutin, PZA, and EMB
given for 2 months followed by INH and RIF (or rifabutin)
for 4 months when the disease is caused by organisms known
or presumed to be susceptible to first-line anti-TB drugs (185)
(AI). When the organism is susceptible to INH, RIF, and PZA,
EMB should be discontinued (AI).
The optimal duration of therapy for HIV-1–related TB disease
remains controversial. Studies in developing countries have
shown that patients with HIV-1–related TB respond well to
standard 6-month treatment regimens, with rates of treatment
failure and relapse similar to those of HIV-uninfected patients
(196). However, it is unclear whether these results are applicable
to patients with advanced HIV-1 disease and TB. While awaiting
definitive randomized comparisons in HIV-1–infected patients
with TB disease, 6 months of therapy is probably adequate for
the majority of cases, but prolonged therapy (up to 9 months)
is recommended (as in HIV-negative patients) for patients with
a delayed clinical or bacteriological response to therapy
(symptomatic or positive culture results at or after 2 months of
therapy, respectively) or perhaps with cavitary disease on chest
radiograph (BII).
Intermittent dosing (twice- or thrice- weekly) facilitates
DOT by decreasing the total number of encounters required
between the patient and the provider, making observed
therapy more practical to deliver. However, once- or twice-
weekly dosing has been associated with an increased rate of
acquired rifamycin resistance among patients with advanced
HIV-1 disease (CD4+ T lymphocyte count <100 cells/µL).
Acquired rifamycin resistance was relatively common with
once-weekly rifapentine plus INH and also occurred in trials
of twice-weekly rifabutin plus INH and twice-weekly RIF
plus INH (197–199). Therefore, once-weekly rifapentine is
contraindicated among HIV-1–infected patients (EI), and
it is recommended that RIF- and rifabutin-based regimens
be given at least three times a week for patients with TB and
advanced HIV-1 disease (CD4+ T lymphocyte count <100
cells/µL) (AII). Although treatment approaches to this
population need to be further evaluated in prospective trials,
a prudent management strategy consists of daily DOT during
the first 2 months of therapy and thrice-weekly DOT during
the continuation phase of anti-TB therapy (198) (BII).
Monitoring and Adverse Events
 Close follow-up, consisting of clinical, bacteriologic, and
occasionally, laboratory and radiographic evaluations, is
essential to ensure treatment success. In patients with
pulmonary TB, at least one sputum specimen for microscopic
examination and culture should be obtained at monthly
intervals until two consecutive specimens are negative on
culture (AII). Drug susceptibility tests should be repeated on
isolates from patients who have positive cultures after 3 months
of treatment. Patients who have positive cultures after 4 months
of treatment should be considered as having failed therapy
and managed accordingly. For patients with extrapulmonary
TB, the frequency and types of evaluations will depend on
the sites involved and the ease with which specimens can be
obtained.
A detailed clinical assessment should be performed at least
monthly to identify possible medication intolerance and to
assess adherence. As a routine, monitoring blood tests for
patients being treated with first-line drugs unless baseline
abnormalities were identified is unnecessary (AII). More
frequent clinical and laboratory monitoring is indicated for
patients with underlying liver disease, including hepatitis C
co-infection.
INH, RIF, and PZA all can cause drug-induced hepatitis,
and the risk might be increased in patients taking other
potentially hepatotoxic agents or in persons with underlying
liver dysfunction. However, because of the effectiveness of these
drugs (particularly INH and RIF), they should be used, if at
all possible, even in the presence of preexisting liver disease
(AIII). Frequent clinical and laboratory monitoring should
be performed to detect any exacerbation.
Independent of HIV status for all patients with TB disease,
multiple treatment options exist if serum aminotransaminases
are >3 times the upper limit of normal before the initiation of
treatment, and the abnormalities are not thought to be caused
by TB disease. One option is to use standard therapy with
frequent monitoring. A second option is to treat with RIF,
EMB, and PZA for 6 months, avoiding INH (BII). A third
option is to treat with INH and RIF for 9 months,
supplemented by EMB for the first 2 months, thereby avoiding
PZA (BII). Among patients with severe liver disease, a regimen
with only one hepatotoxic agent, generally RIF plus EMB,
can be given for 12 months, preferably with another agent,
such as a fluoroquinolone, for the first 2 months (CIII). As
previously indicated, treatment might need to be lengthened
for patients who are HIV-1-infected. For patients who develop
worsening hepatic function on treatment, a specialist should
be consulted.
Tests to monitor hepatotoxicity (aminotransferases,
bilirubin, and alkaline phosphatase), renal function (serum
creatinine), and platelet count should be obtained for all
patients started on treatment for TB. At each monthly visit,
patients taking EMB should be asked about possible visual
disturbances including blurred vision or scotomata. Monthly
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testing of visual acuity and color discrimination is
recommended for patients taking doses that, on a milligram
per kilogram basis, are greater than those listed in
recommended doses and for patients receiving the drug for
>2 months.
Patients with TB disease caused by strains of M. tuberculosis
resistant to at least INH and RIF (multidrug-resistant [MDR])
are at high risk for treatment failure and further acquired drug
resistance. Such patients should be referred to or have
consultation obtained from specialized treatment centers as
identified by the local or state health departments or CDC.
Although patients with strains resistant to RIF alone have a
better prognosis than patients with MDR strains, they are also
at increased risk for treatment failure and additional resistance
and should be managed in consultation with an expert.
Antiretroviral Therapy in the Management
of TB Disease and Paradoxical Reactions
 Rifamycin drugs are essential components of short-course
regimens for treatment of TB disease. However, substantial
adverse pharmacologic interactions occur between rifamycins
and commonly used antiretroviral drugs (e.g., PIs and
NNRTIs) as a result of changes in drug metabolism resulting
from induction of the hepatic cytochrome P-450 (CYP450)
enzyme system (200,201). Of the available rifamycins, RIF is
the most potent CYP450 inducer and rifabutin has
substantially less inducing activity. Despite such interactions,
a rifamycin should generally not be excluded from the TB
treatment regimen among patients receiving potent ART,
except in unusual circumstances (AII).
Either RIF or rifabutin can be used with NRTIs (199,200).
Rifabutin can be used with certain PIs or NNRTIs (other than
delavirdine) and has fewer problematic drug interactions than
does rifampin (Table 5). Adjustments in rifabutin or elements
of the ART regimen might be necessary with certain
combinations. Two antiretroviral drug regimens have been
associated with a favorable outcome when administered with
RIF: efavirenz (potentially using an increased dose of
800 mg/day) plus 2 NRTIs and ritonavir (600 mg twice daily)
plus 2 NRTIs. Serum concentrations of nevirapine might be
adequate even in the presence of concentrations of RIF
associated with enzyme induction, but clinical data are lacking.
RIF should not be used with nelfinavir, saquinavir, indinavir,
amprenavir, atazanavir, or dual PI combinations using low
dose ritonavir (<200 mg twice daily) for which dosing
guidelines are not available (EII).
The optimal time for initiating ART during TB treatment
is unknown. Because of the risk for prolonged airborne
transmission of M. tuberculosis, initiation of treatment for TB
disease should never be delayed (AI). Early initiation of ART
(within the first 2–4 weeks after the start of TB therapy) might
decrease HIV-1 disease progression but might be associated
with a relatively high incidence of side effects and paradoxical
reactions (some severe enough to warrant discontinuation of
both antiretroviral and anti-TB drugs). Delaying the initiation
of ART for 4–8 weeks after starting antituberculous therapy
has the potential advantages of being better able to ascribe a
specific cause for a drug side effect, decreasing the severity of
paradoxical reactions, and decreasing the adherence challenge
for the patient. Until controlled studies are conducted to
evaluate the optimal time for starting ART in patients with
HIV-1–associated TB disease, this decision should be
individualized on the basis of the patient’s initial response to
TB therapy, occurrence of side effects, and acceptance of
multidrug ART. For these considerations, health-care providers
should avoid beginning the simultaneous administration of
both potent ART and combination chemotherapy for TB;
most health-care providers would wait at least 4–8 weeks
(BIII). Patients already receiving ART at the time treatment
for TB is started require a careful assessment of the ART
regimen and, if necessary, changes to ensure optimum
treatment of the HIV-1 infection in the setting of TB therapy.
Because of the difficulties associated with the accurate
diagnosis of an adverse drug reaction and in determining the
responsible agent, the first-line anti-TB drugs should not be
stopped permanently without strong evidence that the anti-
TB drug was the cause of the reaction. In such situations,
consultation with an expert in treating TB in persons with
HIV-1 infection is recommended.
Patients might experience temporary exacerbation of
symptoms, signs, or radiographic manifestations of TB disease
after beginning anti-TB treatment. This phenomenon is
termed a paradoxical (or immune reconstitution) reaction. This
reaction occurs among non-HIV-1–infected persons, but it is
more common among those with HIV-1 infection, particularly
those treated with ART. These reactions presumably develop
as a consequence of reconstitution of immune responsiveness
brought about by ART or perhaps by treatment of TB itself
(202–206). Signs of a paradoxical reaction can include high
fevers, increase in size and inflammation of involved lymph
nodes, new lymphadenopathy, expanding central nervous
system lesions, worsening of pulmonary parenchymal
infiltrations, and increasing pleural effusions. Such findings
should be attributed to a paradoxical reaction only after a
thorough evaluation has excluded other possible causes,
especially TB therapy failure.
A paradoxical reaction that is not severe should be treated
symptomatically with nonsteroidal anti-inflammatory agents
without a change in anti-TB or antiretroviral therapy (BIII).
Approaches to the management of severe reactions (e.g., high
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fever, airway compromise from enlarging lymph nodes, enlarging
serosal fluid collections, and sepsis syndrome) have not been
studied. However, case reports have documented improvements
with the use of prednisone or methylprednisolone used at a
dose of approximately 1mg/kg body weight and gradually
reduced after 1–2 weeks (202–206) (CIII).
Management of Drug Resistance
and Treatment Failure
If resistance to INH (with or without resistance to
streptomycin) is detected, INH and streptomycin, if used,
should be discontinued and the patient treated with a 6-month
regimen of RIF, PZA, and EMB, which is nearly as effective
as the conventional INH-containing regimen (BII).
Alternatively, treatment with RIF and EMB for 12 months
can be used, preferably with PZA during at least the initial 2
months (BII).
Treatment regimens for TB disease caused by RIF
monoresistant strains are less effective, and patients infected
with these strains are at increased risk for relapse and treatment
failure. A minimum of 12–18 months of treatment with INH,
EMB, and a fluoroquinolone (e.g., levofloxacin) with PZA
administered during the first 2 months is recommended (BIII).
An injectable agent (e.g., amikacin or capreomycin) might be
included in the first 2–3 months for patients with severe disease.
Patients with MDR-TB are at high risk for treatment failure
and relapse and require especially close follow-up during (and
often after) treatment. Treatment regimens for MDR-TB
should be individualized, taking into account the resistance
pattern, relative activities of available anti-TB agents, the extent
of disease, and presence of co-morbid conditions. The
management of MDR-TB is complex and should be
undertaken only by an experienced specialist or in close
consultation with specialized treatment centers (AIII).
Prevention of Recurrence
Secondary prophylaxis (chronic maintenance therapy) for
patients who have successfully completed a recommended
regimen of treatment for TB disease is unnecessary (DII).
However, reinfection can occur.
Special Considerations During Pregnancy
 HIV-1–infected pregnant women who do not have
documentation of a negative TST result during the preceding
year should be tested during pregnancy. The frequency of
anergy is not increased during pregnancy, and routine anergy
testing for HIV-1–infected pregnant women is not
recommended (207–210).
The diagnostic evaluation for TB disease in pregnant women
is the same as for nonpregnant adults. Chest radiographs with
abdominal shielding result in minimal fetal radiation exposure.
An increase in pregnancy complications, including preterm
birth, low birthweight, and intrauterine growth retardation,
might be observed among pregnant women with either
pulmonary or extrapulmonary TB not confined to the lymph
nodes, especially when treatment is not begun until late in
pregnancy (207–213).
Therapy of TB disease during pregnancy should be the same
as for the nonpregnant adult, but with attention given to the
following considerations (BIII):
• INH is not teratogenic in animals or humans.
Hepatotoxicity might occur more frequently in pregnancy
and the postpartum period (214). Certain health-care
providers recommend monthly monitoring of
transaminases during pregnancy and the postpartum
period (CIII).
• RIF is not teratogenic in humans. Because of a potential
increased risk for RIF-related hemorrhagic disease among
neonates born to women receiving anti-TB therapy during
pregnancy, prophylactic vitamin K, 10 mg, should be
administered to the neonate (BIII).
• PZA is not teratogenic among animals. Experience is
limited with use in human pregnancy. Although WHO
and the International Union Against Tuberculosis and
Lung Diseases (215,216) have made recommendations
for the routine use of PZA in pregnant women, it has not
been recommended for general use during pregnancy in
the United States because data characterizing its effects in
this setting are limited (217). If PZA is not included in
the initial treatment regimen, the minimum duration of
therapy should be 9 months.
• EMB is teratogenic among rodents and rabbits at doses
that are much higher than those used among humans.
No evidence of teratogenicity has been observed among
humans. Ocular toxicity has been reported among adults
taking EMB, but changes in visual acuity have not been
detected in infants born after exposure in utero.
Experience during pregnancy with the majority of the second
line drugs for TB is limited. MDR-TB in pregnancy should
be managed in consultation with an expert. Therapy should
not be withheld because of pregnancy (AIII). The following
concerns should be considered when selecting second-line anti-
TB drugs for use among pregnant women:
• Although no longer a first line agent, streptomycin use
has been associated with a 10% rate of VIII nerve toxicity
in infants exposed in utero; its use during pregnancy
should be avoided if possible (DIII).
• Hearing loss has been detected in approximately 2% of
children exposed to long-term kanamycin therapy in utero;
like streptomycin, this agent should generally be avoided
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if possible (DIII). There is a theoretical risk of ototoxicity
in the fetus with in utero exposure to amikacin and
capreomycin, but this risk has not been documented, and
these drugs might be alternatives when an aminoglycoside
is required for treatment of MDR-TB (CIII).
• Because arthropathy has been noted in immature animals
with the use of quinolones during pregnancy, quinolones
are generally not recommended in pregnancy and among
children aged <18 years (CIII). However, >200 cases of
ciprofloxacin use in pregnancy have been reported to
various pregnancy registries, and its use has not been
associated with arthropathy or birth defects after in utero
exposure. Thus, quinolones can be used in pregnancy for
drug-resistant TB, if required based on susceptibility
testing (CIII).
• Para-aminosalicylic acid (PAS) has been associated with
occipital bone defects when administered during
pregnancy to rats (217,218). PAS is not teratogenic among
rats or rabbits. A possible increase in limb and ear
anomalies was reported among 143 pregnancies with first
trimester exposure in one study (218). No specific pattern
of defects and no increase in rate of defects have been
detected in other human studies, indicating that this agent
can be used with caution if needed (CIII).
• Ethionamide has been associated with an increased risk for
several anomalies among mice, rats, and rabbits following
high dose exposure; no increased risk for defects was noted
with doses similar to those used among humans, but
experience is limited with use during human pregnancy.
• No data are available from animal studies or reports of




 Organisms of the Mycobacterium avium complex (MAC)
are ubiquitous in the environment (219–224). M. avium is
the etiologic agent in >95% of patients with AIDS who develop
disseminated MAC disease (219–224). An estimated 7%–12%
of adults have been previously infected with MAC, although
rates of disease vary in different geographic locations
(220,221,224). Although certain epidemiologic associations
have been identified, no environmental exposure or behavior
has been consistently associated with the subsequent
development of MAC disease in susceptible persons.
The mode of transmission for MAC infection is thought to be
through inhalation, ingestion, or inoculation through respiratory
or gastrointestinal tract portals of entry. Household or close
contacts of those with MAC disease do not appear to be at
increased risk for experiencing disease, and person-to-person
transmission is unlikely.
In the absence of effective combination ART or chemopro-
phylaxis in those with advanced immunosuppression, the
incidence of disseminated MAC disease among persons with
AIDS ranges from 20%–40% (220–222). For those with a
CD4+ T lymphocyte count <100 cells/µL who are receiving
effective prophylaxis or those who have responded to ART
with a sustained increase in CD4+ T lymphocyte count to
levels >100–200 cells/µL, the overall incidence rate has been
estimated at 2 cases per 100 person-years. Most cases of MAC
disease occur among persons with CD4+ T lymphocyte counts
<50 cells/µL. Other factors that are associated with increased
susceptibility to MAC disease are high plasma HIV-1 RNA
levels (>100,000 copies/mL), previous opportunistic infections
(particularly CMV disease), previous colonization of the res-
piratory or gastrointestinal tract with MAC, and reduced in
vitro lymphoproliferative immune responses to M. avium
antigens, possibly reflecting defects in T-cell repertoire.
Clinical Manifestations
 MAC disease among patients with AIDS, in the absence of
ART, is generally a disseminated multiorgan infection
(225–229). Early symptoms might be minimal and might
precede detectable intermittent or continuous mycobacteremia
by several weeks. Symptoms include fever, night sweats, weight
loss, fatigue, diarrhea, and abdominal pain.
Immune reconstitution inflammatory syndrome, characterized
by focal lymphadenitis with fever, is a systemic inflammatory
response with signs and symptoms that are clinically
indistinguishable from active infection and is similar to paradoxical
reactions observed with TB disease (230–232). Bacteremia is
absent. The syndrome has been described among patients with
subclinical or established MAC disease and advanced
immunosuppression who begin ART and have a rapid and marked
increase in CD4+ T lymphocyte count (>100 cells/µL). This
syndrome might be benign and self-limited or might be severe
and require systemic anti-inflammatory therapy to alleviate
clinical symptoms.
Other localized manifestations of MAC disease have been
reported most commonly among persons who are receiving
and who have responded to ART. Localized syndromes include
cervical or mesenteric lymphadenitis, pneumonitis,
pericarditis, osteomyelitis, skin or soft tissue abscesses, genital
ulcers, or CNS infection.
Laboratory abnormalities particularly associated with
disseminated MAC disease include anemia (often out of
proportion to that expected for stage of HIV-1 disease) and
elevated liver alkaline phosphatase (219–225,233–235).
Hepatomegaly, splenomegaly, or lymphadenopathy
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(paratracheal, retroperitoneal, para-aortic, or less commonly
peripheral) might be identified on physical examination or by
radiographic or other imaging studies. Other focal physical
findings or laboratory abnormalities might occur in the context
of those localized disease syndromes previously described.
Diagnosis
A confirmed diagnosis of disseminated MAC disease is based
on compatible clinical signs and symptoms coupled with the
isolation of MAC from cultures of blood, bone marrow, or
other normally sterile tissue or body fluids (233–239). Use of
an Isolator® (Wampole Laboratories, Cranbury, New Jersey)
or a similar blood culture system and inoculation of blood
into Bactec 12B liquid medium, or direct inoculation of
specimens into Bactec 13A bottles (Bactec; Becton Dickinson,
Sparks, Maryland), followed by radiometric detection of
growth, are recommended (237). Species identification should
be performed using specific DNA probes, high performance
liquid chromatography, or biochemical tests.
Other ancillary studies provide supportive diagnostic
information, including AFB smear and culture of stool or
biopsy material obtained from tissues or organs, radiographic
imaging of the abdomen or mediastinum for detection of
lymphadenopathy, or other studies aimed at isolation of
organisms from focal infection sites.
Treatment Recommendations
 Initial treatment of MAC disease should consist of two
antimycobacterial drugs to prevent or delay the emergence of
resistance (240–255) (AI). Clarithromycin is the preferred first
agent (250) (AI); it has been studied more extensively than
azithromycin and appears to be associated with more rapid
clearance of MAC from the blood (240,250,254,255). However,
azithromycin can be substituted for clarithromycin when drug
interactions or clarithromycin intolerance preclude the use of
clarithromcyin (AII). Ethambutol is the recommended second
drug (250) (AI). Some clinicians would add rifabutin as a third
drug (CI). One randomized clinical trial demonstrated that the
addition of rifabutin to the combination of clarithromycin and
ethambutol for the treatment of disseminated MAC disease
improved survival, and in two randomized clinical trials, this
approach reduced emergence of drug resistance (246,251). These
studies were completed before the availability of effective ART.
The addition of rifabutin should be considered in persons with
advanced immunosuppression (CD4+ T lymphocyte count <50
cells/µL), high mycobacterial loads (>2 log10 colony forming
units/mL of blood), or in the absence of effective ART, settings
in which mortality is increased and emergence of drug resistance
are most likely (CIII). If rifabutin cannot be used because of
drug interactions or intolerance (Table 5), a third or fourth
drug may be selected from among either the fluoroquinolones
(ciprofloxacin or levofloxacin) or parenteral amikacin (Table 6),
although data supporting a survival or microbiologic benefit
when these agents are added have not been compelling
(240–253) (CIII).
Patients who have had disseminated MAC disease diagnosed
and who have not previously been treated with or are not
receiving potent ART should generally have ART initiated
simultaneously or within 1-2 weeks of initiation of
antimycobacterial therapy for MAC disease (CIII). If ART
has already been instituted, it should be continued and
optimized for patients with disseminated MAC disease, unless
drug interactions preclude the safe concomitant use of
antiretroviral and antimycobacterial drugs (CIII).
Persons who have symptoms of moderate-to-severe intensity
because of an immune recovery inflammatory syndrome in
the setting of ART should receive treatment initially with
nonsteroidal, anti-inflammatory agents (CIII). If symptoms
fail to improve, short-term (4–8 weeks) systemic corticosteroid
therapy, in doses equivalent to 20–40 mg of oral prednisone
QD, has been successful (256,257) (CIII).
Monitoring and Adverse Events
 Improvement in fever and a decline in quantity of myco-
bacteria in blood or tissue can be expected within 2–4 weeks
after initiation of appropriate therapy. However, for those with
more extensive disease or advanced immunosuppression,
clinical response might be delayed. A repeat blood culture for
MAC should be obtained 4-8 weeks after initiation of
antimycobacterial therapy for patients who fail to have a clinical
response to their initial treatment regimen (i.e., little or no
reduction in fever or systemic symptoms).
Adverse effects with clarithromycin and azithromycin
include nausea, vomiting, abdominal pain, abnormal taste,
and elevations of liver transaminase levels or hypersensitivity
reactions. Doses of clarithromycin >1 g per day for treatment
of disseminated MAC disease have been associated with
increased mortality and should not be used (258) (EI).
Rifabutin doses of >450 mg/day have been associated with
higher risk for adverse drug interactions when used with
clarithromycin or other drugs that inhibit cytochrome p450
isoenzyme 3A4 and might be associated with a higher risk for
experiencing uveitis or other adverse drug reactions (259,260).
Management of Treatment Failure
 Treatment failure is defined by the absence of a clinical
response and the persistence of mycobacteremia after 4–8 weeks
of treatment. Testing of MAC isolates for susceptibility to
clarithromycin and azithromycin is recommended for patients
who fail to microbiologically respond to initial therapy, relapse
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after an initial response, or develop MAC disease while receiving
clarithromycin or azithromycin for prophylaxis; testing for
susceptibility to clarithromycin, azithromycin, ethambutol, and
rifabutin might be helpful in this setting, although the predictive
value for ethambutol and rifabutin with regard to response to
therapy has not been established. The majority of patients who
failed clarithromycin or azithromycin primary prophylaxis in
clinical trials had isolates susceptible to these drugs at the time
MAC disease was detected (237,240,241,251,261). Bactec®
radiometric broth macrodilution is the recommended method
for testing M. avium for susceptibility to antimicrobial agents
(237,250,261). Minimum inhibitory concentrations (MICs)
of >32 µg/mL for clarithromycin or >256 µg/mL for
azithromycin are the suggested thresholds for determination of
resistance based on the Bactec® method for radiometric
susceptibility testing (237,251,261).
Because the number of drugs with demonstrated clinical
activity against MAC is limited, results of susceptibility testing
should be used to construct a new multidrug regimen
consisting of at least two new drugs not previously used and
to which the isolate is susceptible from among the following:
ethambutol, rifabutin, ciprofloxacin or levofloxacin, or
amikacin (CIII). Whether continuing clarithromycin or
azithromycin in the face of resistance provides additional
benefit is unknown (CIII). Clofazimine should not be used
on the basis of the lack of efficacy demonstrated in randomized
trials and the association with increased mortality (247,249)
(EII). Other second-line agents (e.g., ethionamide,
thiacetazone [not available in the United States], or cycloserine)
have been anecdotally combined with these drugs as salvage
regimens. However, their role in this setting is not well defined.
Among patients who have failed initial treatment for MAC
disease or who have antimycobacterial drug resistant MAC
disease, optimizing ART is an important adjunct to second-
line or salvage therapy for MAC disease (AIII).
Adjunctive treatment of MAC disease with immuno-
modulators has not been thoroughly studied, and data are
insufficient to support a recommendation for use (DIII).
Interferon-gamma, tumor necrosis factor-alpha, granulocyte-
macrophage colony-stimulating factor, and interleukin-12,
either alone or in combination with other cytokines, appear
to inhibit intracellular replication or enhance in vitro intrac-
ellular killing of M. avium (256,257,262,263). Use of these
immunomodulators would be a logical adjuvant treatment
for those who fail conventional antimycobacterial therapy.
Prevention of Recurrence
 Adult and adolescent patients with disseminated MAC
disease should receive lifelong secondary prophylaxis (chronic
maintenance therapy) (AII), unless immune reconstitution
occurs as a result of ART (250,264–268). Patients are at low
risk for recurrence of MAC when they have completed a course
of >12 months of treatment for MAC, remain asymptomatic
with respect to MAC signs and symptoms, and have a sustained
increase (e.g., >6 months) in their CD4+ T lymphocyte counts
to >100 cells/µL after ART. Although the numbers of patients
who have been evaluated remain limited and recurrences could
occur, on the basis of these observations and on inference from
more extensive data indicating the safety of discontinuing
secondary prophylaxis for other opportunistic infections
during advanced HIV-1 disease, discontinuing chronic
maintenance therapy among such patients is reasonable
(250,253,267,268) (BII). Certain health-care providers
recommend obtaining a blood culture for MAC, even for
asymptomatic patients, before discontinuing therapy to
substantiate that disease is no longer active, but it is not clear
how often a positive culture will be obtained in such patients.
Secondary prophylaxis should be reintroduced if the CD4+ T
lymphocyte count decreases to <100 cells/µL (AIII).
Special Considerations During Pregnancy
 Diagnostic considerations and indications for treatment are
the same as among nonpregnant adults. Azithromycin is
preferred over clarithromycin as the second agent with
ethambutol or rifabutin because of the occurrence of birth
defects in mice and rats associated with clarithromycin
(269–272) (BIII). Limited data among humans do not indicate
an increased risk for defects among 122 women taking
clarithromycin during the first trimester, although an increased
rate of spontaneous abortions was noted (271). Limited data
are available on the use of azithromycin during the first
trimester in humans (271,272).
Bacterial Respiratory Disease
Epidemiology
Bacterial pneumonia is a common cause of HIV-1 related
morbidity (273,274). Incidence of approximately 100 cases
per 1,000 HIV-1–infected persons per year have been reported,
a rate much higher than in the noninfected population (273).
In a study comparing rates among cohorts with similar other
risk factors for bacterial pneumonia, those with HIV-1
infection were 7.8 times more likely to develop bacterial
pneumonia than HIV-seronegative persons (274). For certain
persons, bacterial pneumonia is a symptom of HIV-1 disease.
Patients can develop serious pneumococcal infections with
relatively preserved CD4+ T lymphocyte counts.
The high rates of bacterial pneumonia and other pyogenic
respiratory tract infections probably result from multiple factors
including qualitative B-cell defects that impair the ability to
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produce pathogen-specific antibody, impaired neutrophil
function or numbers or both, and non-HIV–related factors (e.g.,
cigarette smoking, use of crack cocaine, IDU, alcoholism, or
liver disease). The most consistent predictor of bacterial
infections is the CD4+ T lymphocyte count (275–279).
The etiology of bacterial pneumonia among patients with
HIV-1 infection has been reported (275–285). Consistent
among these has been the relative prominence of Streptococcus
pneumoniae, followed by Haemophilus influenzae, Pseudomonas
aeruginosa, and Staphylococcus aureus. In the majority of studies,
the pathogens of atypical pneumonia (Legionella pneumophila,
Mycoplasma pneumoniae, and Chlamydia pneumoniae) are rarely
encountered.
On the basis of data derived from studies of pneumococcal
bacteremia, infection with S. pneumoniae is 150–300 times more
common among patients with HIV-1 infection than in age-
matched HIV-uninfected populations (282). Recurrent
pneumococcal pneumonia, either with the same or unrelated
serotype, is also more common among HIV-1–infected patients,
with a rate of 8%–25% within 6 months (282,283). Reinfection
with a different strain is more common than relapse.
In the majority of series, H. influenzae (usually nontypable)
is generally the second most common cause of bacterial pneu-
monia (284). In patients with advanced immunosuppression,
S. aureus and P. aeruginosa can cause particularly aggressive
invasive pneumonias, sometimes associated with bacteremia
and frequent relapses after cessation of therapy (285).
As reported in pneumonia studies of non-HIV-1–infected
patients, a high proportion (up to 33%) of patients with
HIV-1 infection will have no specific microbiologic etiology
defined. Many of these undefined cases are believed to be of
possible bacterial etiology based on reviews of clinical and
laboratory data, including response to antibacterial therapy.
Clinical Manifestations
HIV-1–infected patients with bacterial pneumonia generally
present in a similar fashion to those without HIV-1 infection
(i.e., acute illness characterized by chills, rigors, pleuritic chest
pain, and purulent sputum). Physical findings consist of fever,
tachypnea, tachycardia, rales or rhonchi, and other signs of
consolidation.
Lobar consolidation on chest radiograph is commonly
observed and is a predictor of bacterial pneumonia, although
atypical presentations with multilobar, nodular, or
reticulonodular patterns are occasionally described (275–285).
Patients ill over a period of weeks to months are more likely to
have P. jiroveci pneumonia, TB disease, or an endemic chronic
fungal infection (286).
Diagnosis
The pace of the respiratory disease, the underlying CD4+ T
lymphocyte count, the circulating neutrophil count, and the
appearance of the infiltrate should guide the diagnostic
evaluation for bacterial pneumonia. At a minimum, a chest
radiograph, blood cultures, a white blood cell count and, if
available, a Gram’s stain and culture of an adequate expectorated
sputum sample, should be obtained before antibiotic
administration.
Because PCP is a common HIV-1–related respiratory
infection and might co-exist with bacterial pneumonia, an
induced sputum examination for P. jiroveci staining should be
performed in the appropriate clinical settings. These would
include known CD4+ T lymphocyte count <250 cells/µL,
other signs of advanced immunodeficiency (e.g., thrush), a
previous history of PCP or other AIDS-related condition, or
diffuse infiltrates on chest radiograph.
For both clinical and infection-control purposes, sputum
samples (either expectorated or induced) for AFB staining and
TB cultures should be obtained on all HIV-1–infected
hospitalized patients with pulmonary infiltrates in the
appropriate epidemiologic setting. A possible exception would
be the patient who has an acute onset of an illness consistent
with bacterial pneumonia, has no exposure to TB, has a
previous negative TST, and who has not lived in or been
exposed to high-prevalence areas for TB.
In the absence of clinical improvement after initiation of
antibiotic therapy and depending on the clinical history and
radiographic findings, the following supplemental tests might
be useful: urine antigen testing for L. pneumophila and
histoplasmosis; IgM and IgG serology for M. pneumoniae and
C. pneumoniae; serum cryptococcal antigen; CT scanning of
the chest; and bronchoscopy with bronchoalveolar lavage and
biopsy.
Treatment Recommendations
Therapy for HIV-1–related bacterial pneumonia should
target the most commonly identified pathogens, particularly
S. pneumoniae and H. influenzae. Treatment guidelines
appropriate for HIV-1–uninfected patients are applicable to
those with HIV-1 infection (287,288).
Specific recommended regimens include either an extended
spectrum cephalosporin (e.g., cefotaxime or ceftriaxone) or a
fluoroquinolone with activity against S. pneumoniae (e.g.,
levofloxacin, moxifloxacin, or gatifloxacin) (AIII). Combination
therapy with a macrolide or quinolone plus a cephalosporin
should be considered for those with severe illness (AIII).
For high-level penicillin-resistant isolates (MIC >4.0
mg/mL), therapy should be guided by susceptibility results.
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Determining whether meningitis is present is important
because the recommended fluoroquinolones do not reliably
attain adequate cerebrospinal fluid (CSF) levels for treating
pneumococcal meningitis.
Among patients with severe immunodeficiency (CD4+ T
lymphocyte counts <100/mL), a known history of previous
Pseudomonas infection, bronchiectasis, or relative or absolute
neutropenia, broadening empiric coverage to include
P. aeruginosa and other gram-negative bacilli should be
considered. Possible options for therapy include ceftazidime,
cefepime, piperacillin-tazobactam, a carbapenem, or high dose
ciprofloxacin or levofloxacin. For ceftazidime and
ciprofloxacin, other antimicrobial agents would be needed to
provide optimal coverage for gram-positive infections.
Monitoring and Adverse Events
A clinical response (i.e., a reduction in fever and
improvement in laboratory studies, physical findings, and
respiratory symptoms) are generally observed 48–72 hours
after initiation of appropriate therapy. Radiographic
improvement might require additional time for demonstrable
improvement.
Management of Treatment Failure
HIV-1–infected patients who fail to respond to appropriate
antimicrobial therapy, as determined by a lack of reduction in
fever, failure of the total WBC to return toward normal,
persistent or worsening pulmonary signs, symptoms or
radiographic abnormalities, progressive hypoxemia or other
evidence of progressive disease, should undergo further
evaluation, especially bronchoalveolar lavage or transbronchial
biopsy, to search for other infectious and noninfectious causes
of pulmonary dysfunction. Broader spectrum antimicrobial
therapy might be required while additional diagnostic testing
is pursued. Management in consultation with an infectious
disease specialist is recommended.
Prevention of Recurrence
The strategy most effective in preventing bacterial
pneumonia in HIV-1–infected patients is to optimize ART
(AII). No well-documented benefit has been determined for
secondary prophylaxis (chronic maintenance therapy) after
successful completion of antibiotic treatment for bacterial
respiratory tract infections.
Adults and adolescents who have a CD4+ T lymphocyte
count of >200 cells/µL should be administered a single dose
of 23-valent polysaccharide pneumococcal vaccine if they have
not received it during the preceding 5 years (BII). Annual
administration of influenza vaccine might be useful in
preventing pneumococcal superinfection of influenza
respiratory tract infections (BII).
Administration of antibiotic chemoprophylaxis to
HIV-1–infected patients who have frequent recurrences of
serious bacterial respiratory infections should be considered
(CIII). TMP-SMX, administered for PCP prophylaxis and
clarithromycin or azithromycin, administered for MAC
prophylaxis, are appropriate for drug-sensitive organisms.
However, caution is required when using antibiotics solely for
preventing the recurrence of serious bacterial respiratory
infections because of the potential for development of drug-
resistant microorganisms and drug toxicity.
Special Considerations During Pregnancy
The diagnosis of bacterial respiratory tract infections among
pregnant women is the same as for nonpregnant adults, with
appropriate shielding of the abdomen during radiographic
procedures. Bacterial respiratory tracts infections should be
managed as in the nonpregnant adult, with certain exceptions.
Clarithromycin should be avoided because of the occurrence of
birth defects associated with its use among mice and rats (DIII).
Because arthropathy has been observed among immature
animals with the use of quinolones during pregnancy, quinolones
are generally not recommended in pregnancy and among
children aged <18 years. However, >200 cases of ciprofloxacin
use in pregnancy have been reported to various pregnancy
registries, and its use has not been associated with arthropathy
or birth defects after in utero exposure in humans. Therefore,
quinolones can be used in pregnancy for drug-resistant disease
when other alternatives are not available (CIII).
Pneumococcal and influenza vaccine can be administered
during pregnancy, and influenza vaccine is recommended for
all women who will be in the second or third trimester of
pregnancy during the peak of influenza season (AIII). Because
administration of vaccines might be associated with a transient
rise in plasma HIV-1 RNA levels, vaccination of pregnant
women is best done after ART has been initiated to minimize
increases in plasma HIV-1 RNA levels that might increase the
risk for perinatal HIV-1 transmission.
Bacterial Enteric Disease
Epidemiology
The three most common causes of bacterial diarrhea among
patients with HIV-1 infection in developed countries are
Salmonella, Campylobacter, and Shigella species. Patients with
HIV-1 infection are at increased risk for developing
salmonellosis. Two studies in the United States and Europe
reported incidence rates 20–100-fold higher than the incidence
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in the general population without HIV-1 infection (289–292).
As with non-HIV–associated salmonellosis, the probable
source for Salmonella infection is ingestion of contaminated
food, in particular undercooked poultry and eggs (290).
Acquisition of the infection might be facilitated by
HIV-1–associated gastric achlorhydria.
Campylobacter jejuni has a reported incidence among
HIV-1–infected persons, particularly men who have sex with
men (MSM), up to 39 times higher than in the general
population (293,294). Persons with HIV-1 infection,
particularly sexually active MSM, appear to be at increased
risk for developing shigellosis. A population-based surveillance
study conducted in 1996 found the following incidence ratios
compared with the HIV-seronegative and heterosexual
population: MSM and HIV-seronegative 4.9 (95% confidence
interval [CI] = 2.7–8.1); heterosexual and HIV-1 infected 30.6
(95% CI = 12.8–63.0); and MSM and HIV-1 infected 35.7
(95% CI = 25.1–50.4) (295). Shigella bacteremia is more
common among HIV-1–infected persons and might occur in
both mild and severe cases of clinical shigellosis (296). Relapses
in gastroenteritis and bacteremia after appropriate treatment
have also been reported (296).
Clinical Manifestations
The three major clinical syndromes of salmonellosis among
patients with HIV-1 infection include a self-limited
gastroenteritis; a more severe and prolonged diarrheal disease,
associated with fever, bloody diarrhea, and weight loss; and
Salmonella septicemia, which might present with or without
gastrointestinal symptoms. Bacteremia can occur with each
of these syndromes and is more likely to occur among those
with advanced immunosuppression (289–292).
In the United States, the majority of cases of Salmonella
septicemia are caused by nontyphoidal strains, in particular
S. enteritidis and S. typhimurium. Because nontyphoidal
Salmonella bacteremia is rare in immunocompetent hosts, its
diagnosis should prompt consideration of HIV testing.
An additional important feature of Salmonella bacteremia
among patients with AIDS is its propensity for relapse. On
the basis of data from early in the AIDS epidemic, the rate of
recurrent bacteremia was approximately 45% unless chronic
suppressive therapy was administered (289).
Campylobacter disease among those with severe or progressive
immunodeficiency is often associated with more prolonged
diarrhea, invasive disease, bacteremia, and extraintestinal
involvement (293,294). The development of antimicrobial
resistance during therapy, often associated with clinical
deterioration or relapse, is also reported more frequently among
HIV-1–infected persons (297,298).
Shigellosis among persons with HIV-1 infection generally
causes an acute, febrile, diarrheal illness with prominent upper
and lower gastrointestinal symptoms. Bloody diarrhea is more
commonly observed with Shigella infection than with
Salmonella infection (295,296).
Diagnosis
The diagnosis of bacterial enteric infection is established
through cultures of stool and blood. Because of the high rate
of bacteremia associated with Salmonella gastroenteritis, in
particular among patients with advanced HIV-1 disease, blood
cultures should be obtained from any HIV-1–infected patient
with diarrhea and fever.
Persons with HIV-1 are also at risk for disease caused by
nonjejuni Campylobacter species, including C. fetus,
C. upsaliensis, C. laridis, C. cineadi, and C. fennelliae. Although
blood culture systems will generally grow these organisms, rou-
tine stool cultures performed by most laboratories will fail to
identify these more fastidious Campylobacter species. Endos-
copy can be diagnostically useful. If lower endoscopy is per-
formed, ulcerations similar to those seen with cytomegalovirus
colitis might be evident and can only be distinguished through
histopathologic examination and culture.
Treatment Recommendations
Immunocompetent hosts without HIV-1 infection often do
not require treatment for Salmonella gastroenteritis; the
condition is self-limited and treatment might prolong the
carrier state. Although no treatment trials have examined this
strategy among patients with HIV-1 infection, the risk for
bacteremia is sufficiently high that the majority of specialists
recommend treatment of all HIV-1–associated Salmonella
infections (BIII).
The initial treatment of choice for Salmonella infection is a
fluoroquinolone (299) (AIII). Ciprofloxacin is the preferred
agent (299) (AIII); it is likely that other fluoroquinolones
(levofloxacin, gatifloxacin and moxifloxacin) also would be
effective in treatment of salmonellosis among HIV-1–infected
persons, but these have not been well evaluated in clinical
studies (BIII).
The length of therapy for HIV-1–related Salmonella
infection is poorly defined. For mild gastroenteritis without
bacteremia, 7–14 days of treatment is reasonable in an effort
to reduce the risk for extraintestinal spread (BIII). Among
patients with advanced HIV-1 disease (CD4+ T lymphocyte
count <200/mL) or who have Salmonella bacteremia, at least
4–6 weeks of treatment is often recommended (BIII).
Depending on antibiotic susceptibility, alternatives to the
fluoroquinolone antibiotics for Salmonella spp. include
TMP-SMX or expanded spectrum cephalosporins (e.g.,
ceftriaxone or cefotaxime) (BIII).
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As with non-HIV–infected patients, the optimal treatment
of campylobacteriosis among persons with HIV-1 infection is
poorly defined. Among patients with mild disease, certain
clinicians might opt to withhold therapy unless symptoms
persist for more than several days. Increasing resistance to
fluoroquinolones makes the choice of therapy especially
problematic. For mild-to-moderate disease, initiating therapy
with a fluoroquinolone (ciprofloxacin) or a macrolide
(azithromycin), pending susceptibility test results, and treating
for 7 days is a reasonable approach (BIII). Patients with
bacteremia should be treated for at least 2 weeks (BIII), and
adding a second active agent (e.g., an aminoglycoside) might
be prudent (CIII).
Therapy for shigellosis is indicated both to shorten the
duration of illness and to prevent spread of the infection to
others (299) (AIII). The recommended treatment is with a
fluoroquinolone for 3–7 days (AIII). Alternatives to this
treatment include TMP-SMX for 3–7 days or azithromycin
for 5 days (BIII). Cases of Shigella acquired internationally
have high rates of TMP-SMX resistance; in addition,
HIV-1–infected persons have higher rates of adverse effects
related to this agent. As a result, fluoroquinolones are preferred
as first-line.
Treatment of patients who have Shigella bacteremia is less
well defined. Depending on the severity of infection, it might
be reasonable to extend treatment to 14 days, using the agents
described previously (AIII).
Monitoring and Adverse Events
 Patients should be monitored closely for response to
treatment, as defined clinically by improvement in systemic
signs and symptoms and resolution of diarrhea. A follow-up
stool culture to demonstrate clearance of the organism is not
generally required if a complete clinical response has been
demonstrated but should be considered for those who fail to
clinically respond to appropriate antimicrobial therapy, or
when public health considerations dictate the need to ensure
microbiologic cure (e.g., health-care or food service workers).
<Management of Treatment Failure
Treatment failure is defined by the lack of improvement in
clinical signs and symptoms of diarrheal illness and the
persistence of organisms in stool, blood, or other relevant body
fluids or tissue after completion of appropriate antimicrobial
therapy for the recommended duration. Certain patients with
Salmonella bacteremia might remain febrile for 5–7 days
despite effective therapy. Therefore, careful observation is
required to determine the adequacy of the response.
Treatment should be guided by drug susceptibility testing
of isolates recovered in culture. An evaluation of other factors
that might contribute to failure or relapse, such as
malabsorption of oral antibiotics, a sequestered focus of
infection (e.g., an undrained abscess), or adverse drug reactions
that interfere with antimicrobial activity, should be undertaken
as indicated.
Prevention of Recurrence
 HIV-1–infected persons who have Salmonella bacteremia
should receive long-term secondary prophylaxis (chronic main-
tenance therapy) to prevent recurrence. Fluoroquinolones,
primarily ciprofloxacin, are usually the drugs of choice for
susceptible organisms (BII). Chronic suppressive or mainte-
nance therapy is not generally recommended for Campylobacter
or Shigella infections among persons with HIV-1 infection
(EIII). Household contacts of HIV-1–infected persons who
have salmonellosis or shigellosis should be evaluated for per-
sistent asymptomatic carriage of Salmonella or Shigella so that
strict hygienic measures or antimicrobial therapy can be insti-
tuted and recurrent transmission to the HIV-1–infected
person can be prevented (CIII).
Special Considerations During Pregnancy
The diagnosis of bacterial enteric infections among pregnant
women is the same as among nonpregnant women. Bacterial
enteric infections should be managed as in the nonpregnant
adult, with several considerations. Because arthropathy has
been observed among immature animals with the use of
quinolones during pregnancy, quinolones are generally not
recommended in pregnancy and among children aged <18
years. Therefore, expanded spectrum cephalosporins,
TMP-SMX or azithromycin, depending on the organism and
the results of susceptibility testing, should generally be
considered as first-line therapy (CIII). However, >200 cases
of ciprofloxacin use in pregnancy have been reported to various
pregnancy registries, and its use has not been associated with
arthropathy or birth defects after in utero exposure in humans.
Therefore, quinolones can be used in pregnancy for drug-
resistant disease (CIII). Neonatal-care providers should be
informed of maternal sulfa therapy if used near delivery because




Bacillary angiomatosis, first recognized in 1983, and
associated illnesses (e.g., peliosis hepatica) are caused by
bacteria of the genus Bartonella, most commonly Bartonella
henselae and Bartonella quintana (300,301). Seven other
Bartonella species exist and several have been associated with
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bacteremia and endocarditis, but none are seen with increased
frequency in HIV-1– infected persons (300–302).
Cases of bacillary angiomatosis in patients with HIV-1
infection have been linked to cat exposure. Bartonella quintana,
previously known as Rochalimaea quintana, is associated with
louse infestation, causes trench fever (303), and is increasingly
frequent among the homeless and under conditions of poor
sanitation.
Bacillary angiomatosis occurs most often late in HIV-1
infection in patients with a median CD4+ T lymphocyte count
of <50 cells/µL in the majority of case series (300,303).
Bartonellosis is often a chronic illness with disease lasting for
months to years in the majority of patients.
Clinical Manifestations
Bartonella species have been associated with infections
involving every organ system, but the characteristic
presentation is bacillary angiomatosis of the skin. Bacillary
angiomatosis resembles Kaposi sarcoma. Lesions are often
papular, red, with smooth or eroded surfaces, are vascular and
bleed if traumatized. Nodules might be observed in the
subcutaneous tissue and can erode through the skin. Bone
infection has been reported, and such infections are notable
in that they are lytic and painful (304). Bartonella infection of
the liver produces hepatic bacillary peliosis, characterized by
vascular masses in the liver or spleen.
Although isolated organ systems might be the principle focus
of disease, infection results from hematogenous dissemination,
and systemic symptoms of fever, sweats, fatigue, malaise,
weight loss, and other symptoms might accompany localized
syndromes.
Diagnosis
Diagnosis is confirmed by histopathologic examination of
tissue biopsy specimens (300–306). Lesions produce vascular
proliferative histopathology; modified silver stain demonstrates
numerous bacilli. Tissue Gram stain or acid-fast staining is
negative.
Serologic tests exist and are available through CDC (307).
Serologic tests are often positive for many years before the
development of symptoms, underscoring the chronicity of
infection or indicating reactivation disease in the setting of
immunosuppression.
Bartonella spp. can be isolated from blood by using lysis
centrifugation (301,303,305). The organisms are difficult to
isolate from tissue. Growth requires at least 3 weeks in 5% CO2.
PCR methods have been developed for the identification and
speciation of Bartonella but are only available as research tools.
Treatment Recommendations
No randomized, controlled clinical trials have evaluated
antimicrobial treatment of bartonellosis. Erythromycin and
doxycycline have been used successfully to treat bacillary
angiomatosis, peliosis hepatica, bacteremia, and osteomyelitis
and are considered first-line treatment for bartonellosis on
the basis of reported experience in case series (300–307) (AII).
Therapy should last at least 3 months (AII). Doxycyline is the
treatment of choice for central nervous system bartonellosis
(AIII). Clarithromycin or azithromycin have been associated
with clinical response in certain cases and are considered second
line alternatives (BII), although treatment failures have been
reported with both drugs.
The beta-lactams (penicillins and first-generation
cephalosporins) have no appreciable in vitro activity and are
not recommended for treatment of bartonellosis (DII).
Quinolones have variable in vitro activity and clinical response
in case reports; as a result, they are not generally recommended
as first-line therapy but might be tried as second-line
alternatives (CIII).
Management of Treatment Failure
Among patients who fail to respond to initial treatment,
one or more of the second-line alternative regimens should be
considered (AIII). Among patients who relapse, lifelong
therapy is recommended (AIII).
Prevention of Recurrence
Relapse or reinfection with Bartonella has sometimes
followed a course of primary treatment. Although no firm
recommendation can be made about secondary prophylaxis
(chronic maintenance therapy) in this setting, long-term
suppression of infection with erythromycin or doxycycline
should be considered (CIII).
Special Considerations During Pregnancy
 Pregnancy has been associated with a more severe course
and possible increased risk for death with acute infection caused
by B. bacilliformis in immunocompetent patients (308). No
data are available on the potential impact of pregnancy on
Bartonella infections among HIV-1–infected persons.
Similarly, B. bacilliformis infections during pregnancy might
increase the risk for spontaneous abortion and stillbirth and
can be transmitted to the fetus. No data are available on the
effect of other Bartonella infections on pregnancy outcome.
Diagnosis of Bartonella infections in pregnant women should
be the same as in nonpregnant adults. Treatment during
pregnancy should be with erythromycin rather than
tetracyclines because of the increased hepatotoxicity and
staining of fetal teeth and bones associated with the use of
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Recent reports indicate a resurgence of infections with
Treponema pallidum, the etiologic agent of syphilis, among men
in several U.S. cities and in Western Europe, possibly because
of relaxed safer sex practices of those who view HIV-1 infection
as a disease manageable if not curable with effective ART
(309–314). HIV-1 infection appears to alter the diagnosis,
natural history, management, and outcome of T. pallidum
infection (315–318). This section focuses on specific guidelines
for the management of syphilis among HIV-1–infected patients.
A more comprehensive review of the recommendations for the
treatment of syphilis is available (319).
Clinical Manifestations
 The impact of HIV-1 infection on syphilis pathogenesis,
disease severity, response to treatment, and long-term sequelae
is not well documented. As among HIV-uninfected persons,
primary syphilis commonly presents as a single painless nodule
at the site of contact that rapidly ulcerates to form a classic
chancre; however, among HIV-infected persons, multiple or
atypical chancres occur, and primary lesions might be absent
or missed.
Progression to secondary syphilis generally follows 2–8 weeks
after primary inoculation and reflects ongoing replication and
dissemination of T. pallidum in the absence of an effective
host immune response. Although more rapid progression or
severe disease might be present among HIV-1–infected persons
with advanced immunosuppression, the clinical manifestations
are similar to those among HIV-uninfected persons. The
manifestations of secondary syphilis are protean, involving
virtually all organ systems. The most common manifestations
appear to be macular, maculopapular, or pustular skin lesions
(or condyloma lata in moist genital or intertriginous areas),
usually beginning on the trunk and spreading peripherally,
characteristically involving palms and soles and accompanied
by generalized lymphadenopathy and constitutional symptoms
of fever, malaise, anorexia, arthralgias, and headache
(317–319). Secondary syphilis, particularly acute syphilitic
meningitis, must be distinguished from acute primary HIV-1
infection. The previously described constitutional symptoms,
along with nonfocal CNS symptoms and CSF abnormalities
(e.g., lymphocytic pleocytosis with a mildly elevated CSF
protein) are common to both (320–322).
The signs and symptoms of secondary syphilis might persist
from a few days to several weeks before resolving or evolving
to latent or later stages. As among HIV-uninfected patients,
latent syphilis is not associated with overt clinical signs and
symptoms, but relapse of manifestations of secondary syphilis
might occur, most commonly in the first 1–4 years following
infection.
Manifestations of “late” syphilis generally include
neurosyphilis, cardiovascular syphilis, and gummatous syphilis,
but might present as slowly progressive disease that can affect
any organ system. Certain manifestations of neurologic
complications or neurosyphilis progress more rapidly or occur
earlier in the course of disease among persons with HIV-1
infection and are not truly late complications or manifestations.
Asymptomatic neurosyphilis, which might be the most
commonly described syndrome, is defined as the absence of
symptoms but with one or more abnormalities of CSF (i.e.,
elevated protein, lymphocytic cellular infiltrate, or positive
serologic tests).
Manifestations of symptomatic neurosyphilis (i.e., meningitis
or meningovascular or parenchymatous disease) among
HIV-1–infected persons will probably be similar to those in the
HIV-uninfected population. However, concomitant uveitis and
meningitis might be more common among HIV-1–infected
patients with syphilis.
Diagnosis
The diagnosis of syphilis depends on a variety of tests that
either directly detect the organism (e.g., darkfield microscopy
or direct fluorescent antibody-Treponema Pallidum (DFA-TP)
or serum antibodies against it (e.g., FTA-ABS and TP-TA),
or indirectly indicate the presumptive presence of T. pallidum
by detecting nontreponemal antibodies generated during
infection (e.g., VDRL and RPR) (317,319,323). Clinical
experience indicates that concurrent HIV-1 infection probably
does not change the performance of standard tests for the
diagnosis of syphilis, but this concern has not been formally
studied.
Early-stage disease (i.e., primary, secondary and early-latent
syphilis) among HIV-1–infected patients is confirmed by the
identical procedures used for the HIV-uninfected populations
(darkfield microscopy of a mucocutaneous lesion sample and
standard serologic tests). HIV-1 infection does not decrease
the sensitivity or specificity of darkfield microscopy. Responses
to nontreponemal serologic tests (i.e., VDRL and RPR) might
be atypical (i.e., higher, lower, or delayed) among
HIV-1–infected versus HIV-uninfected patients with early-
stage syphilis, but no data indicate that treponemal tests
perform differently among HIV-1–infected compared with
uninfected patients. Similar to HIV-uninfected persons, false-
negative serologic tests have been reported among
HIV-1–infected patients with documented T. pallidum
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infection. Therefore, if the clinical suspicion of syphilis is high
and serologic tests do not confirm the diagnosis, other
diagnostic procedures (e.g., biopsy, darkfield examination, or
direct fluorescent antibody staining of lesion material) should
be pursued.
By definition, patients presenting with latent syphilis have
serological evidence of disease in the absence of clinical or
other laboratory abnormalities (i.e., normal CSF profiles).
Patients with early-latent syphilis by definition have
documented infection of <1 year; patients with late-latent
syphilis have documented infection for >1 year, or the duration
of infection is not known. The diagnostic testing for detection
of late-stage disease (e.g., cardiovascular and gummatous
syphilis) among HIV-1–infected patients is the same as for
the HIV-uninfected population.
Diagnosis of neurosyphilis is established by examination of
the CSF, which might indicate mild mononuclear pleocytosis
(10–200 cells/µL), normal or mildly elevated protein
concentration, or a reactive CSF-VDRL (319,324). The
CSF-VDRL is specific but not sensitive, and a reactive test
establishes the diagnosis of neurosyphilis but a nonreactive
test does not exclude the diagnosis. In comparison, CSF
treponemal tests (e.g., the CSF FTA-ABS) are sensitive but
not specific, and a nonreactive test excludes the diagnosis of
neurosyphilis, but a reactive test does not establish the
diagnosis. Calculated indices (e.g., ITPA-index) are of limited
value in establishing the diagnosis of neurosyphilis. PCR-based
diagnostic methods are not recommended as a diagnostic test
for neurosyphilis.
A reactive CSF-VDRL and a CSF WBC >10 cells/µL
support the diagnosis of neurosyphilis; the majority of
specialists would not base the diagnosis solely on elevated CSF
protein concentrations in the absence of these other
abnormalities. HIV-1 infection itself might be associated with
mild mononuclear CSF pleocytosis (5–15 cells/µL),
particularly among persons with peripheral blood CD4+ T
lymphocyte counts >500 cells/µL. Establishing the diagnosis
of neurosyphilis might be more difficult among such persons.
If neurosyphilis cannot be excluded by a nonreactive CSF
treponemal test, such persons should be treated for
neurosyphilis, despite the acknowledged uncertainty of the
diagnosis.
Treatment Recommendations
Management of HIV-1–infected patients with syphilis is
similar to the management of HIV-uninfected persons with
the disease (319,325,326). However, closer follow-up is
recommended to detect potential treatment failures or disease
progression. All patients with syphilis, regardless of disease
stage, should be evaluated for clinical evidence of CNS or
ocular involvement. Those with neurologic or ocular
symptoms or signs should undergo CSF examination to rule
out neurosyphilis. HIV-1–infected patients with late-latent
syphilis, including those with syphilis of unknown duration,
also should undergo CSF examination. Certain specialists
recommend CSF examination for all HIV-1–infected patients
with syphilis, regardless of stage. Similar to the HIV-uninfected
population, HIV-1–infected patients with active tertiary
syphilis (i.e., aortitis and gumma) or who fail treatment for
non-neurologic syphilis should undergo CSF examination.
Patients with CSF abnormalities consistent with neurosyphilis
should be treated for neurosyphilis.
HIV-1–infected persons with early-stage (i.e., primary,
secondary, or early latent) syphilis should receive a single
intramuscular (IM) injection of 2.4 million units of benzathine
penicillin G (AII). Alternative therapies, including oral
doxycycline, ceftriaxone, and azithromycin, have not been
sufficiently evaluated in HIV-1–infected patients to warrant
use as first-line treatment. If the clinical situation requires the
use of an alternative to penicillin, treatment should be
undertaken with close clinical monitoring (BIII). In a
randomized clinical trial, amoxicillin administered with
probenecid, which increases CSF amoxicillin levels, did not
improve clinical outcome of early stage disease and is not
recommended (325) (DII).
In HIV-1–infected patients with late-latent syphilis for
whom the CSF examination excludes the diagnosis of
neurosyphilis, treatment with three weekly intramuscular
injections of 2.4 million units benzathine penicillin G is
recommended (AIII). Alternative therapy with doxycycline
100 mg by mouth twice a day for 28 days has not been
sufficiently evaluated in HIV-1–infected patients to warrant
use as first-line treatment. If the clinical situation requires the
use of an alternative to penicillin, treatment should be
undertaken with close clinical monitoring (BIII).
HIV-1–infected patients with clinical evidence of late-stage
(tertiary) syphilis (cardiovascular or gummatous disease)
should have a CSF examination to rule out neurosyphilis before
initiating therapy (AIII). The complexity of tertiary syphilis
management is beyond the scope of these guidelines and
providers treating tertiary disease are advised to consult an
infectious disease specialist (AIII).
HIV-1–infected patients with clinical or laboratory evidence
of neurosyphilis (i.e., CNS involvement including otic and
ocular disease, even with a normal CSF) should receive
intravenous aqueous crystalline penicillin G, 18–24 million
units daily, administered 3–4 million units IV every 4 hours
or by continuous infusion for 10–14 days (AII) or procaine
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penicillin 2.4 million units IM once daily plus probenecid
500 mg orally four times a day for 10–14 days (319,327,328)
(BII). HIV-1–infected patients who are allergic to sulfa-
containing medications should not be administered the IM
alternative because they are very likely to be allergic to
probenecid (DIII). IM procaine penicillin without probenecid
does not achieve sufficient penicillin levels in CSF to treat
neurosyphilis.
Because neurosyphilis treatment regimens are of shorter
duration than those used in late-latent syphilis, certain
specialists recommend following neurosyphilis treatment with
3 weeks of benzathine penicillin, 2.4 million units IM weekly.
However, no consensus has been reached about the need for
this practice (CIII). Among penicillin allergic patients,
penicillin desensitization followed by one of the penicillin
regimens listed previously is the preferred approach (BIII).
However, limited data indicate that ceftriaxone (2 g daily IV
for 10–14 days) might be an alternative regimen (CIII).
Monitoring and Adverse Events
 Clinical and serologic responses to treatment of early stage
(i.e., primary, secondary, and early-latent) disease should be
monitored at 3, 6, 9, 12, and 24 months after therapy. Serologic
responses to treatment might differ among HIV-1–infected
patients compared with HIV-uninfected persons, including
temporal pattern of response and proportion of subjects
achieving serologically defined treatment success (at least a
fourfold decrease in titer).
After successful treatment for syphilis among HIV-1–infected
and uninfected patients, some might remain “serofast,” meaning
that serum nontreponemal test titers remain reactive at low and
unchanging titers, generally <1:8, for extended periods of time
(up to the lifetime of the patient). The clinical significance of
the serofast state is unclear, but it probably does not represent
treatment failure. Serologic detection of potential re-infection
should be based on at least a fourfold increase in titer above the
established serofast baseline.
Response to therapy of late-latent syphilis should be
monitored using nontreponemal serologic tests at 3, 6, 12,
18, and 24 months to ensure at least a fourfold decline in
titer. Two retrospective studies reported that concomitant
HIV-1 infection was associated with poorer CSF and serologic
responses to neurosyphilis therapy (326,327). Repeat CSF
examination should be performed at 3 and 6 months after
completion of therapy and then every 6 months until the CSF
white blood cell count is normal and the CSF-VDRL is
nonreactive. Because of the complex nature of neurosyphilis,
treatment should be undertaken in consultation with an
infectious disease specialist.
Management of Treatment Failure
Re-treatment of patients with early stage syphilis should be
considered for those who 1) do not experience at least a fourfold
decrease in serum nontreponemal test titers 6–12 months after
therapy, 2) have a sustained fourfold increase in serum
nontreponemal test titers after an initial reduction after
treatment, or 3) have persistent or recurring clinical signs or
symptoms of disease (BIII). If CSF examination does not
confirm the diagnosis of neurosyphilis, such patients should
receive 2.4 million units IM benzathine penicillin G
administered at 1-week intervals for 3 weeks (BIII). Certain
specialists have also recommended a course of aqueous penicillin
G IV or procaine penicillin IM plus probenecid, as described
for treatment of neurosyphilis above, in this setting (CIII). If
titers fail to respond appropriately after re-treatment, repeat CSF
evaluation or re-treatment might not be beneficial (CIII).
Patients with late-latent syphilis should have a repeat CSF
examination and be retreated if they have clinical signs or
symptoms of syphilis, have a fourfold increase in serum
nontreponemal test titer, or experience an inadequate serologic
response (less than fourfold decline in nontreponemal test titer)
within 12–24 months of therapy (BIII). If the CSF examination
is consistent with CNS involvement, re-treatment should follow
the neurosyphilis recommendations (AIII); those without a
profile indicating CNS disease should receive a repeat course of
benzathine penicillin, 2.4 million units IM weekly for 3 weeks
(BIII), although certain specialists recommend following the
neurosyphilis recommendations in this setting (CIII).
Re-treatment of neurosyphilis should be considered if the CSF
WBC count has not decreased after 6 months after completion
of treatment, or if the CSF-VDRL remains reactive 2 years after
treatment (BIII).
Secondary Prevention and Maintenance
Therapy
No recommendations have been developed indicating the need
for secondary prophylaxis or prolonged chronic maintenance
antimicrobial therapy for syphilis in HIV-1–infected patients.
Special Considerations During Pregnancy
All pregnant women should be screened for syphilis at the
first prenatal visit. In areas where syphilis prevalence is high
or among women at high risk (e.g., uninsured, women living
in poverty, commercial sex workers, and injection-drug users),
testing should be repeated at 28 weeks of gestation and at
delivery. All women delivering a stillborn infant after 20 weeks
of gestation should also be tested for syphilis. Syphilis screening
should also be offered at sites providing episodic care to
pregnant women at high risk including emergency
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departments, jails, and prisons. No infant should leave the
hospital without documentation of maternal syphilis serology
status during pregnancy (329).
The rate of transmission and adverse outcomes of untreated
syphilis are highest with primary, secondary, and early latent
syphilis during pregnancy and decrease with increasing
duration of infection thereafter. Pregnancy does not appear to
alter the course, manifestations, or diagnostic test results of
syphilis infection among adults. The diagnosis should be made
the same as among nonpregnant adults. Concurrent syphilis
infection might increase the risk for perinatal transmission of
HIV-1 to the infant, although an increased risk has not been
consistently reported (330–333).
Treatment during pregnancy should consist of the same
penicillin regimen as recommended for the given disease stage
among nonpregnant, HIV-1–infected adults. Because of
treatment failures reported after single injections of benzathine
penicillin among HIV-uninfected pregnant women (334),
certain specialists recommend a second injection 1 week after
the initial injection for pregnant women with early syphilis
(319,335). Because of additional concerns about the efficacy
of standard therapy in HIV-1–infected persons, a second
injection 1 week after the first for HIV-1–infected pregnant
women should be considered (BIII).
No alternatives to penicillin have been proven effective and
safe for treatment of syphilis during pregnancy or for prevention
of fetal infection. Pregnant women who have a history of
penicillin allergy should be referred for skin testing and
desensitization and treatment with penicillin (319) (AIII).
Erythromycin does not reliably cure fetal infection; tetracyclines
should not be used during pregnancy because of hepatotoxicity
and staining of fetal bones and teeth (EIII). Efficacy data with
azithromycin or ceftriaxone are insufficient to support a
recommendation for their use in this setting (DIII).
A Jarisch-Herxheimer reaction occurring during the second
half of pregnancy might precipitate preterm labor or fetal
distress (336). Consideration should be given to providing
fetal and contraction monitoring for 24 hours after initiation
of treatment for early syphilis of pregnant women who are
>20 weeks of gestation, especially in the setting of abnormal
ultrasound findings indicative of fetal infection (BIII).
Alternatively, women should be advised to seek obstetric
attention after treatment if they notice contractions or a
decrease in fetal movement.
Repeat serologic titers should be performed in the third
trimester and at delivery for women treated for syphilis during
pregnancy. Titers can be conducted monthly for women at
high risk for reinfection. The clinical and antibody response
should be appropriate for the stage of disease, although the
majority of women will deliver before their serologic response
can be definitively assessed.
Mucocutaneous Candidiasis
Epidemiology
Oropharyngeal and esophageal candidiasis are common
(337). The majority of infection is caused by Candida albicans.
Fluconazole (or azole) resistance is predominantly the conse-
quence of previous exposure to fluconazole (or other azoles),
particularly repeated and long-term exposure (338–340). In
this setting, C. albicans resistance has been accompanied by a
gradual emergence of non-albicans Candida species, particu-
larly C. glabrata, as a cause of refractory mucosal candidiasis,
particularly in patients with advanced immunosuppression
(338,341).
The occurrence of oropharyngeal or esophageal candidiasis
is recognized as an indicator of immune suppression, and these
are most often observed in patients with CD4+ T lymphocyte
counts <200 cells/µL (337). In contrast, vulvovaginal
candidiasis is common among healthy, adult women and is
unrelated to HIV-1 status. Recurrent vulvovaginal candidiasis
alone should not be considered a sentinel of HIV-1 infection
among women. The introduction of ART has led to a dramatic
decline in the prevalence of oropharyngeal candidiasis and a
marked diminution in cases of refractory disease.
Clinical Manifestations
Oropharyngeal candidiasis is characterized by painless,
creamy white, plaque-like lesions of the buccal or
oropharyngeal mucosa or tongue surface. Lesions can be easily
scraped off with a tongue depressor or other instrument. Less
commonly, erythematous patches without white plaques can
be seen on the anterior or posterior upper palate or diffusely
on the tongue. Angular chelosis is also noted on occasion and
may be caused by Candida.
Esophageal candidiasis is occasionally asymptomatic but
often presents with fever, retrosternal burning pain or
discomfort, and odynophagia. Endoscopic examination reveals
whitish plaques similar to those observed with oropharyngeal
disease that might progress to superficial ulceration of the
esophageal mucosa, with central or surface whitish exudates.
Vulvovaginitis might be mild to moderate and sporadic,
similar in presentation to that in normal hosts, and
characterized by a creamy to yellow-white adherent vaginal
discharge associated with mucosal burning and itching. In
those with more advanced immunosuppression, episodes
might be more severe, more frequently recurrent, of longer
duration, or refractory to treatment.
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Diagnosis
 Diagnosis of oropharyngeal candidiasis is usually clinical
and based on the appearance of lesions. The feature that
distinguishes these from oral hairy leukoplakia is the ability
to scrape off the superficial whitish plaques. If laboratory
confirmation is required, a scraping for microscopic
examination for yeast forms using a potassium hydroxide
(KOH) preparation provides supportive diagnostic
information. Cultures of clinical material identify the species
of yeast present.
The diagnosis of esophageal candidiasis requires endoscopic
visualization of lesions with histopathologic demonstration
of characteristic Candida yeast forms in tissue and culture
confirmation of the presence of Candida species. The diagnosis
of vulvovaginal candidiasis is based on the clinical presentation
coupled with the demonstration of characteristic yeast forms
in vaginal secretions examined microscopically after KOH
preparation. Culture confirmation is rarely required but might
provide supportive information. Because self-diagnosis of
vulvovaginitis is unreliable, microscopic confirmation is
required to avoid unnecessary exposure to inappropriate
treatments.
Treatment Recommendations
Although initial episodes of oropharyngeal candidiasis can
be adequately treated with topical therapy, including
clotrimazole troches or nystatin suspension or pastilles (BII),
oral fluconazole is as effective and, in certain studies, superior
to topical therapy and is more convenient and generally better
tolerated (342) (AI). Itraconazole oral solution for 7–14 days
is as effective as oral fluconazole but less well tolerated (AI).
Ketoconazole and itraconazole capsules are less effective than
fluconazole because of their more variable absorption and
should be considered second line alternatives (DII).
Systemic therapy is required for effective treatment of
esophageal candidiasis (AII). A 14–21-day course of either
fluconazole or itraconazole solution is highly effective (AI).
As with oropharyngeal candidiasis, ketoconazole and
itraconazole capsules are less effective than fluconazole because
of variable absorption (DII). Although caspofungin (AII) and
voriconazole (AII) are effective in treating esophageal
candidiasis among HIV-1–infected patients, experience is
limited and fluconazole remains the preferred agent. Although
symptoms of esophageal candidiasis might be mimicked by
other pathogens, a diagnostic trial of antifungal therapy is often
appropriate before endoscopy is undertaken to search for other
causes of esophagitis.
Uncomplicated vulvovaginal candidiasis is observed in 90%
of HIV-1–infected women and responds readily to short-
course oral or topical treatment with any of several therapies
including single-dose regimens (AII):
• topical azoles (clotrimazole, butaconazole, miconazole,
ticonazole, or terconazole) for 3–7 days;
• topical nystatin 100,000 units daily for 14 days;
• itraconazole oral solution 200 mg twice a day for 1 day or
200 mg daily for 3 days; or
• oral fluconazole 150 mg for 1 dose.
Complicated vaginitis (prolonged or refractory episodes) is
observed in approximately 10% of patients and requires
antimycotic therapy for >7 days (AII).
Monitoring and Adverse Events
For the majority of patients, response to therapy is rapid,
with improvement in signs and symptoms within 48–72 hours.
Short courses of topical therapy rarely result in adverse effects,
although patients might experience cutaneous hypersensitivity
reactions, with rash and pruritis. Patients might experience
gastrointestinal upset with oral azole treatment. Patients treated
for >7–10 days with azoles might experience hepatotoxicity.
If prolonged therapy is anticipated (>21 days), periodic
monitoring of liver chemistry studies should be considered.
Management of Treatment Failure
Treatment failure is generally defined as signs and symptoms
of oropharyngeal or esophageal candidiasis that persist for more
than 7–14 days of appropriate therapy. Fluconazole-refractory
oropharyngeal candidiasis will respond at least transiently to
itraconazole solution in approximately two thirds of persons
(AII). Amphotericin B oral suspension (1 mL four times daily
of the 100 mg/mL suspension) is sometimes effective among
patients with oropharyngeal candidiasis who do not respond
to itraconazole (CIII); however, this product is not available
in the United States. Intravenous amphotericin B is usually
effective and can be used among patients with refractory disease
(BII). Fluconazole-refractory esophageal candidiasis should
be treated with caspofungin (BIII) or intravenous
amphotericin B, either conventional or liposomal or lipid
complex formulations (BII).
Prevention of Recurrence
 The majority of HIV specialists do not recommend secondary
prophylaxis (chronic maintenance therapy) of recurrent
oropharyngeal or vulvovaginal candidiasis because of the
effectiveness of therapy for acute disease, the low mortality
associated with mucosal candidiasis, the potential for resistant
Candida organisms to develop, the possibility of drug
interactions, and the cost of prophylaxis (DIII). However, if
recurrences are frequent or severe, an oral azole, fluconazole
(CI), or itraconazole solution (CI) (or for recurrent vulvovaginal
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candidiasis, daily prophylaxis with any topical azole [CII])
should be considered. Other factors that influence choices related
to such therapy include impact of recurrences on the patient’s
well-being and quality of life, need for prophylaxis for other
fungal infections, cost, toxicities, drug interactions, nutritional
status, and potential to induce drug resistance among Candida
and other fungi.
Prolonged use of systemically absorbed azoles, specifically
among patients with low CD4+ T lymphocyte counts (i.e.,
<100 cells/µL) increases the risk for developing azole resistance.
Adults or adolescents who have a history of one or more
episodes of documented esophageal candidiasis should be
considered candidates for secondary prophylaxis. Fluconazole
100–200 mg daily is appropriate (BI). However, potential azole
resistance should be considered when long-term azoles are
considered.
Special Considerations During Pregnancy
 Pregnancy increases the risk for vaginal colonization with
Candida species. Diagnosis of oropharyngeal, esophageal, and
vulvovaginal candidiasis is the same as among nonpregnant
adults.
Fluconazole is teratogenic in high doses in animal studies
(343,344). Among humans, four cases of an unusual cluster
of defects (i.e., craniofacial and skeletal) have been reported
after prolonged use at high doses in the first trimester of
pregnancy (345,346). Teratogenic effects have not been
described among animals at doses similar to those used in
humans, and anomalies do not appear to be increased among
infants born to women receiving single-dose fluconazole
treatment in the first trimester (347–349). Itraconazole is
teratogenic among rats and mice (i.e., skeletal defects,
encephalocele, and macroglossia) at high doses (350). Similar
to fluconazole, no increase in anomalies has been noted among
women exposed to treatment doses in the first trimester.
Invasive or refractory esophageal Candida infections should
be treated the same in pregnancy as in the nonpregnant woman,
with the exception that amphotericin B should be substituted
for fluconazole or itraconazole (if indicated) in the first
trimester if similar efficacy is to be expected (351) (BIII).
Cryptococcosis
Epidemiology
Virtually all HIV-1–associated cryptococcal infections are
caused by Cryptococcus neoformans var neoformans. Before the
advent of ART, approximately 5%–8% of HIV-1–infected
patients in developed countries acquired disseminated
cryptococcosis (352,353). The incidence has declined
substantially with use of effective ART. The majority of cases
of infection are observed among patients who have CD4+ T
lymphocyte counts of <50 cells/µL.
Clinical Manifestations
Cryptococcosis among patients with AIDS most commonly
occurs as a subacute meningitis or meningoencephalitis with fever,
malaise, and headache (352). Classic meningeal symptoms and
signs (e.g., neck stiffness or photophobia) occur in approximately
one fourth to one third of patients. Certain patients might present
with encephalopathic symptoms (e.g., lethargy, altered mentation,
personality changes, and memory loss).
Analysis of the CSF usually indicates a mildly elevated serum
protein, normal or slightly low glucose, and a few lymphocytes
and numerous organisms. The opening pressure in the CSF is
elevated (with pressures >200 mm of water) in up to 75% of
patients. Disseminated disease is a common manifestation,
with or without concurrent meningitis. Approximately half
of patients with disseminated disease have evidence of
pulmonary rather than meningeal involvement. Symptoms and
signs of pulmonary infection include cough or dyspnea and
abnormal chest radiographs. Skin lesions might be observed.
Diagnosis
 Cryptococcal antigen is almost invariably detected in the CSF
at high titer in patients with meningitis or meningoencephalitis.
Up to 75% of patients with HIV-1–associated cryptococcal
meningitis have positive blood cultures; if disseminated or other
organ disease is suspected in the absence of meningitis, a fungal
blood culture is also diagnostically helpful. The serum cryptococcal
antigen is also usually positive and detection of cryptococcal
antigen in serum might be useful in initial diagnosis (354).
Treatment Recommendations
 Untreated cryptococcal meningitis is fatal. The recommended
initial treatment for acute disease is amphotericin B, usually
combined with flucytosine, for a 2-week duration followed by
fluconazole alone for an additional 8 weeks (AI). This approach
is associated with a mortality of <10% and a mycologic response
of approximately 70% (355,356).
The addition of flucytosine to amphotericin B during acute
treatment does not improve immediate outcome but is well
tolerated for 2 weeks and decreases the risk for relapse (355,
356). Lipid formulations of amphotericin B appear effective.
The optimal dose of lipid formulations of amphotericin B has
not been determined, but AmBisome has been effective at doses
of 4 mg/kg body weight/daily (356,357) (AI).
After a 2-week period of successful induction therapy,
consolidation therapy should be initiated with fluconazole
administered for 8 weeks or until CSF cultures are sterile
Vol. 53 / RR-15 Recommendations and Reports 33
(355,356,358) (AI). Itraconazole is an acceptable though less
effective alternative (358) (BI). Combination therapy with
fluconazole (400–800 mg/daily) and flucytosine is effective
for treating AIDS-associated cryptococcal meningitis (359).
However, because of the toxicity of this regimen (especially
myelotoxicity and gastrointestinal toxicity), it is recommended
only as an alternative option for persons unable to tolerate or
unresponsive to standard treatment (BII).
Increased intracranial pressure might cause clinical
deterioration despite a microbiologic response, probably
reflects cerebral edema, and is more likely if the CSF opening
pressure is >200 mm H2O (355, 360). In one large clinical
trial, 93% of deaths occurring within the first 2 weeks of
therapy and 40% of deaths occurring within weeks 3–10 were
associated with increased intracranial pressure (360). The
opening pressure should always be measured when a lumbar
puncture is performed (360).
The principal initial intervention for reducing symptomatic
elevated intracranial pressure is repeated daily lumbar punctures
(AII). CSF shunting should be considered for patients in whom
daily lumbar punctures are no longer being tolerated or whose
signs and symptoms of cerebral edema are not being relieved
(BIII). Whether reducing opening pressure leads to a reduction
in the mortality and morbidity associated with cerebral edema
is unknown. No role exists for acetazolamide to reduce
intracranial pressure (DIII).
Monitoring and Adverse Events
A repeat lumbar puncture to ensure clearance of the
organism is not required for those with cryptococcal meningitis
and improvement in clinical signs and symptoms after
initiation of treatment. If new symptoms or clinical findings
occur after 2 weeks of treatment, a repeat lumbar puncture
should be performed.
Serum cryptococcal antigen is not helpful in management
because changes in titer do not correlate with clinical response
(354). Serial measurement of CSF cryptococcal antigen might
be more useful but requires repeated lumbar punctures and is
not routinely recommended for monitoring response.
Patients treated with amphotericin B should be monitored
for dose-dependent nephrotoxicity and electrolyte
disturbances. Supplemental colloidal fluids might reduce the
risk for nephrotoxicity during treatment (CIII). Infusion-
related adverse reactions (e.g., fever, chills, renal tubular
acidosis, hypokalemia, orthostatic hypotension, tachycardia,
nausea, headache, vomiting, anemia, anorexia, and phlebitis)
might be ameliorated by pretreatment with acetaminophen,
diphenhydramine, or corticosteroids administered
approximately 30 minutes before the infusion (CIII). Lipid
formulations of amphotericin B are less toxic.
Azotemic patients receiving flucytosine should have their
blood levels monitored to prevent bone marrow suppression
and gastrointestinal toxicity; peak serum levels (2 hours after
an oral dose) should be <100 mg/mL. Persons treated with
fluconazole should be monitored for hepatotoxicity, although
this toxicity is rare.
Management of Treatment Failure
 Treatment failure is defined as clinical deterioration despite
appropriate therapy (assuming increased intracranial pressure
is being adequately treated as described previously), the lack
of improvement in signs and symptoms after 2 weeks of
appropriate therapy, or relapse after an initial clinical response.
A repeat lumbar puncture should be performed (if a shunt is
not already in place) to ascertain whether or not intracranial
pressure has increased. Although fluconazole resistance has
been reported with C. neoformans, it is rare. Susceptibility
testing is not routinely recommended, and susceptibility
techniques have not been standardized for this purpose.
The optimal therapy for those with treatment failure is not
known. Those who have failed on fluconazole should be treated
with amphotericin B with or without flucytosine as indicated
previously, and therapy should be continued until a clinical
response occurs (BIII). Higher doses of fluconazole in
combination with flucytosine also might be useful (BIII).
Unlike caspofungin, voriconazole has activity against
Cryptococcus spp. in vitro and might be an alternative.
Prevention of Recurrence
Patients who have completed initial therapy for cryptococcosis
should be administered lifelong suppressive treatment (i.e.,
secondary prophylaxis or chronic maintenance therapy) (AI),
unless immune reconstitution occurs as a consequence of ART.
Fluconazole (AI) is superior to itraconazole (BI) for preventing
relapse of cryptococcal disease and is the preferred drug
(361,362).
Adult and adolescent patients appear at low risk for recurrence
of cryptococcosis when they have successfully completed a course
of initial therapy, remain asymptomatic with regard to signs
and symptoms of cryptococcosis, and have a sustained increase
(i.e. >6 months) in their CD4+ T lymphocyte counts to
>100–200 cells/µL after ART. The numbers of such patients
who have been evaluated remain limited. On the basis of these
observations and inference from more extensive data regarding
safety of discontinuing secondary prophylaxis for other
opportunistic infections during advanced HIV-1 disease,
discontinuing chronic maintenance therapy among such patients
is a reasonable consideration (CIII). Certain HIV specialists
would perform a lumbar puncture to determine if the CSF is
culture-negative and antigen negative before stopping therapy
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even if patients are asymptomatic; other specialists do not believe
this is necessary. Maintenance therapy should be re-initiated if
the CD4+ T lymphocyte count decreases to <100–200 cells/µL
(AIII).
Special Considerations During Pregnancy
Diagnosis and treatment for cryptococcosis among
HIV-1–infected pregnant women are the same as for
nonpregnant women. Considerations about the use of
amphotericin B, fluconazole, and itraconazole are the same as
those for mucocutaneous and invasive candidiasis (i.e.,
amphotericin B should be used in the first trimester to avoid
the potential for teratogenicity with fluconazole or itraconazole).
Flucytosine is teratogenic in rats at high doses, but not at
doses similar to human exposure (363). No reports exist about
its use in the first trimester of pregnancy in humans.
Flucytosine might be metabolized to 5-fluoruracil. It should
be used in pregnancy only if clearly indicated.
Histoplasmosis
Epidemiology
 Histoplasmosis is caused by the dimorphic fungus
Histoplasma capsulatum and occurs in 2%–5% of patients with
AIDS who reside in areas in the United States where the disease
is endemic (e.g., the Midwest and Puerto Rico) and who are
not receiving ART (364–366). In areas where the disease is
not endemic, it most often occurs among those who have
previously lived in an area where the disease is endemic.
Histoplasmosis is acquired by inhalation of microconidia
of the mycelial phase of the organism, but reactivation of latent
infection might be a mechanism for disease in certain patients.
Disseminated histoplasmosis usually occurs among persons
with CD4+ T lymphocyte counts <150 cells/µL; localized
pulmonary histoplasmosis might occur among persons with
CD4+ T lymphocyte counts >300 cells/µL. The incidence of
histoplasmosis appears to have declined with the use of potent
ART.
Clinical Manifestations
The most common clinical presentation of histoplasmosis
among patients with AIDS is disseminated multiorgan disease.
Patients usually have fever, fatigue, and weight loss; respiratory
tract symptoms of cough, chest pain, and dyspnea might occur
in up to 50% of patients (367). Symptoms and signs might be
limited to the respiratory tract for those with higher CD4+ T
lymphocyte counts and localized pulmonary histoplasmosis.
Septic shock syndrome occurs in <10% of patients. CNS,
gastrointestinal, and cutaneous manifestations each occur in
<10% of cases, and other sites might be less commonly involved.
Diagnosis
Detection of Histoplasma antigen in blood or urine is a
sensitive method for rapid diagnosis of disseminated
histoplasmosis but insensitive for pulmonary infection.
Antigen is detected in the urine of 95% and serum of 85% of
patients with disseminated histoplasmosis (368) and might
be present in bronchoalveolar lavage fluid or CSF of patients
with pulmonary or meningeal involvement. Fungal stain of
blood smears or tissues also might yield a rapid diagnosis, but
the sensitivity is <50%.
H. capsulatum can be isolated from blood, bone marrow,
respiratory secretions or localized lesions in >85% of cases,
but isolation can take 2–4 weeks (367,368). Serologic tests
are positive in approximately two thirds of cases but are rarely
helpful in the acute diagnosis of histoplasmosis disease.
Diagnosis of meningitis poses added difficulties. Fungal
stains are usually negative, and CSF cultures are positive in no
more than half of cases (369). Antigen or anti-Histoplasma
antibodies can be detected in the CSF in up to 70% of cases.
Among certain patients, none of these tests are positive, and a
presumptive diagnosis of Histoplasma meningitis might be
appropriate if the patient has disseminated histoplasmosis and
findings of CNS infection not explained by another cause.
Treatment Recommendations
 Patients with severe disseminated histoplasmosis who meet
one or more selected criteria (temperature >102oF [>39oC],
systolic blood pressure <90 mm Hg, pO2 <70 torr, weight
loss >5%, Karnofsky performance score <70, hemoglobin <10
g/dL, neutrophil count <1000 cells/µL, platelet count
<100,000 cells/µL, aspartate aminotransferase >2.5 times
normal, bilirubin or creatinine >2 times normal, albumin <3.5
g/dL, coagulopathy, presence of other organ system
dysfunction, or confirmed meningitis) should be treated with
intravenous amphotericin B, either the deoxycholate
formulation or liposomal amphotericin B, for the first 3–10
days until they clinically improve (370,371) (AI). In a
randomized clinical trial, liposomal amphotericin B was more
effective than the standard deoxycholate formulation (371),
inducing a more rapid and more complete response, lowering
mortality, and reducing toxicity (BI). Intravenous itraconazole
200 mg/day after an initial higher dose induction period might
be used for persons who cannot tolerate amphotericin B (BIII).
Patients responding well after completion of initial
amphotericin B therapy for 3–10 days might be switched to
oral therapy with itraconazole capsules to complete 12 weeks
of treatment and then placed on maintenance treatment (372)
(AII). Itraconazole solution would be logical to use, but no
trials document efficacy and tolerability in this setting.
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Fluconazole 800 mg daily is less effective than itraconazole
(373), but is recommended as an alternative if patients cannot
tolerate itraconazole (CII).
For persons with confirmed meningitis, amphotericin B
should be continued for 12–16 weeks, followed by maintenance
therapy (AII). Fluconazole has been recommended previously
among HIV-1–uninfected persons with meningitis following
amphotericin B; however, because of the data documenting
efficacy of itraconazole in persons with HIV-1 disease and
nonmeningeal histoplasmosis, itraconazole should be used in
this setting (AII). Among persons with mild illness, therapy
with itraconazole capsules for 12 weeks is recommended (AII).
Acute pulmonary histoplasmosis in an HIV-1–infected
patient with intact immunity, as indicated by a CD4+ T
lymphocyte count >500 cells/µL, might not require therapy
and should be managed in a similar way to infection in an
otherwise noncompromised host (370) (AIII).
Prevention of Recurrence
Patients who complete initial therapy for histoplasmosis
should be administered lifelong suppressive treatment (i.e.,
secondary prophylaxis or chronic maintenance therapy) with
itraconazole 200 mg twice daily (373) (AI). Certain specialists
recommend serum levels be tested to ensure free itraconazole
concentrations of at least 1 mg/mL or free plus hydroxylated
metabolite of 2 µg/mL. The metabolite also has antifungal
activity.
Although patients might be at low risk for recurrence of
systemic mycosis when their CD4+ T lymphocyte counts
increase to >100 cells/µL in response to ART, the number of
patients who have been evaluated is insufficient to warrant a
recommendation to discontinue secondary prophylaxis in this
setting.
Special Considerations During Pregnancy
Treatment is the same as for nonpregnant adults. Because
fluconazole is teratogenic in high doses in animal studies and
itraconazole is teratogenic in high doses among rats and mice,
as with other invasive fungal infections, amphotericin B should
be substituted for itraconazole or fluconazole (if indicated) in
the first trimester (BIII).
Coccidioidomycosis
Epidemiology
Coccidioidomycosis is caused by Coccidioides immitis and
occurs predominantly in the Southwestern United States where
the disease is endemic. However, sporadic cases might be
diagnosed in areas where the disease is not endemic as a result
of reactivation of previous infection. The incidence of disease
in endemic areas was from 2%–5% in the pre-ART era. Increased
risk is associated with extensive exposure to disturbed soil.
Both localized pneumonia and disseminated infection are
usually observed in those with CD4+ T lymphocyte counts
<250 cells/µL. The use of ART appears to have reduced the
incidence in this patient population.
Clinical Manifestations
 The two most common clinical presentations of
coccidioidomycosis are disseminated disease and meningitis.
Disseminated disease is associated with generalized
lymphadenopathy, skin nodules or ulcers, peritonitis, liver
abnormalities, and bone and joint involvement. Localized
meningeal disease results in symptoms of lethargy, fever,
headache, nausea or vomiting, or confusion and occurs in
approximately 10% of patients. Among those with meningeal
involvement, CSF analysis typically demonstrates a
lymphocytic pleocytosis with CSF glucose levels <50 mg/dL.
CSF protein might be normal or mildly elevated.
Diagnosis
 The diagnosis of coccidioidomycosis is confirmed by culture
of the organism from clinical specimens or by demonstration
of the typical spherule on histopathological examination of
involved tissue. Blood cultures are positive in a minority of
patients. C. immitis serology is frequently positive among
HIV-1–infected patients with coccidioidomycosis and is useful
in diagnosis. Complement fixation serology (IgG) is generally
positive in the CSF in coccidioidal meningitis.
Treatment Recommendations
For nonmeningeal pulmonary or disseminated disease,
amphotericin B is the preferred initial therapy (374,375) (AII).
Data evaluating lipid formulations of amphotericin B are
limited such that appropriate dosing recommendations cannot
be made.
Therapy with amphotericin B should continue until clinical
improvement is observed, which usually occurs after
administration of 500–1,000 mg. Certain specialists would
use an azole antifungal concurrently with amphotericin B
(BIII). Fluconazole or itraconazole might be appropriate
alternatives for patients with mild disease (374,375) (BIII).
Coccidioidal meningitis should be treated with fluconazole,
which has been reported to be successful in approximately
80% of patients with C. immitis meningitis (376) (AII).
Treatment for patients with meningeal disease requires
consultation with a specialist. Intrathecal amphotericin B is
the most accepted alternative but is toxic (CIII).
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Prevention of Recurrence
Patients who complete initial therapy for coccidioidomycosis
should be administered lifelong suppressive therapy (i.e.,
secondary prophylaxis or chronic maintenance therapy) using
either fluconazole 400 mg daily or itraconazole 200 mg twice
daily (AII). Although patients might be at low risk for
recurrence of systemic mycosis when their CD4+ T lymphocyte
counts increase to >100 cells/µL in response to ART, the
numbers of patients who have been evaluated are insufficient
to warrant a recommendation to discontinue secondary
prophylaxis in this setting.
Special Considerations During Pregnancy
 Coccidioides infections appear to be more likely to
disseminate if acquired during pregnancy among HIV-
uninfected women, with the risk increasing with increasing
gestational age (377). This increased risk might be related to
the agonistic effect of estradiol and progesterone, both found
at high levels during pregnancy, on the growth of C. immitis
(378). The risk for dissemination among HIV-1–infected
pregnant women has not been evaluated. Invasive fungal
infections should be treated the same in pregnancy as in the
nonpregnant woman, with the exception that amphotericin
B is the preferred agent in the first trimester because of the
potential teratogenic risks of the azoles if efficacy is expected
to be superior or similar to that of the azoles (BIII).
Aspergillosis
Epidemiology
Aspergillosis, most frequently caused by Aspergillus fumigatus
but occasionally by other Aspergillus species, was more common
before the advent of potent ART among patients with advanced
HIV-1 disease (379). Specific risk factors include neutropenia,
low CD4+ T lymphocyte count, use of corticosteroids,
exposure to broad spectrum antibacterial therapy, and previous
pneumonia or other underlying lung disease. Patients who
have had HIV-1–associated aspergillosis diagnosed typically
have extremely low CD4+ T lymphocyte counts (i.e., <50
cells/µL), a history of other AIDS-defining opportunistic
infections, and are not receiving ART.
Clinical Manifestations
Two major syndromes have been described among patients
with AIDS: respiratory tract disease (either semi-invasive
pseudomembranous tracheitis or invasive pneumonitis) and
CNS infection occurring as a febrile diffuse meningoencepha-
litis syndrome with vascular infarction as a central feature
(based on the predilection of Aspergillus organisms to invade
blood vessel walls). Semi-invasive pseudomembranous trache-
itis is associated with fever, cough, dyspnea, stridor or wheez-
ing caused by airway constriction, culminating in airway
obstruction if untreated. Endoscopic examination demon-
strates a confluent, exudative pseudomembrane adherent to
the tracheal wall. Invasive pneumonitis occurs with fever,
cough, dyspnea, chest pain, hemoptysis, and hypoxemia; chest
radiograph demonstrates either a diffuse interstitial pneumoni-
tis or a localized wedge-shaped dense infiltrate representing
pulmonary infarction, related to the predilection of the
organisms for invasion of vascular endothelium.
Diagnosis
A definitive diagnosis requires the presence of relevant
clinical signs and symptoms and the histopathologic
demonstration of organisms in biopsy specimens obtained
from involved sites or from a site that is expected to be sterile
(e.g., liver or brain). A presumptive diagnosis of respiratory
tract disease can be made in the absence of a tissue biopsy if
Aspergillus spp. are cultured from a respiratory sample, a
compatible lesion or syndrome is present, and no alternative
causative process is identified. Serologic testing is not helpful.
Treatment Recommendations
 The recommended treatment for invasive aspergillosis is
voriconazole. Amphotericin B, either conventional or lipid
formulations, in doses equivalent to 1 mg/kg body weight/
daily of standard amphotericin B is an alternative regimen
(AIII). Voriconazole has not been studied in this patient
population. Caspofungin is approved for patients failing to
tolerate or improve with standard therapy; however, it has not
been studied in this patient population.
Monitoring and Adverse Events
Patients should be monitored for adverse effects related to
amphotericin B. Airway obstruction can result from extensive
pseudomembrane formation in those with tracheitis.
Pulmonary infarction and progressive interstitial pneumonitis
can lead to respiratory failure.
Management of Treatment Failure
The overall prognosis is poor among patients with advanced
immunosuppression and in the absence of effective ART.
Treatment failure is generally defined as failure to respond to
initial therapy or progression of clinical signs and symptoms
despite appropriate therapy.
No data are available to guide recommendations for the
management of treatment failure. If amphotericin B was used
initially, substitution with voriconazole might be considered;
the alternative approach would be rational for those who began
therapy with voriconazole (BIII).
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Prevention of Recurrence
No data are available to base a recommendation for or against
chronic maintenance or suppressive therapy among those who
have successfully completed an initial course of treatment (CIII).
Special Considerations During Pregnancy
As with other invasive fungal infections, aspergillosis should
be treated the same in pregnancy as in the nonpregnant adult,
with the exception that amphotericin B is the preferred agent
in the first trimester because of the potential teratogenic risks
for the azoles, if efficacy is expected to be superior or similar
to that of the azoles (BIII).
Cytomegalovirus Disease
Epidemiology
 Cytomegalovirus (CMV) is a double-stranded DNA virus
in the Herpesvirus family that might reactivate to cause
disseminated or localized end-organ disease among patients
with advanced immunosuppression who have been previously
infected with CMV. The majority of infections derive from
reactivation of latent infection.
Before potent ART, an estimated 30% of patients with AIDS
experienced CMV retinitis some time between the diagnosis
of AIDS and death (380–382). Incidence for new cases of
CMV end-organ disease have reached <2–3 cases per 100
person-years; for those with established CMV retinitis,
recurrences continue at a rate estimated at <25% of the peak
during the mid-1990s.
End•organ disease caused by CMV occurs among persons
with advanced immunosuppression, typically those with CD4+
T lymphocyte counts <50 cells/µL, who are either not receiving
or have failed to respond to ART (380–382). Other risk factors
include previous OIs, particularly MAC disease, and high
plasma HIV-1 RNA levels (>100,000 copies/mL).
Clinical Manifestations
Retinitis is the most common clinical manifestation of CMV
end-organ disease. CMV retinitis usually occurs as unilateral
disease, but in the absence of therapy, viremic dissemination
results in bilateral disease in the majority of patients.
Peripheral retinitis might be asymptomatic or present with
floaters, scotomata, or peripheral visual field defects. Central
retinal lesions or lesions impinging on the macula are associated
with decreased visual acuity or central field defects. The
characteristic ophthalmologic appearance of CMV lesions
includes perivascular fluffy yellow-white retinal infiltrates,
typically described as a focal necrotizing retinitis, with or
without intraretinal hemorrhage, and with little inflammation
of the vitreous unless immune recovery with potent ART
intervenes (380). Blood vessels near the lesions might appear
to be sheathed. Occasionally, the lesions might have a more
granular appearance.
In the absence of ART or specific anti-CMV therapy, retinitis
invariably progresses, usually within 10–21 days after
presentation. Progression of retinitis occurs in “fits and starts”
and causes a characteristic brushfire pattern, with a granular,
white leading edge advancing before an atrophic, gliotic scar.
Colitis is the second most common manifestation, occurring
in 5%–10% of persons with AIDS and CMV end-organ
disease (381). The most frequent clinical manifestations are
fever, weight loss, anorexia, abdominal pain, debilitating
diarrhea, and malaise. Extensive mucosal hemorrhage and
perforation can be life-threatening complications.
Esophagitis caused by CMV, which occurs in <5%–10% of
persons with AIDS who develop CMV end-organ disease,
causes fever, odynophagia, nausea, and occasionally mid-
epigastric or retrosternal discomfort (366). CMV pneumonitis
is uncommon, but when it occurs, it presents with shortness
of breath, dyspnea on exertion, a nonproductive cough, and
hypoxemia, associated with interstitial infiltrates on chest
radiograph.
CMV neurologic disease causes dementia, ventriculo-
encephalitis, or ascending polyradiculomyelopathy (382).
Patients with dementia typically have lethargy, confusion, and
fever, but the clinical presentation might mimic that of
HIV-1 dementia. CSF generally demonstrates lymphocytic
pleocytosis (although a mixture of neutrophils and lympho-
cytes might be seen), low-to-normal glucose levels, and
normal-to-elevated protein levels. Patients with ventriculo-
encephalitis have a more acute course, with focal neurologic
signs, often including cranial nerve palsies or nystagmus, and
rapid progression to death. Periventricular enhancement of
CT or MRI images is indicative of CMV ventriculoencephalitis
rather than HIV-1–related neurologic disease. CMV
polyradiculomyelopathy causes a Guillian-Barre–like syn-
drome characterized by urinary retention and progressive
bilateral leg weakness. The clinical symptoms generally progress
over several weeks to include loss of bowel and bladder con-
trol and to flaccid paraplegia. A spastic myelopathy has been
reported and sacral paresthesia might occur. The CSF gener-
ally indicates a neutrophilic pleocytosis (usually 100–200
neutrophils/mL and some erythrocytes) accompanied by
hypoglycorrhachia and elevated protein levels.
Diagnosis
 CMV viremia can be detected by PCR, antigen assays, or
blood culture and is generally detected in end-organ disease,
but viremia also might be present in the absence of end-organ
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disease (383–387). The presence of serum antibodies to CMV
is not diagnostically useful. A negative IgG antibody level
indicates that CMV is unlikely to be the cause of the disease
process being investigated (although rarely, primary CMV
infection occurs and is associated with end-organ disease), but
certain patients with advanced immunosuppression might
serorevert from antibody positive to antibody negative; as a
result, a negative CMV IgG antibody test does not definitively
eliminate the possibility of CMV disease.
The diagnosis of CMV retinitis is generally made on the basis
of recognition of characteristic retinal changes observed on
funduscopic examination by an experienced ophthalmologist.
The demonstration of mucosal ulcerations on endoscopic
examination combined with colonoscopic or rectal biopsy with
histopathological demonstration of characteristic intranuclear
and intracytoplasmic inclusions are required for the diagnosis
of CMV colitis (381). The diagnosis of CMV esophagitis is
established by the presence of extensive large, shallow ulcers of
the distal esophagus and biopsy evidence of intranuclear
inclusion bodies in the endothelial cells with an inflammatory
reaction at the edge of the ulcer (366,381).
Culturing CMV from a biopsy or cells brushed from the
colon or the esophagus is not sufficient to establish the
diagnosis of CMV colitis or esophagitis because certain persons
with low CD4+ T lymphocyte counts might be viremic and
have positive cultures for CMV in the absence of clinical disease
(366). Diagnosis of CMV pneumonitis should be made in
the setting of pulmonary interstitial infiltrates and
identification of multiple CMV inclusion bodies in lung tissue,
and the absence of other pathogens that are more commonly
associated with pneumonitis in this population (385). CMV
neurologic disease is diagnosed on the basis of a compatible
clinical syndrome and the presence of CMV in cerebrospinal
fluid or brain tissue (382,387). Detection of CMV is greatly
enhanced by PCR in this setting (383,387).
Treatment Recommendations
The choice of initial therapy for CMV retinitis should be
individualized based on the location and severity of the
lesion(s), the level of underlying immune suppression, and
other factors such as concomitant medications and ability to
adhere to treatment (AIII). Oral valganciclovir, intravenous
ganciclovir, intravenous ganciclovir followed by oral
valganciclovir, intravenous foscarnet, intravenous cidofovir,
and the ganciclovir intraocular implant coupled with
valganciclovir are all effective treatments for CMV retinitis
(388–393) (AI).
The ganciclovir intraocular implant plus oral valganciclovir
is superior to once daily intravenous ganciclovir (and
presumably to once-daily oral valganciclovir) for preventing
relapse of retinitis (388–393) (AI). For this reason, certain
HIV specialists recommend the intraocular implant plus
valganciclovir as the preferred initial therapy, particularly for
patients with immediately sight-threatening lesions (adjacent
to the optic nerve or fovea); others prefer oral valganciclovir
alone (BII).
Among patients with peripheral lesions that are not
immediately sight-threatening, oral valganciclovir is preferable
to the ganciclovir intraocular implant, intravenous ganciclovir,
or intravenous foscarnet (AII) (391) because of its greater ease
of administration and lack of surgical or catheter-associated
complications. However, any of the treatment regimens can
be chosen because epidemiologic studies and clinical trials have
not demonstrated substantially reduced rates of loss of visual
acuity among patients treated with the ganciclovir implant
compared with those treated with systemic therapies (AII)
(392,393).
Certain clinicians would not treat small peripheral CMV
retinitis lesions if ART is to be initiated soon because immune
recovery might ultimately control the retinitis. However,
immune recovery uveitis might be more common among
patients given less aggressive anti-CMV therapy (394–397).
Therefore, treatment of CMV retinitis until sufficient immune
recovery occurs (i.e., CD4+ T lymphocyte count >100 cells/µL
for 3–6 months) is still preferred (AIII).
For therapy of colitis or esophagitis, the majority of specialists
would treat with intravenous ganciclovir or foscarnet (or with
oral valganciclovir if symptoms are not severe enough to
interfere with oral absorption) for 21–28 days (BII) or until
signs and symptoms have resolved. Certain HIV specialists
would withhold therapy unless moderate to severe symptoms
justify the use of systemic treatment (BIII) if ART is soon to
be initiated or can be optimized. Treatment should be
considered for persons with histologic evidence of CMV
pneumonitis who do not respond to treatment of other
pathogens (AIII).
For neurological disease, initiating therapy promptly is
critical for an optimal clinical response. Although combination
treatment with ganciclovir and foscarnet might be preferred
as initial therapy to stabilize disease and maximize response
(BII), this approach is associated with substantial rates of
adverse effects, and optimal treatment for neurologic disease
if ART can be optimized is unknown.
Studies are underway to evaluate the utility of pre-emptive
therapy with systemic treatment among patients with CMV
viremia and no evidence of organ system disease. Until such
studies are completed, treatment of CMV viremia in the
absence of organ system involvement is not recommended
(DIII).
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No data are available to demonstrate that starting ART among
treatment-naïve patients with CMV retinitis would have an
adverse effect on retinitis, gastrointestinal disease, or pneumonitis,
or worsen immune recovery uveitis if this occurs. Therefore, no
reason exists to delay initiation of appropriate ART, which should
be administered to those with acute CMV retinitis, gastrointestinal
disease, or pneumonitis (BIII). Although, no data indicate that
immune recovery inflammatory reactions worsen CMV
neurologic disease syndromes, because of the localized morbidity
that might occur with such an inflammatory reaction, a brief
delay in initiation of ART in this setting until clinical improvement
occurs might be prudent (CIII).
Monitoring and Adverse Events
Management of CMV retinitis requires close monitoring
by an experienced ophthalmologist and the primary clinician.
Dilated indirect ophthalmoscopy should be performed at the
time of diagnosis of CMV retinitis, after completion of
induction therapy, 1 month after the initiation of therapy,
and monthly thereafter while the patient is on anti-CMV
treatment (AIII). Monthly fundus photographs, using a
standardized photographic technique that documents the
appearance of the retina, provide the optimum method for
following patients and detecting early relapse (AIII).
Adverse effects of ganciclovir include neutropenia,
thrombocytopenia, nausea, diarrhea, and renal dysfunction.
Adverse effects of foscarnet include anemia, nephrotoxicity,
electrolyte abnormalities, and neurologic dysfunction. Seizures
have been reported with both ganciclovir and foscarnet. For
patients receiving ganciclovir or foscarnet, monitoring of
complete blood counts and serum electrolytes and renal
function should be performed twice weekly during induction
therapy and once weekly thereafter (AIII). Cidofovir is
associated with dose-related nephrotoxicity and hypotony. For
patients receiving intravenous cidofovir, blood urea nitrogen,
creatinine, and urinalysis should be performed before each
infusion; administration of the drug is contraindicated if renal
dysfunction or proteinuria is detected.
Immune recovery uveitis is an immunologic reaction to
CMV characterized by inflammation in the anterior chamber
or vitreous in the setting of immune recovery after initiation
of ART and is generally observed among those with a
substantial rise in CD4+ T lymphocyte counts in the 4–12
weeks after initiation of ART (394–397). Ocular complications
of uveitis include macular edema and the development of
epiretinal membranes, which can cause loss of vision.
Treatment usually requires periocular corticosteroids or short
courses of systemic corticosteroids. Estimated response rates
are approximately 50%.
Management of Treatment Failure
For patients without immune recovery after initiation of
ART and who are receiving chronic maintenance therapy with
systemic anti-CMV drugs, relapse of retinitis is likely to occur
over time. Although drug resistance might be responsible for
some episodes of relapse, early relapse is most often caused by
the limited intraocular penetration of systemically
administered drugs (398–400). Because it results in greater
drug levels in the eye, the placement of a ganciclovir implant
in a patient who has relapsed while receiving systemic treatment
(IV ganciclovir or oral valganciclovir) is generally
recommended and often will control the retinitis for 6–8
months until the implant requires replacement (401,402)
(BIII).
Reinduction with the same drug followed by reinstitution
of maintenance therapy can control the retinitis, although for
progressively shorter periods of time (403), and the majority
of specialists recommend this approach for initial treatment
of relapsed disease (AII). Changing to an alternative drug at
the time of first relapse typically does not result in superior
control of the retinitis but should be considered if drug
resistance is suspected or if side effects or toxicities interfere
with optimal courses of the initial agent (403) (AIII).
Combination ganciclovir and foscarnet are generally superior
to systemic therapy with either agent alone for patients with
relapsed retinitis (403) but is accompanied by greater toxicity;
this approach might be considered for patients who are not
candidates for other alternatives (BI).
Drug resistance occurs among patients receiving long-term
therapy (404–406). Reported rates typically are <10% during
the first 3 months of therapy but increase to 25%–30% by 9
months of therapy (404–406). Reported rates are similar for
ganciclovir, foscarnet, and cidofovir (404,405). Low-level
resistance to ganciclovir occurs through mutations in the CMV
UL97 (phosphotransferase) gene, and high-level resistance to
ganciclovir typically occurs because of mutations in both the
CMV UL97 and UL54 (DNA polymerase) genes (407–410).
Resistance to foscarnet and resistance to cidofovir each occur
because of mutations in the CMV UL54 gene. High-level
resistance to ganciclovir is frequently associated with cross-
resistance to cidofovir (409) and occasionally to foscarnet
(411).
Although early relapse is generally not a result of resistance,
later relapse often is. Because patients with resistant CMV
nearly always have mutations in the CMV UL97 gene, and
because a limited number of mutations produce the majority
of cases of resistance, resistance testing in peripheral blood
using a CMV DNA PCR assay and sequencing for CMV
UL97 mutations or using a point mutation assay (412,413)
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might be reasonable for patients who relapse on therapy.
Although this approach also has not been validated, certain
specialists would recommend performance of resistance testing
using this technique, if available, to guide therapy in those
with repeated relapses of CMV disease (CIII).
Patients with low-level ganciclovir-resistant isolates in the
eye might respond to a ganciclovir implant because of the
higher local levels of ganciclovir resulting from this form of
therapy. However, patients with high-level ganciclovir resistant
isolates typically will not respond and will require a switch to
alternative therapy. Repetitive intravitreous injections of
fomivirsen can be used for relapsed retinitis (BI) but should
be combined with systemic therapy (414) (AI).
Prevention of Recurrence
 After induction therapy, secondary prophylaxis (i.e., chronic
maintenance therapy) is recommended for life (90,386–390)
(AI), unless immune reconstitution occurs as a result of ART.
Regimens demonstrated to be effective for chronic suppression
in randomized, controlled clinical trials include parenteral or
oral ganciclovir, parenteral foscarnet, combined parenteral
ganciclovir and foscarnet, parenteral cidofovir, and (for retinitis
only) ganciclovir administration through intraocular implant
or repetitive intravitreous injections of fomivirsen (AI). Oral
valganciclovir has been approved by FDA for both acute
induction therapy and for maintenance therapy, although
published data are limited.
Repetitive intravitreous injections of ganciclovir, foscarnet,
and cidofovir have been effective for secondary prophylaxis of
CMV retinitis in uncontrolled case series. Intraocular therapy
alone does not provide protection to the contralateral eye or
to other organ systems and typically is combined with oral
valganciclovir.
The choice of a chronic maintenance regimen for patients
treated for CMV disease should be made in consultation with
a specialist. For patients with retinitis, this decision should be
made in consultation with an ophthalmologist and should
take into consideration the anatomic location of the retinal
lesion, vision in the contralateral eye, the immunologic and
virologic status of the patient, and the patient’s response to
ART.
Patients with immediately vision-threatening lesions need
prompt anti-CMV therapy because progression of the retinitis
can occur during the time in which immune recovery is
occurring. Daily oral ganciclovir is less effective than daily
intravenous ganciclovir for maintenance therapy (389) and
with the availability of oral valganciclovir should no longer be
used (DIII) (391). Patients with immediately sight-threatening
retinitis still might benefit most from the use of the ganciclovir
implant and its superior ability to control retinitis progression
(BIII). However, replacement of the ganciclovir implant at
6–8 months might not be necessary for those with sustained
immune recovery. If the ganciclovir implant is used, it should
be combined with oral valganciclovir until immune recovery
occurs (BIII).
Chronic maintenance therapy is not routinely recommended
for gastrointestinal disease but should be considered if relapses
occur (BII). A role for maintenance therapy for CMV
pneumonitis has not been established (CIII).
Discontinuing secondary prophylaxis (chronic maintenance
therapy) should be considered for patients with a sustained
(> 6 months) increase in CD4+ T lymphocyte counts
>100–150 cells/µL in response to ART (415–420) (BII). Such
decisions should be made in consultation with an
ophthalmologist and should take into account such factors as
magnitude and duration of CD4+ T lymphocyte increase,
anatomic location of the retinal lesions, vision in the
contralateral eye, and the feasibility of regular ophthalmologic
monitoring (BII). All patients who have had anti-CMV
maintenance therapy discontinued should continue to undergo
regular ophthalmologic monitoring for early detection of
CMV relapse and for immune recovery vitritis/uveitis (AIII).
Relapse of CMV retinitis occurs among patients whose anti-
CMV maintenance therapies have been discontinued and
whose CD4+ T lymphocyte counts have decreased to <50
cells/µL (420). Therefore, reinstitution of secondary
prophylaxis should occur when the CD4+ T lymphocyte count
has decreased to <100–150 cells/µL (AIII). Relapse has been
reported among patients whose CD4+ T lymphocyte counts
are >100 cells/µL, but such reports are rare. Because of the
potential for rapid relapse of retinitis when CD4+ T
lymphocyte counts decline and the potential for rapid decline
of CD4+ T lymphocyte counts with interruption of ART,
patients with immune reconstitution not receiving CMV
maintenance therapy should still undergo ophthalmologic
monitoring (BIII).
Special Considerations During Pregnancy
 The diagnostic considerations among pregnant women are
the same as for the nonpregnant women. Indications for
treatment of CMV infection during pregnancy are the same
as for those in nonpregnant HIV-1–infected adults (AIII).
For retinal disease, use of intraocular implants or intravitreous
injections for local therapy should be considered in pregnancy
if possible to limit fetal exposure to systemically administered
antiviral drugs (CIII). Close ophthalmologic monitoring must
be maintained, and systemic therapy should then be added as
indicated after delivery.
Ganciclovir is embryotoxic among rabbits and mice and
teratogenic (i.e., cleft palate, anophthalmia, aplastic kidney
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and pancreas, and hydrocephalus) in rabbits (421–423). Safe
use in human pregnancy after organ transplantation has been
reported (421,422). On the basis of very limited data and
weighing toxicity of the various drugs, ganciclovir is the
treatment of choice during pregnancy (BIII). No experience
has been reported with the use of valganciclovir in human
pregnancy. Concerns are expected to be the same as with
ganciclovir. The fetus should be monitored by fetal movement
counting in the third trimester and by periodic ultrasound
monitoring after 20 weeks of gestation to look for evidence of
hydrops fetalis indicating substantial anemia.
Foscarnet is associated with an increase in skeletal anomalies
or variants in rats and rabbits. No experience with use early in
human pregnancy has been reported. A single case report of use
in the third trimester described normal infant outcome (424).
Because primary toxicity is renal, monitoring of amniotic fluid
volumes by ultrasound is recommended weekly after 20 weeks
of gestation to detect oligohydramnios. Cidofovir is embryotoxic
and teratogenic (i.e., meningomyelocele and skeletal
abnormalities) among rats and rabbits. No experience with use
in human pregnancy has been reported.
Rarely, ultrasound findings in the fetus (e.g., cerebral
calcifications, abdominal and liver calcifications, hydrops,
microcephaly, ventriculomegaly, ascites, and echogenic fetal
bowel) might indicate the possibility of in utero CMV infection
among pregnant women with CMV end organ disease (425).
In this case, consideration of invasive testing (i.e., amniocentesis
and fetal umbilical blood sampling) must be individualized based
on clinical history and serologic findings, gestational age,
potential risk for HIV-1 transmission, and maternal preference
(426). Referral to a maternal-fetal medicine specialist for
evaluation, counseling, and potential further testing is
recommended.
On the basis of data in HIV-uninfected women, transmission
of CMV from mother to infant might occur in utero. However,
symptomatic infection in the newborn is usually related to
primary CMV infection in the mother during pregnancy, and
because >90% of HIV-1–infected pregnant women are CMV
antibody positive in the majority of studies, the risk for
symptomatic infection in the fetus is low (427–431).
Therefore, treatment of maternal CMV infection, if
asymptomatic, during pregnancy solely to prevent infant
infection is not indicated (DIII).
Herpes Simplex Virus Disease
Epidemiology
 Infections with human herpes simplex virus type 1 (HSV-1)
and type 2 (HSV-2) are common, with a seroprevalence among
adults of HSV-1 approaching 80% and of HSV-2 among
persons aged >12 years in the United States of 21.9% (432).
Approximately 95% of HIV-1–infected persons are
seropositive for either HSV-1 or HSV-2 (432–434). The
availability of potent ART has not had an impact on these
data.
Clinical Manifestations
HSV orolabialis is the most common manifestation of
HSV-1 infection, presenting with a sensory prodrome in the
affected area, rapidly followed by the evolution of lesions from
papule to vesicle, ulcer, and crust stages on the lips. Ulcerative
lesions are usually the only stage observed on mucosal surfaces.
The course of illness in untreated subjects is 7–10 days. Lesions
recur 1–12 times per year and are often triggered by sunlight
or stress.
HSV genitalis is the more common manifestation of HSV-2
infection. Perineal lesions on keratinylated skin are similar in
appearance and evolution to external orofacial lesions. Local
symptoms include a sensory prodrome consisting of pain and
pruritis. Ulcerative lesions are usually the only stage observed
on vaginal or urethral mucosal surfaces. Mucosal disease is
generally accompanied by dysuria, vaginal, or uretheral
discharge; inguinal lymphadenopathy, particularly in primary
infection, is common with perineal disease (434). In
profoundly immunocompromised patients, extensive, deep,
nonhealing ulceration of the perineum/buttocks might occur.
These lesions have been most often reported in those with
CD4+ T lymphocyte counts of <100 cells/µL and also might
be more commonly associated with acyclovir-resistant virus.
HSV keratitis, neonatal HSV, HSV encephalitis, and
herpetic whitlow are similar in presentation and treatment to
those diseases observed in HIV-seronegative persons but might
be more severe. HSV retinitis occurs as acute retinal necrosis,
occasionally in the setting of HSV encephalitis. HSV
encephalitis occurs among HIV-1–infected persons, but no
evidence indicates that it is more severe or common than
among HIV-uninfected persons.
Diagnosis
 HSV infections are usually diagnosed empirically on the
basis of characteristic skin, mucus membrane, or ophthalmic
lesions. With unusual presentations or lesions that do not
respond to therapy, swabs from a fresh lesion can be submitted
to the diagnostic virology laboratory for Tzanck smear, viral
culture, or HSV antigen detection and subsequent antiviral
susceptibility testing if necessary.
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Treatment Recommendations
 Orolabial lesions can be treated with oral famciclovir,
valacyclovir, or acyclovir for 7 days (AII). Moderate-to-severe
mucocutaneous HSV lesions are best treated initially with
intravenous acyclovir (435–437) (AII). Patients may be
switched to oral therapy after the lesions have begun to regress.
Therapy should be continued until the lesions have completely
healed. Initial or recurrent genital HSV should be treated with
oral famciclovir, valacyclovir, or acyclovir for 7–14 days (AII).
Trifluridine is the treatment of choice for herpes keratitis, one
drop onto the cornea (437) every 2 hours, not to exceed 9
drops/day; it is not recommended for longer than 21 days
(AII). Intravenous acyclovir, 10 mg/kg body weight every 8
hours for 14–21 days, is required for HSV encephalitis (AII).
Monitoring and Adverse Events
 Famciclovir, valacyclovir, and acyclovir might occasionally
be associated with nausea, vomiting, and diarrhea. Rarely,
patients receiving higher doses of valacyclovir or acyclovir
might experience renal dysfunction. For patients receiving
high-dose IV acyclovir, monitoring of renal function is
recommended at initiation of treatment, and once or twice
weekly for the duration of treatment, particularly for those
with underlying renal dysfunction or those receiving prolonged
therapy. Thrombotic thrombocytopenic purpura/hemolytic
uremic syndrome resulting in death has been reported among
HIV-1–infected patients treated with high-dose valacyclovir
but has rarely been reported at conventional doses among
persons with HIV-1 disease (438).
Management of Treatment Failure
Treatment failure related to resistance to antiviral drugs
should be suspected if lesions do not indicate signs of resolution
within 7–10 days after initiation of therapy. Among
immunocompromised patients with suspected acyclovir-
resistant HSV, a lesion culture should be obtained and, if virus
is isolated, susceptibility testing performed to confirm drug
resistance (437).
The treatment of choice for acyclovir-resistant HSV is IV
foscarnet (439) (AI). Topical trifluridine or cidofovir also has been
used successfully for lesions on external surfaces, although
prolonged application for 21–28 days or longer might be required.
Prevention of Recurrence
 Chronic therapy with acyclovir is not required after lesions
resolve. However, persons who have frequent or severe
recurrences can be administered daily suppressive therapy with
oral acyclovir, oral famciclovir, or oral valacyclovir (438,440)
(AI). Intravenous foscarnet or cidofovir can be used to treat
infection caused by acyclovir-resistant isolates of HSV, which
are routinely resistant to ganciclovir (AII).
Special Considerations During Pregnancy
Diagnosis of mucocutaneous and visceral HSV infections
is the same in pregnancy as among nonpregnant adults.
Treatment of visceral and symptomatic mucocutaneous HSV
infections and suppressive therapy for frequent recurrences
should be offered during pregnancy as they would be for
nonpregnant women (AIII). Acyclovir is the antiviral drug
with the most reported experience in pregnancy and appears
to be safe (441). Acyclovir is the first choice for therapy of
HSV infections in pregnancy (AIII). Valacyclovir is the
prodrug of acyclovir. Although experience with use of this
drug in pregnancy is limited, its safety profile is expected to
be similar to acyclovir (441–444).
Famciclovir was not teratogenic in animal studies but
experience with use during human pregnancy is limited.
Exposures to this drug during pregnancy should be reported
to the Famciclovir Registry (888-669-6682). Because of
potential teratogenicity and toxicity, foscarnet should be
reserved for severe mucocutaneous or visceral HSV infections
that have failed to respond to high dose acyclovir, valacyclovir,
or famciclovir.
An additional concern with HSV during pregnancy is the
potential for transmission to the fetus and neonate. The rate of
transmission to the fetus and neonate among HIV-1–infected
pregnant women co-infected with HSV is not known. Although
isolated cases of in utero transmission with primary infection
during pregnancy among HIV-uninfected women have been
reported, the predominant risk, regardless of HIV-1 co-infection,
is from maternal genital shedding at delivery. Cesarean delivery
is recommended for women with a prodrome or visible HSV
genital lesions at the onset of labor (425) (BIII).
Use of acyclovir in late pregnancy suppresses genital herpes
outbreaks and shedding in late pregnancy among
HIV-seronegative women and might reduce the need for
Cesarean delivery for recurrent HSV (426). However, the safety
and efficacy of this strategy has not been evaluated among
HIV-1–infected women who are more likely to have antibody
to HSV-2 and to have both symptomatic and asymptomatic
reactivation of genital HSV (426). Therefore, the use of
acyclovir specifically to reduce the need for Cesarean delivery
among HIV-1–infected women is not recommended (DIII).
Varicella Zoster Virus Disease
Epidemiology
Up to 95% of the adult population is seropositive for varicella
zoster virus (VZV), and recurrent disease in the form of herpes
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zoster occurs in 3%–5% of all adults but becomes more
prevalent in the elderly and the immunocompromised host.
The incidence of herpes zoster is 15–25 times greater in
HIV-1–infected persons than in the general population and
3–7 times greater than among the elderly. Zoster among
HIV-1–infected adults can occur at any CD4+ T lymphocyte
count; more advanced immunosuppression might be associated
with altered manifestations of VZV infection but does not appear
to substantially alter the overall incidence of VZV.
Clinical Manifestations
Herpes zoster (shingles) might follow a prodrome of pain
that resembles a burn or muscle injury in the affected
dermatome; skin lesions, which are similar to chickenpox in
appearance and evolution, develop in the same dermatome.
Extensive cutaneous dissemination and visceral involvement
have been reported but are rare.
Progressive outer retinal necrosis is a VZV-associated entity
that typically occurs among HIV-1–infected persons with
CD4+ T lymphocyte counts <50 cells/µL. This rapidly
progressive necrotizing herpetic retinopathy is often associated
with dermatomal zoster and is characterized by multifocal
retinal opacification with little or no ocular inflammation
(445,446) and rapid visual loss.
Acute retinal necrosis occurs as a peripheral necrotizing
retinitis with yellowish thumbprint lesions, retinal vascular
sheathing, and vitritis with a high rate of visual loss, often
caused by retinal detachment. This syndrome can occur in
immunologically normal and immunologically deficient
persons. Among patients with HIV-1 infection, acute retinal
necrosis can occur at any CD4+ T lymphocyte count, although
it more often occurs at higher CD4+ T lymphocyte counts,
and progressive outer retinal necrosis more often occurs at
lower CD4+ T lymphocyte counts.
Chickenpox, the principal clinical manifestation of primary
VZV in childhood or adulthood, is uncommon in adults and
adolescents with HIV-1 infection. When chickenpox occurs,
it begins with a respiratory prodrome, followed by the
appearance of pruritic vesiculopapular lesions that are more
numerous on the face and trunk than on the extremities.
Lesions evolve over a 5-day period through macular, papular,
vesicular, pustular, and crust stages. In profoundly
immunocompromised hosts, vesicles can persist for weeks and
coalesce to form large lesions that resemble a burn.
VZV has been associated with transverse myelitis,
encephalitis, and vasculitic stroke among HIV-uninfected
persons. Anecdotal reports of these syndromes exist among
HIV-1–infected patients.
Diagnosis
 Zoster and chickenpox are generally diagnosed empirically
on the basis of the appearance of characteristic lesions. When
lesions are atypical or the diagnosis is uncertain, swabs from a
fresh lesion or a sample of biopsied tissue can be submitted
for viral culture or antigen detection.
Treatment Recommendations
The recommended treatment for localized dermatomal
herpes zoster is famciclovir or valacyclovir for 7–10 days (AII).
If cutaneous lesions are extensive or if clinical evidence of
visceral involvement is observed, intravenous acyclovir should
be initiated and continued until cutaneous lesions and visceral
disease are clearly resolving (447) (AII). Because of its
immunosuppressive effects and the absence of data to support
benefit with its use in this patient population, adjunctive
corticosteroid therapy to prevent postherpetic neuralgia is not
recommended (DIII).
Progressive outer retinal necrosis is rapidly progressive and
leads to profound loss of vision. Because of the rapidity of
disease progression, recommended treatment is high-dose
intravenous acyclovir in combination with foscarnet (AIII).
Acute retinal necrosis typically responds to IV acyclovir,
followed by oral valacyclovir (CIII). Concomitant laser retinal
photocoagulation might be needed to prevent retinal
detachments.
Intravenous acyclovir for 7–10 days is the recommended
initial treatment for immunocompromised adults and
adolescents with chickenpox (448) (AIII). Switching to oral
therapy after the patient has defervesced if no evidence of
visceral involvement exists might be permissible (449) (AII).
Oral acyclovir is the recommended treatment (20 mg/kg body
weight up to a maximum dose of 800 mg four times daily),
but valacyclovir or famciclovir would be reasonable alternatives
(BII).
Monitoring and Adverse Events
Recommendations are the same as for HSV.
Management of Treatment Failure
Treatment failure caused by drug resistance should be
suspected if lesions do not indicate signs of resolution within
10 days of initiation of therapy or if they evolve to a verrucous
appearance. A lesion culture should be obtained, and if virus
is isolated, susceptibility testing performed to confirm antiviral
drug resistance and to support the need for intravenous
therapy. Among patients with suspected or proven acyclovir-
resistant VZV infections, treatment with intravenous foscarnet
is the recommended alternative therapy (439) (AI).
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Prevention of Recurrence
 No drug has been proven to prevent the recurrence of zoster
(shingles) among HIV-1–infected persons.
Special Considerations During Pregnancy
 Diagnosis of zoster and chickenpox during pregnancy is
the same as among nonpregnant adults. Treatment of zoster
during pregnancy should be the same as for nonpregnant
women. Oral valacyclovir therapy is the preferred treatment
for HIV-1–infected pregnant women who experience
chickenpox during pregnancy (BI). Intravenous acyclovir
should be used if parenteral therapy is indicated the same as
for nonpregnant adults with varicella (BI). Women should be
monitored closely for signs of pneumonitis or other systemic
manifestations and hospitalized for observation and potential
administration of intravenous acyclovir for any respiratory
symptoms or signs of severe disease.
HIV-seronegative women with primary VZV infection (i.e.,
chickenpox) during pregnancy have a 0.4% risk for
transmitting infection resulting in congenital varicella
syndrome in the infant when infection occurs at or before 12
weeks of gestation. The risk increases to 2.2% with infection
at 13–20 weeks, and is negligible after 20 weeks (450). Specific
risks among HIV-1–infected women with primary VZV
infection during pregnancy have not been reported. Women
with primary VZV during the first half of pregnancy should
be counseled about the risks and offered detailed ultrasound
surveillance for findings indicative of fetal congenital varicella
syndrome (450). Provision of varicella zoster immune globulin
(VZIG) does not alter the risk of congenital varicella syndrome
(450).
Infants born to women who have chickenpox anytime from
5 days before through 2 days after delivery should receive VZIG
to reduce the severity and mortality rate of neonatal infection
acquired during maternal viremia (450) (AII). The maternal
care provider should notify the infant’s medical provider




Human herpesvirus-8 (HHV-8) is a transmissible DNA
virus with a seroprevalence in the United States of 1%–5%.
The seroprevalence is considerably greater among MSM,
regardless of HIV-1 infection, and is also much higher in
certain Mediterranean countries (10%–20%) and in parts of
sub-Saharan Africa (30%–80%). HHV-8 is associated with
all forms of Kaposi sarcoma (i.e., classic, endemic, transplant-
related, and AIDS-related), and certain rare neoplastic
disorders (e.g., primary effusion lymphoma and multicentric
Castleman disease). The precise pathogenesis is unclear even
though seroconversion to HHV-8 precedes the development
of these tumors (451). Patients who are HHV-8 seropositive
and have HHV-8 DNA in their peripheral blood have a greatly
enhanced risk (approximately ninefold) for experiencing
Kaposi sarcoma compared with HHV-8 seropositive men
without HHV-8 DNA in their blood (452).
The overall incidence of Kaposi sarcoma was as high as 20%
among patients with AIDS before the advent of effective ART.
However, even before the widespread use of ART, the incidence
had declined, which certain specialists attribute to the use of
ganciclovir, foscarnet, and cidofovir for the acute and
maintenance treatment of CMV disease (based on data
demonstrating that these agents inhibit the replication of
HHV-8 in vitro) (453–455). Studies indicate that patients
receiving ganciclovir or foscarnet (but not acyclovir) have a
reduced rate for developing Kaposi sarcoma (390,456–458)
or lesion regression after ganciclovir or foscarnet therapy
(459,460). Anecdotal reports exist of lesion regression among
patients who have been treated with potent ART, and despite
the lack of precise epidemiologic studies, the incidence of
Kaposi sarcoma has declined dramatically after the
introduction of protease inhibitor drugs and ART. Primary
effusion lymphoma and multicentric Castleman disease remain
rare.
Kaposi sarcoma, primary effusion lymphoma, and
multicentric Castleman disease are described most frequently
among HIV-1–infected persons with more advanced
immunosuppression (CD4+ T lymphocyte counts of <200
cells/µL), although they can occur at any CD4+ T lymphocyte
count.
Clinical Manifestations
Because the principal clinical manifestations of HHV-8
infection are neoplastic diseases, the occurrence, diagnosis, and
treatment recommendations for these entities are beyond the
scope of this report.
Diagnosis
Routine screening for HHV-8 by PCR or serologic testing
is not indicated for HIV-1–infected persons.
Treatment Recommendations
Although ganciclovir, foscarnet, and cidofovir have in vitro
activity against HHV-8, and limited studies indicate these
agents might be associated with reduced disease progression
or lesion regression, larger and more definitive studies are
needed to determine whether antiviral therapy has a useful
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role in managing HHV-8–associated diseases. Potent ART that
suppresses HIV-1 replication reduces the frequency of
occurrence of Kaposi sarcoma among HIV-1–infected persons
and should be considered for all persons who qualify for such
therapy (BII).
Prevention of Recurrence
Effective suppression of HIV-1 replication with ART among
HIV-1–infected patients with Kaposi sarcoma might prevent
Kaposi sarcoma progression or occurrence of new lesions and
should be considered for all persons with evidence of active
Kaposi sarcoma (BII).
Special Considerations During Pregnancy
The seroprevalence of HHV-8 infection among
HIV-1–infected pregnant women varies widely by geographic
area, ranging from 1.7% among U.S.-born and 3.6% among
Haitian-born women in New York City to 11.6% among
pregnant women from four other U.S. cities (461). Pregnancy
does not appear to affect the prevalence of antibodies to
HHV-8 or the antibody levels (462). HHV-8 seropositivity
does not appear to impact pregnancy outcome. Routine
screening for HHV-8 by PCR or serology is not indicated for
pregnant women.
Diagnosis of Kaposi sarcoma or other HHV-8–associated
neoplasms in pregnancy should be the same as among
nonpregnant women. Recommendations for the treatment of
HHV-8 malignancies are beyond the scope of this report.
Treatment should be undertaken in consultation with a
specialist.
Perinatal transmission of HHV-8 occurs but appears to be
infrequent. A study of 32 mother-infant pairs indicated that
maternal HHV-8 infection might increase the risk for perinatal
transmission of HIV-1, although no evidence of HHV-8
infection was identified among HIV-1-infected infants (463).
Data indicate increased mortality through 24 months among
HIV-1–infected infants born to HHV-8 seropositive compared
with HHV-8 seronegative mothers (464–471). Evidence
supporting vertical transmission during pregnancy or the
intrapartum period includes cases of Kaposi sarcoma
developing shortly after birth (464,465), higher risk for
transmission with higher maternal antibody titer (and by
inference higher HHV-8 viral titers) (466), and detection of
HHV-8 DNA by PCR in specimens drawn at birth from
infants born to HHV-8 seropositive mothers. The majority of
studies demonstrate a rate of persistent antibody positivity in
children of 2%–29% by age 4 years with the majority of studies
documenting a substantially higher rate of seropositivity
among children born to HHV-8 antibody positive compared





Progressive multifocal leukoencephalopathy (PML) is an
AIDS-defining neurologic disease caused by the JC polyoma
virus. The JC virus is an ubiquitous polyoma virus; the name
is derived from the initials of the first patient from whom this
virus was isolated. The majority of humans are infected early
in life, and 70% of adults have detectable serum antibodies.
Clinical Manifestations
 No known symptoms associated with acute JC virus infec-
tion exist. PML is the only known disease caused by the JC
virus. This disease has an insidious onset and produces a neu-
rologic syndrome that progresses relatively rapidly over weeks
or months, characterized by cognitive dysfunction, dementia,
seizures, ataxia, aphasia, cranial nerve deficits, hemiparesis or
quadriparesis, and eventually coma. Typical computed tomo-
graphic abnormalities include single or multiple hypodense,
nonenhancing cerebral white matter lesions, although cerebel-
lum and brain stem are occasionally involved.
Diagnosis
A confirmed diagnosis of PML requires a compatible clinical
syndrome and radiographic findings coupled with brain biopsy
demonstrating characteristic pathologic foci of demyelination
and oligodendrocytes with enlarged nuclei and basophilic-
staining intranuclear material. Whether a brain biopsy will
yield information that will alter the clinical course of a patient
presenting with a demyelinating disease is a clinical judgement.
PCR detection of JC virus DNA in CSF provides supportive
diagnostic information in the presence of a compatible clinical
syndrome and radiographic findings, and can be used for
diagnosis when a brain biopsy is not feasible.
Treatment Recommendations
No effective therapy for JC virus exists. Randomized clinical
trials have evaluated vidarabine and cidofovir; neither is
effective in producing clinical improvement and neither is
recommended (472,473) (EI). When ART is initiated and
CD4+ T lymphocyte counts rise, certain patients will
experience neurologic improvement and others might become
neurologically stable. However, reports have documented
patients experiencing worse neurologic manifestations after
initiation of ART. In certain instances, this worsening is caused
by an immune reconstitution inflammatory syndrome; other
cases represent the natural history of PML.
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Prevention of Recurrence
No role exists for antiviral agents in the prevention of
recurrence or progression of PML.
Human Papillomavirus Disease
Epidemiology
Human papillomavirus (HPV) infection of the anogenital
tract results in a spectrum of disease, ranging from self-limited,
transient infection to squamous cell cancer. HPV is the
etiologic agent of genital warts and condyloma acuminata. A
small number of HPV types (typically HPV types 6, 11, 40,
42, 53, or 54) are associated with warts on the external
anogenital skin and types 6 and 11 account for approximately
90% of lesions in the majority of series (474–476).
Genital tract HPV infections are thought to be transmitted
by sexual contact (476). Lesions sometimes occur at anatomic
locations away from sites of direct contact (477). Both the
incidence and prevalence of genital warts is increased among
patients with HIV-1 infection (478,479). The incidence of
genital warts is increased by >10 times among HIV-1–infected
women compared with uninfected women (479).
In parallel with the increased prevalence of genital tract HPV
infection, cervical intraepithelial neoplasia (CIN) and anal
intraepithelial neoplasia (AIN), associated with certain HPV
subtypes (16, 18, 31, 35 and others) occur with increased
frequency among HIV-1–infected women compared with
HIV-seronegative women. The relative risk for CIN is 5–10
times higher for HIV-1 seropositive women. Additional factors
that contribute to increased risk for CIN include being black,
having a history of smoking, younger age at first intercourse,
and the number of sex partners.
HIV-1–infected women with CIN manifest higher grade
lesions than HIV-seronegative women, particularly in the
setting of lower CD4+ T lymphocyte counts and higher plasma
HIV-1 RNA levels (480–483) and are at higher risk for having
HPV-associated lesions elsewhere in the anogenital tract
including the vagina, vulva and anus, potentially associated
with vaginal intraepithelial neoplasia (VAIN), vulvar
intraepithelial neoplasia (VIN), and AIN (484). Women with
high-grade CIN or vulvar cancer might have a high incidence
of both AIN and invasive anal cancer.
MSM have a high prevalence of anal HPV infection and
AIN, and those who are HIV-1–infected, particularly those
with lower CD4+ T lymphocyte counts, are at even higher
risk than those who are not (485–487). In addition to the
high incidence of anal HPV infection and AIN among
HIV-1–infected men and women, the incidence of anal cancer
is higher in these groups than in the general population.
Although data are limited, effective ART does not appear to
substantially influence the short-term natural history of CIN,
AIN, or other forms of intraepithelial neoplasia.
Clinical Manifestations
The principal manifestation of genital HPV infection is the
presence of a cauliflower-like, pedunculated lesion or lesions
that might be a few millimeters to as much as 1–2 centimeters
in diameter or flat, keratotic plaques and dome-shaped papules
(often keratotic). Multiple lesions are usually present and they
often occur in clusters. Lesions might occur at multiple sites
in the anogenital tract. Certain patients are asymptomatic,
although those with perianal lesions might complain about
pain on defecation or perianal itching.
No characteristic symptoms are associated with CIN. Vaginal
bleeding might occasionally accompany cervical or vaginal lesions.
Lesions might be visible on the ectocervix, typically at the squamo-
columnar junction, during routine pelvic examination. VAIN,
VIN, AIN, or frank malignancy might occur with bleeding or
itching and lesions might be visible or palpable.
Diagnosis
HPV disease can be diagnosed by clinical inspection, and
further diagnostic testing is not generally required. The entire
anogenital tract should be carefully inspected for visual signs
of warts. A digital examination of the vulvar, vaginal, and
perianal regions and the anal canal should be performed as
part of routine evaluation. Digital examination should be
performed after collection of a cervical or anal Papanicolou
(Pap) smear because lubricant may obscure the interpretation
of Pap smears.
If uncertainty about the etiology of visible lesions or the
presence or absence of high-grade dysplasia or malignancy
exists, the diagnosis can be confirmed by a biopsy. Even typical
condylomata among HIV-1–infected persons might have foci
of high-grade dysplasia. Biopsies of warts should be considered
earlier in the evaluation in those with HIV-1 infection than
among uninfected persons.
Testing for HPV DNA is available, but no clinical
indications exist for routine testing of anogenital warts for the
presence or type of HPV. Guidelines should be followed for
routine Pap smear and colposcopic monitoring to detect
dysplasia among HIV-1–infected women (Table 3) (488). If a
Pap smear is performed and returns with a cytologic
interpretation reporting “atypical squamous cells of uncertain
significance” (ASCUS) or “atypical squamous cells-cannot rule
out high-grade disease” (ASC-H), an HPV Hybrid Capture™
test can be performed. If the HPV Hybrid Capture™ test
reveals an oncogenic HPV type, or if the Pap smear
interpretation reports a low-grade squamous intraepithelial
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lesion (LSIL) or a high-grade SIL (HSIL), colposcopic
evaluation and directed biopsy are recommended.
Although formal guidelines recommending anal Pap smear
screening have not been adopted, certain specialists
recommend anal cytologic screening for HIV-1–infected men
and women. High-resolution anoscopy (HRA) should be
considered if the anal Pap smear indicates ASCUS or ASC-H
and should be performed if a person has LSIL or HSIL on
anal Pap smear. Visible lesions should be biopsied to determine
the level of histologic changes and to rule out invasive cancer.
Treatment Recommendations
Treatments are available for genital warts, but none is
uniformly effective. The rate of recurrence is high with most
modalities (489). Data are limited on the response of
HIV-1–infected patients to the available treatments for genital
warts. In the absence of data specific to the HIV-1–infected
population, guidelines for the treatment of sexually transmitted
diseases should be followed. Data are insufficient to
recommend a single treatment modality for all patients, and
more than one treatment option might be required for
refractory or recurrent lesions among patients with HIV-1
infection.
Patient-applied treatments are generally recommended for
uncomplicated external lesions, and consist of the following
options (CIII):
• Podofilox is an antimitotic agent that should be applied
topically to wart lesions as a 0.5% solution or a 0.5% gel;
twice daily applications for 3 consecutive days can be
repeated weekly for up to 4 weeks (BIII). The efficacy is
40%–60% in immunocompetent subjects (490,491).
• Imiquimod is a topical cytokine inducer that recruits an
inflammatory response to the site of the wart. A 5% cream
formulation is applied to lesions at bedtime and removed
in the morning by washing. The drug should be applied
on three nonconsecutive nights/week for up to 16 weeks
(BII). The efficacy of imiquimod in immunocompetent
persons is 30%–70%; the overall response in HIV-1
seropositive persons might be lower than in
immunocompetent persons (492–494).
Provider-applied treatments are generally recommended for
complex or multicentric lesions or those lesions inaccessible
to patient-applied treatments (CIII). Options are summarized
as follows:
• Cryotherapy with liquid nitrogen should be applied until
each lesion is thoroughly frozen. Certain specialists
recommend allowing the lesion to thaw and freezing a
second time in each session. Cryotherapy sessions can be
repeated every 1–2 weeks up to 3–4 times (BIII). The
efficacy of cryotherapy is 60%–80%.
• Trichloroacetic or bichloroacetic acids act as caustic agents
to kill wart tissue. They can be made in an 80%–95%
aqueous solution and applied to each lesion. The treatment
can be repeated weekly for 3–6 weeks (BIII). The expected
efficacy is 60%–80%.
• Surgical treatments include excision by scissor, shave, or
curette or by electrosurgery (BIII). Laser surgery can also
be used, but is generally more expensive (CIII). The
efficacy of surgical removal can approach 100% depending
on the location of the lesions.
• Topical application of cidofovir has reported activity
against genital warts (495,496) in limited, uncontrolled
studies (CIII). No topical formulation is commercially
available.
• Podophyllin resin is a crude extract that contains
podophyllotoxin and other cytotoxins and induces wart
necrosis after topical application. It is prepared as a 10%–
25% suspension in tincture of benzoin. It is applied by
the provider to all lesions (up to 10 cm2 of skin area) and
then removed by washing a few hours later. Applications
can be repeated weekly for 3–6 weeks (CIII). Efficacy
ranges from 20%–80%.
• Intralesional interferon is not generally recommended
because of its high cost, difficult administration, and
potential for systemic side effects (i.e., fever, fatigue,
myalgias, and leukopenia) (DIII). The overall efficacy of
interferon is no better than other therapies, and it has not
been specifically studied for genital warts among
HIV-1-infected persons.
The management of CIN among HIV-1–infected patients
should not differ from recently published guidelines (488)
(AIII). The majority of specialists recommend observation
without specific intervention for CIN 1 unless lesions persist
over an 18–24 month period of follow-up, evolve to CIN 2
or worse, or there is poor adherence to routine monitoring.
Conventional therapies used for treatment of CIN 2 or 3
include cryotherapy, laser therapy, cone biopsy, and a loop
electrosurgical excision procedure (LEEP). LEEP is generally
the preferred mode of treatment (BIII). Recurrence rates of
40%–60% after treatment have been reported among
HIV-1–infected women undergoing these procedures (497).
For AIN, data are insufficient to recommend a specific
treatment approach; because the majority of lesions are not
visible to the patient, the majority of specialists recommend
use of one or more of the provider-applied treatments outlined
previously (CIII) (Table 4). Treatment decisions are based on
assessment of the size and location of the lesion and the grade
of histology. The least aggressive approaches should be tried
first whenever possible (CIII). If a lesion is too large or if
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treatment is expected to produce substantial morbidity, then
certain specialists recommend following patients without
treatment and periodic examinations to monitor for
development of cancer. A study reported a low success rate for
surgical fulguration of widespread AIN 2 or 3 among
HIV-1–infected persons (498). No indications exist for
radiation therapy for patients with AIN in the absence of
evidence of invasive cancer (EIII).
The results of studies do not indicate that treatment for
CIN or AIN should be modified for patients receiving ART.
Conversely, no evidence indicates that ART should be
instituted or modified for the purpose of treating CIN or AIN
(CIII), although limited data indicate that ART might be
associated with improved response rates.
Monitoring and Adverse Effects
As efficacy varies with each of the treatments for genital
warts, and recurrences are common, patients should be
monitored by physical examination for evidence of recurrence.
The major toxicity of podofilox and topical podophyllin is
local skin irritation. Also, if podophyllin is applied to a large
treatment area, systemic absorption can cause nausea,
vomiting, and CNS effects. The major toxicity of imiquimod
is inflammation at the application site. The major toxicity of
cryotherapy is local pain. The major side effects of surgical
treatment for genital warts are local pain, bleeding, and
secondary infection. The major adverse events associated with
acid cauterization are local pain and irritation or ulceration of
adjacent normal skin. Intralesional interferon is associated with
systemic toxicities of interferon, including fever, fatigue,
myalgia, malaise, depression, and other influenza-like
symptoms.
For patients with CIN 1 that has not been treated with one
of the outlined interventions, Pap smears or colposcopy should
be performed every 4–6 months to monitor for persistence or
progression of lesions. As the recurrence of CIN and cervical
cancer after conventional therapy is increased among
HIV-1–infected persons, patients should be carefully followed
after treatment with frequent cytologic screening and
colposcopic examination when indicated according to
published guidelines (498,499).
Management of Treatment Failure
Treatment failure is defined as the persistence or recurrence
of lesions after appropriate therapy. If evidence exists of
persistent or recurrent genital warts, re-treatment with any of
the modalities previously described should be considered,
preferably with an alternative modality to the one that
previously failed (AIII). For persistent or recurrent CIN 2 or
3, repeat loop excision or one or more of the other treatment
modalities should be considered (AIII) (499).
Prevention of Recurrence
No indication exists for secondary prophylaxis (chronic
maintenance therapy) with any of the conventional modalities
to prevent recurrence of genital warts. Patients with CIN
should be monitored with frequent cytologic screening and,
when indicated, colposcopic examination for recurrent lesions
(AI). In a study of HIV-1–infected women treated for high-
grade cervical lesions using conventional therapies, low-dose
intravaginal 5-fluorouracil (i.e., 2 g twice weekly for 6 months)
reduced the short-term risk for recurrence and possibly the
grade of recurrence (500). However, clinical experience with
this therapy is too limited to provide a recommendation for
its use (CIII).
Special Considerations During Pregnancy
The decision about whether to treat genital warts during
pregnancy should be individualized on the basis of the extent
of the warts, concurrent symptoms, gestational age, and patient
preference (CIII). Podophyllin and podofilox should not be
used during pregnancy (EIII). Use of podophyllin has been
associated with an increased risk for fetal death in several animal
models and case reports in humans, but not with congenital
anomalies. No experience with imiquimod in human
pregnancy has been reported; therefore, its use in pregnancy
is not recommended (DIII). No anomalies have been observed
among animals with use during pregnancy.
Other topical treatments (e.g., bichloroacetic and
trichloroacetic acid) and ablative therapies (i.e., laser,
cryotherapy, and excision) can be used during pregnancy.
Cervical warts should be biopsied to rule out concomitant
dysplasia. Increased bleeding might occur with cervical biopsy
during pregnancy.
All pregnant women should have a Pap smear at their initial
prenatal visit unless a normal cervical cytology result has been
obtained within the past year. Cytobrush sampling can be done
during pregnancy (501). Pregnant women with abnormal
cervical cytology results should undergo colposcopy and
cervical biopsy of any abnormalities. Increased bleeding might
occur with cervical biopsy during pregnancy. Endocervical
curettage should not be done during pregnancy (502,503)
(DIII).
Repeat cytology with or without colposcopy should be
conducted at 34–36 weeks of gestation to rule out progression
of dysplasia. Women with any grade of cervical dysplasia can
deliver vaginally (if otherwise appropriate based on obstetrical
and HIV parameters) with repeat colposcopy and definitive
therapy completed postpartum. Women with suspected
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cervical cancer should be referred to a gynecologic oncologist
for definitive diagnosis, treatment, and delivery planning
because vaginal delivery is not recommended with invasive
cervical cancer (504).
Pregnancy appears to increase the rate of detection of genital
HPV DNA among HIV-uninfected women and might be
associated with an increased frequency and rate of growth of
genital warts (505–507). The effect of pregnancy on genital
HPV detection among HIV-1–infected women has not been
evaluated.
Transmission of genital HPV type 6 and 11 from vaginal
secretions at delivery is the presumed mechanism of early onset
recurrent laryngeal papillomatosis in infants. Although rare,
this condition occurs more frequently among infants delivered
vaginally compared with those delivered by Cesarean section
(505,506–508). No change in obstetrical management is
indicated for women with HPV infection unless extensive
condylomata are present that might impede vaginal delivery
or cause extensive bleeding (509–512).
Hepatitis C Virus Disease
Epidemiology
 Chronic hepatitis C is caused by hepatitis C virus (HCV),
a single-stranded RNA virus. Six distinct genotypes and
approximately 50 subtypes have been described. Genotype 1
infection accounts for approximately 75% of all HCV
infections in the United States; genotypes 2 and 3 are more
prevalent in Western Europe. Both HCV and HIV-1 are
efficiently transmitted through large or repeated percutaneous
exposure to infectious blood. Numerous studies have
documented a high rate of HCV co-infection (50%–90%)
among HIV-1–infected injection-drug users and persons with
hemophilia (513–516). Other potential modes of transmission
of HCV include mother-to-infant (the rate is approximately
5% but increases to 17% if the mother is HIV-1–infected),
needlestick, or sexual (515–522).
Data from a large cross-sectional analysis of a heterogeneous
group of HIV-1–infected persons participating in clinical trials
in the United States indicates that 16.1% were HCV
co-infected (523). The majority of co-infected persons had a
history of injection-drug use. Long-term studies of persons
with HCV alone indicate that approximately 2%–20% of
those with chronic HCV infection experience cirrhosis within
approximately 20 years after acute infection; older age at the
time of infection, male sex, and the presence of concomitant
alcoholism increase the frequency (524–528).
HIV-1 infection appears to speed the rate of progression of
chronic hepatitis C to end-stage liver disease (ESLO) to as little
as 10 years after exposure (528–534); however, this accelerated
progression has not been observed in all studies. Data from a
meta-analysis indicate that the average risk for progressive liver
disease is 2.9 times higher among HCV/HIV-1 co-infected
persons than among persons infected only with HCV (535).
Factors that adversely influence disease progression among
HCV/HIV-1 co-infected persons include older age, lower CD4+
T lymphocyte count, and a history of alcoholism. Evaluation
of liver histology with an established measure (METAVIR
scoring system) indicates the presence of more extensive fibrosis
as well as a greater rate of fibrosis progression among
HCV/HIV-1 co-infected persons than among those with HCV
infection alone (532).
Whether HCV accelerates progression of HIV-1 disease is
unknown (536–538). More recent studies have reported that
HCV infection might accelerate progression of HIV-1
infection, although whether HCV co-infection worsens
immunologic dysfunction is unknown (530,538–540).
Clinical Manifestations
Acute hepatitis C is not often recognized because of a high
rate of asymptomatic or mildly symptomatic presentation. A
limited proportion (<20%) of patients with acute infection
have symptoms characteristic of acute hepatitis including low
grade fever, mild right-upper-quadrant pain, nausea, vomiting,
anorexia, dark urine, and jaundice. Liver transaminases (serum
alanine aminotransferase [ALT] and aspartate aminotransferase
[AST]) might be elevated.
Chronic hepatitis C is often asymptomatic, although
complaints of fatigue are common. Serum cryoglobulins are
present (60%) but rarely (<5%) cause symptomatic skin, renal,
or neurologic manifestations. With progression of liver disease,
patients might experience stigmata of portal hypertension
including spider angiomata, temporal wasting, splenomegaly,
caput medusa, ascites, jaundice, pruritis, and encephalopathy.
A small subset of patients experience cutaneous manifestations
including leukocytoclastic vasculitis and porphyria cutanea
tarda. A rapidly progressive form of hepatitis C, called fibrosing
cholestatic hepatitis, has been reported among patients who
are immunosuppressed after solid-organ transplantation. This
also might occur among HIV-1–infected patients (541).
Serum transaminase levels often fluctuate among patients
with chronic HCV infection, regardless of HIV-1 co-infection,
and long periods of normal serum transaminase levels might
occur, although the majority of patients with chronic HCV
infection have evidence of liver injury on liver biopsy (542).
This injury might occur after years of relatively quiescent
infection (543). A weak association between the degree of ALT
elevation and the severity of liver injury has been reported,
but studies have not been consistent.
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Diagnosis
All HIV-1–infected patients should be tested for evidence
of chronic HCV infection. Initial testing for HCV should be
performed using the most sensitive immunoassays licensed
for detection of antibody to HCV in blood. To confirm the
presence of chronic infection, persons positive for antibody
to HCV should be tested for HCV RNA by a qualitative HCV
RNA assay with a lower limit of detection of <50 IU/mL.
Additional, more specific anti-HCV testing by a recombinant
immunoblot assay (RIBA) should be performed for patients
with a positive anti-HCV result by immunoassay and a
negative test for HCV RNA.
False negative anti-HCV immunoassay results might occur
among HIV-1–infected persons, but this is uncommon with
the most sensitive immunoassays (523,544). Seroreversion in
patients with low CD4+ T lymphocyte counts has been
described (531). If serologic test results are indeterminate,
testing for HCV RNA should be performed.
Both qualitative and quantitative assays are available for
HCV RNA testing. Three diagnostic assays have been approved
by FDA for qualitative detection of HCV RNA. Two of the
assays use RT-PCR and have a lower limit of detection of
50–100 IU/mL; the third uses transcription mediated
amplification and has a lower limit of detection of 10 IU/mL.
A single positive qualitative HCV RNA result is sufficient to
confirm the diagnosis of active HCV infection, but a negative
result cannot exclude viremia because RNA levels might
transiently decline below the limit of detection in persons with
active infection. A repeat qualitative assay can be performed
to confirm the absence of active infection.
Quantitative tests for HCV RNA include quantitative
RT-PCR or branched DNA (bDNA) signal amplification
assays. An HCV RNA standard has been established that
permits normalization of viral titers in IUs; these are not
indicative of the number of viral particles in a sample. Although
the result in IU/mL provides a reasonable estimate of HCV
viral load, substantial variability exists among available assays,
and if serial values are required to evaluate disease or monitor
antiviral therapy, continued use of the same quantitative assay
for all assessments is recommended. HCV viral load does not
correlate with degree of histologic injury observed on liver
biopsy and does not serve as a surrogate for measuring disease
severity, but it does provide important prognostic information
about the response to antiviral therapy. Quantitative HCV
RNA is also useful for monitoring response to therapy.
Co-infected persons should be tested for other comorbid
liver conditions. Certain specialists recommend screening for
hepatocellular carcinoma using alfa-fetoprotein (AFP) and
hepatic ultrasound imaging performed at 6-month intervals
among HIV-uninfected patients with chronic HCV infection
and documented cirrhosis. Although no data are available to
evaluate the predictive value of this approach among
HIV-1–infected patients, certain specialists recommend that
such screening also be considered for co-infected persons with
cirrhosis. An abnormal AFP level should prompt further
imaging studies to identify focal mass lesions in the liver
parenchyma.
Numerous imaging modalities are available to evaluate liver
parenchymal changes including ultrasonography and scans
using single-photon emission computed tomography
(SPECT), CT, or MRI technology. Ultrasonography is
recommended as the initial test for screening for liver
parenchymal changes, cirrhosis, or preliminary detection of
mass lesions. Use of SPECT, CT, or MRI scanning should
generally be limited to evaluation of hepatic mass lesions
among patients with elevated AFP levels and cirrhosis. Hepatic
CT without contrast should not be employed because a meta-
analysis has documented this to be inferior to biphasic/triphasic
CT for identification of small masses in the liver. Testing for
ALT levels is the simplest and least expensive test to assess
activity of liver disease and should be performed as part of the
initial diagnostic evaluation; however, it is nonspecific, and a
single abnormal result provides limited useful information.
Liver biopsy remains the only definitive test for evaluation
of fibrosis stage, and although data among HIV-1–infected
patients are limited, fibrosis stage is the most reliable means
to assess prognosis and provide information for decisions about
the need for initiation of therapy. Therefore, in the absence of
a contraindication to liver biopsy, a liver biopsy is
recommended for all HIV-1–infected persons with chronic
HCV co-infection who are candidates for antiviral therapy,
although certain HIV specialists would initiate antiviral
therapy without a pre-treatment liver biopsy.
Because data about response to antiviral therapy are limited
for HIV-1 co-infected patients with HCV genotype 2, 3 or
other nongenotype 1 disease, information is limited to base a
specific recommendation about whether testing for genotype
is useful in this population; however, certain specialists
recommend performance of HCV genotype to assist in making
a decision to treat chronic hepatitis C. Because up to 80% of
patients with HCV genotype 2 or 3 disease respond favorably
to antiviral therapy, a decision to treat is more straightforward,
and a pretreatment liver biopsy might not be necessary for
those with genotype 2 or 3 disease. If performed, liver biopsies
should be evaluated by pathologists with training and
experience in hepatic histology (545).
Complex matrix models using noninvasive test results might
reliably separate patients with minimal fibrosis from those with
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cirrhosis but fail to clearly distinguish intermediate stages of
fibrotic disease progression and should not supplant liver
biopsy at this time (546). Additional studies evaluating a variety
of noninvasive methods for determining stage of fibrosis in
the absence of a liver biopsy are ongoing.
Complications of percutaneous liver biopsy (i.e.,
hemorrhage, biliary peritonitis, and pneumothorax) occur at
rates of 1–3 per 1,000 cases. Higher complication rates are
reported among patients with or without HIV-1 infection who
have substantial thrombocytopenia, coagulation defects, or
liver lesions with high vascularity. Although these might not
be absolute contraindications to liver biopsy, among these
patients, transjugular liver biopsy might be the preferred
approach (547). Patients with hemophilia should have
adequate platelet factor replacement before a liver biopsy is
performed (548,549).
Treatment Recommendations
Because of the scarcity of published experience treating HIV-
1/HCV co-infected persons, practice is dictated largely by
principles established for the treatment of HIV-uninfected
persons. All patients with chronic hepatitis C should be
counseled to avoid alcohol consumption because of the
potential increased risk for fibrotic progression (532,548,549).
Because fulminant hepatic failure from hepatitis A virus
infection occurs at increased frequency in persons with chronic
liver disease, persons susceptible to HAV should receive 2 doses
of HAV vaccine (BIII). HAV vaccine should be administered
before the CD4+ T lymphocyte count declines to <200
cells/µL because the response will probably be better (90). In
addition, susceptible HIV-1–infected persons at risk for HBV
infection should receive the hepatitis B vaccine series.
Antiviral treatment should be considered for all patients with
chronic hepatitis C infection (AI). Treatment is recommended
for patients at increased risk for development of cirrhosis (i.e.,
those with chronic hepatitis C who have detectable plasma
HCV RNA levels on a qualitative assay, liver biopsy histologic
findings of portal or bridging fibrosis and at least moderate
inflammation and necrosis, and persistently elevated ALT levels
>2 times the upper limit of normal) (BI). Although patients
with normal or only minimally elevated (<2 times the upper
limit of normal) ALT levels are likely to have mild disease,
some might progress to advanced fibrosis and cirrhosis.
Controversy exists about whether to take a biopsy and treat
these patients.
Several factors should be considered when making a decision
to treat, including genotype, degree of fibrosis, patient
motivation, symptoms, severity of other underlying conditions,
age, and the need for and the type of concomitant ART. As
disease progression is likely to be slow among co-infected
patients with mild elevations of ALT and no or minimal fibrosis
or inflammatory changes on liver biopsy, these patients might
not need treatment and should be monitored periodically with
serial determinations of ALT and repeat liver biopsy. The most
appropriate intervals to monitor such patients have not been
determined.
No data are available to evaluate the safety and effectiveness
of antiviral treatment of HCV for HIV-1 co-infected patients
with advanced fibrosis or compensated cirrhosis, although
some specialists would consider treatment for such patients.
Treatment with interferon (IFN)-based therapies is relatively
contraindicated among patients with decompensated liver
disease, indicated by coagulopathy, encephalopathy, ascites,
or history of bleeding varices (DIII). Liver transplantation,
where feasible, should be the primary treatment option for
patients with decompensated liver disease (CIII). However,
data about the safety and effectiveness of liver transplantation
among HIV-1–infected adults are insufficient to recommend
its use outside of clinical studies (550).
The goals of antiviral treatment of chronic hepatitis C
include eradication of HCV infection, prevention of histologic
progression of hepatic fibrosis and, among persons with HCV-
related cirrhosis, prevention of hepatic decompensation,
hepatocellular carcinoma, and death. Although the goals of
therapy might not be achievable in all patients, histologic and
clinical benefits of therapy might not be limited just to persons
with clearance of virus (551–553). Approved therapies for
chronic hepatitis C among HIV-uninfected persons include
monotherapy with standard interferons (interferon [IFN] alfa-
2a, alfa-2b, or IFN alfacon-1) or pegylated (PEG) IFNs (alfa-
2a and alfa 2b) and combination therapy with standard or
PEG IFN alfa 2a or alfa-2b plus ribavirin.
Among HIV-uninfected patients, the combination of PEG
IFN plus ribavirin is associated with substantially higher rates
of sustained virologic response compared with standard IFNs
alone or with ribavirin. Also among HIV-uninfected patients,
ribavirin doses adjusted by weight are associated with improved
efficacy and less ribavirin-associated toxicity than fixed
ribavirin doses. On the basis of ease of administration (once-
weekly injection) and the superior efficacy in HIV-uninfected
persons, PEG IFN alfa-2a or -2b plus ribavirin has largely
replaced use of standard IFN alfa plus ribavirin for the
treatment of chronic hepatitis C infection (554). Retrospective
series and limited, uncontrolled, prospective clinical trials
demonstrate that IFN alfa-2b plus ribavirin is reasonably well
tolerated and might eradicate HCV infection among certain
HIV-1-infected patients (555–557). Results from two
prospective, randomized, controlled trials comparing PEG IFN
alfa-2a plus ribavirin with standard IFN alfa-2a plus ribavirin
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in HIV-1–infected patients with HCV co-infection
demonstrate safety and superior efficacy of PEG IFN alfa-2a
plus ribavirin compared with conventional IFN plus ribavirin
(558). Approximately one third of those without a virologic
response who underwent liver biopsy had histologic
improvement in fibrosis, despite the absence of a virologic
response in one trial (558). On the basis of these data, PEG
IFN alfa-2a 180 mcg administered weekly by subcutaneous
injection (or PEG IFN alfa-2b 1.5 mcg/kg) plus oral ribavirin
in a dose of 600–1,400 mg daily based on weight is the
recommended treatment for chronic hepatitis C among
HIV-1–infected persons (AI).
Patients with contraindications for the use of ribavirin (e.g.,
unstable cardiopulmonary disease, pre-existing anemia
unresponsive to erythropoietin, or hemoglobinopathy) can be
treated with PEG IFN alfa (2a or 2b) monotherapy (AII).
However, decreased rates of sustained virologic response are
expected among patients not receiving ribavirin.
The optimal duration of HCV therapy among
HIV-1–infected persons is unknown. While awaiting data
from ongoing clinical trials, the majority of specialists follow
recommendations for HIV-uninfected persons. The duration
of treatment using combination therapy with PEG IFN plus
ribavirin is 48 weeks for patients with HCV genotype 1 disease
who demonstrate an early virologic response (a decrease of at
least 2 log10 in HCV viral load as measured by quantitative
HCV RNA levels) during the first 12 weeks of treatment (AI).
Patients with genotype 1 disease who fail to achieve an early
virologic response by week 12 have limited chance of achieving
a sustained virologic response regardless of duration of therapy,
and treatment may be discontinued after 12 weeks in such
patients (BI). The recommended treatment duration is 24
weeks for HIV-1–infected persons with genotype 2 or 3 disease
(BII); certain specialists would treat for 48 weeks for
co-infected patients with genotype 2 or 3 disease
(554,559,560) (CIII).
Preliminary data among HIV-1–infected patients indicate
that the HCV virologic response correlates with pretreatment
CD4+ T lymphocyte count (i.e., higher response rates have
been observed among patients with baseline CD4+ T
lymphocyte counts >500 cells/µL) (561). Therefore, treatment
for HCV should be considered before a decline in CD4+ T
lymphocyte count to <500 cells/µL for patients with HIV-1
co-infection (BIII). Conversely, for HIV-1–infected patients
with CD4+ T lymphocyte counts <500 cells/µL, initiation of
ART should be considered before treatment for chronic
hepatitis C (BIII). Clinical trials evaluating this approach are
in progress.
Monitoring and Adverse Events
Quantitative HCV RNA levels are the best estimate of
treatment response. Reliability and value of serial quantitative
measurement as a marker of treatment response remains to be
determined, particularly in clinical practice settings where
variation in specimen handling and shipping might decrease
validity of HCV RNA change.
A sustained virologic response (SVR) is defined as the
absence of detectable HCV RNA, using a qualitative or
quantitative HCV RNA assay with a lower limit of detection
of 50 IU/mL, at 24 weeks after the end of antiviral treatment.
Relapse is defined as the absence of detectable HCV RNA at
the end of treatment (ETR) that is not sustained over time.
Nonresponse is defined as the absence of an ETR or a SVR.
However, even in the absence of a SVR, several studies have
demonstrated improved liver histology after completion of a
course of antiviral treatment.
HIV-1–infected patients should have a quantitative HCV
RNA assay performed at the end of 12 and 24 weeks of
treatment, and those with undetectable HCV RNA levels
should have an HCV RNA assay repeated 24 weeks after
completion of therapy. It is reasonable for co-infected patients
who achieve a sustained virologic response to undergo serial
HCV RNA testing at 6-month intervals for an additional
1–2 years to exclude late virologic relapse (or re-infection with
HCV for those at risk for continued exposure).
The major toxicities of IFN alfa (PEG or standard) include
influenza-like symptoms (e.g., fever, myalgia, headache, and
fatigue), neuropsychiatric abnormalities (e.g., depression and
cognitive dysfunction), cytopenias (e.g., thrombocytopenia
and neutropenia including a reduction in CD4+ T lymphocyte
count), retinopathy, neuropathy, and exacerbation of
autoimmune disease. Depression might be severe enough to
trigger suicide. Depending on the severity of these toxicities
and individual patient tolerance, they might be dose-limiting
or interfere with the ability to complete a course of treatment.
The major toxicities of ribavirin include dose-dependent
hemolytic anemia, cough, and dyspepsia. In addition, in vitro
data have demonstrated drug-drug antagonism between
ribavirin and the anti-HIV pyrimidine nucleoside analogues
(e.g., zidovudine, stavudine, zalcitabine, and lamivudine). The
clinical significance of these drug-drug interactions has not
been determined. In addition, ribavirin might potentiate the
intracellular activity of didanosine through inhibition of
inosine monophosphate dehydrogenase. Case reports have
indicated the interaction of RBV and didanosine might lead
to clinically significant inhibition of mitochondrial DNA
polymerase gamma, resulting in severe pancreatitis and lactic
acidosis in certain patients (561–564). Until further safety
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data are available, the combination of ribavirin and didanosine
is generally contraindicated (DIII).
Complete blood counts, a CD4+ T lymphocyte count, and
mental health should be evaluated before initiation of anti-
HCV therapy, and the therapy should be monitored at regular
intervals during treatment. Adverse effects of IFN alfa and
ribavirin might be modified by the use of adjunctive agents
such as antidepressants (neuropsychiatric), filgrastim
(neutropenia) and erythropoietin (anemia). Although available
data are insufficient to recommend the routine use of these
agents in the management of HCV, their use should be
considered on a case-by-case basis.
Management of Treatment Failure
No recommendations are available for treatment of patients
who fail to respond to initial antiviral treatment of chronic
hepatitis C. Certain patients might benefit from retreatment
with PEG IFN-based regimens depending on their previous
response, tolerance, and adherence to and the type of previous
therapy (i.e., conventional IFN monotherapy), the potential
potency of the new treatment regimen, the severity of liver
disease, and viral genotype and other underlying factors that
influence response.
Limited data in non-HIV-1–infected persons with HCV
indicate that 15%–20% of nonresponders treated with
conventional IFN formulations alone or in combination with
ribavirin will achieve a SVR when re-treated with PEG IFN
and ribavirin. Those who achieved a decline in HCV RNA to
levels <100,000 IU/mL during initial treatment with IFN
monotherapy or those with genotypes 2 or 3 appear to have
better response rates to retreatment. Additional studies
evaluating retreatment are in progress.
Prevention of Recurrence
For HIV-1 and HCV co-infected patients, durability of
treatment response and the requirement for chronic
maintenance therapy to prevent recurrence are unknown.
Therefore, no recommendations are available for chronic
maintenance therapy in this setting.
Special Considerations During Pregnancy
Pregnant HIV-1–infected women should be tested for HCV
infection if not previously tested to allow appropriate
management for them and their infants. Transaminase levels
tend to decrease and HCV RNA levels to increase during
pregnancy. Transaminases might increase transiently
postpartum (565–567).
Treatment of chronic hepatitis C during pregnancy is not
indicated and is not recommended (DIII). Both IFN and
ribavirin are contraindicated in pregnancy. Although IFNs are
not teratogenic among rats, mice, or rabbits, they are
abortifacient at high doses in monkeys and should not be used
in pregnant women because of the direct antigrowth and
antiproliferative effects of these agents. Approximately 30 cases
of human exposure to IFNs during pregnancy have been
reported, about half in the first trimester, without clear adverse
effects (568–570).
Ribavirin is labeled as FDA category X because of its
teratogenicity at low doses in multiple animal species. Defects
noted in animals include limb abnormalities, craniofacial
defects, exencephaly, and anophthalmia. This drug should not
be used during pregnancy (EIII). Women of child bearing
potential and men receiving ribavirin should be counseled
about the risks and need for consistent contraceptive use during
and for 6 months after completion of ribavirin therapy (571).
Evaluation, including liver biopsy, can be delayed until >3
months after delivery to allow potential pregnancy-related
changes in disease activity to resolve. Hepatitis A and hepatitis
B vaccination can be given during pregnancy (572).
The risk for perinatal transmission varies from zero among
HIV-1-seronegative women with undetectable HCV RNA
levels, to 4%–8% among predominantly HIV-seronegative
women with detectable HCV RNA, to 22% among
HIV-1–infected women (573–576). The risk for perinatal
transmission of HCV is consistently higher among
HIV-1–infected compared with HIV-seronegative women,
potentially related to higher HCV RNA levels in
HIV-1–infected women or concurrent injection drug use.
Perinatal transmission of HCV in both HIV-seronegative
and HIV-1–infected women also is potentially related to
higher HCV RNA levels, although this finding has been
inconsistent (573).
Mother-to-child transmission of HIV-1 also might be more
frequent among HCV co-infected women compared with
HIV-1–infected women without concomitant HCV infection
(577). Mode of delivery and breast feeding do not appear to
influence HCV transmission in HIV-seronegative women, but
elective Cesarean delivery might be protective against
transmission of HCV among HIV-1–infected women
(573,574,576). The adjusted odds ratio for perinatal
transmission of HCV with scheduled Cesarean delivery among
HIV-1 infected, HCV seropositive women was 0.36 (0.2–0.8)
compared with other modes of delivery in one large study;
however, this study did not control for concomitant perinatal
transmission of HIV-1 (576).
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Hepatitis B Virus Disease
Epidemiology
Hepatitis B virus (HBV) is the leading cause of chronic liver
disease worldwide (578,579). In developed countries, HBV is
transmitted primarily through sexual contact and injection-
drug use. Even though risk factors are similar, HBV is
transmitted more efficiently than HIV-1 (578–580). Although
up to 90% of HIV-1–infected persons have at least one serum
marker of previous exposure to HBV (581,582), only
approximately 10% have chronic hepatitis B, as evidenced by
the detection of hepatitis B surface antigen (HBsAg) in the
serum persisting for a minimum of 6 months (583,584).
HIV-1 infection is associated with an increased risk for the
development of chronic hepatitis B after HBV exposure
(584–586). Limited data indicate that co-infected patients with
chronic hepatitis B infection have higher HBV DNA levels
and are more likely to have detectable hepatitis B e antigen
(HBeAg) (587,588), accelerated loss of protective hepatitis B
surface antibody (anti-HBs), and an increased risk for liver-
related mortality and morbidity (589).
Clinical Manifestations
Although certain patients are asymptomatic, symptoms of
acute HBV infection include fatigue, right-upper-quadrant
abdominal pain, nausea, vomiting, fever, and arthralgias
followed by jaundice. Although persons with chronic hepatitis
B infection might have nonspecific symptoms such as fatigue
and right-upper-quadrant abdominal pain, chronic hepatitis
B is often clinically inapparent until the onset of ESLD
manifested as ascites, coagulopathy, caput medusa, palmar
erythema, jaundice, hepatomegaly, splenomegaly, variceal
bleeding, or hepatic encephalopathy. Ancillary manifestations
of chronic hepatitis B disease also include polyarteritis nodosa,
glomerulonephritis, and vasculitis.
Diagnosis
All HIV-1–infected persons should be tested for HBV (90).
The optimal testing strategy for co-infected persons has not
been determined. Testing for HBsAg, hepatitis B core antibody
(anti-HBc), and hepatitis B surface antibody (anti-HBs) is
recommended because this strategy will detect the majority of
persons with chronic hepatitis B and those who need
vaccination. Serum HBV DNA has been detected in certain
persons without HBsAg in whom anti-HBc was the only serum
marker of infection (590,591). The interpretation of an isolated
anti-HBc is difficult both because false-positive tests for anti-
HBc occur and because the clinical significance of anti-HBc
alone or with low levels of HBV DNA, even in those with
elevated ALT levels, is not known (590–593).
Chronic hepatitis B is defined as detection of HBsAg for >6
months. Patients with chronic HBV infection should be tested
for HBeAg and antibody to HBeAg (anti-HBe).
Severity of liver disease should be assessed initially and at
least every 6 months with ALT, albumin, prothrombin time,
platelet count, complete blood count, and bilirubin. Transient
or persistent elevations in liver transaminases might occur just
before loss of HBeAg, on discontinuation of anti-HBV therapy,
in association with lamivudine resistance, with hepatotoxicity
from anti-HIV therapy or other drugs, or with the acquisition
of another hepatitis virus infection such as HAV, HCV, or
hepatitis delta virus (HDV) (594–597).
Certain specialists also would obtain a test to quantify the
circulating HBV DNA in patients diagnosed with chronic
hepatitis B on the basis of serologic testing (598). Several assays
for HBV DNA are available, but results are not
interchangeable. HBV DNA levels are usually high in chronic
infection (108–1010 copies/mL of blood); however, available
data indicate that HBV DNA levels do not predict progression
of liver disease or response to therapy in a manner analogous
to plasma HIV-1 RNA levels (598).
Patients with chronic hepatitis B are at increased risk for
hepatocellular carcinoma (HCC). In HIV-seronegative
patients certain specialists recommend monitoring patients
with chronic hepatitis B every 6–12 months with an AFP level
or ultrasound of the liver, especially if the patient is in a high-
risk group (i.e., age >45 years, cirrhosis, or a family history of
HCC) (598,599); however, the effectiveness of this screening
strategy has not been determined. Among HIV-1–infected
patients, the risk for and natural history of HBV-related HCC
have not been studied; therefore, the optimal HCC screening
method and interval are not known. Until more data become
available, it seems reasonable to consider periodic (every
6–12 months) AFP and ultrasound screening among patients
with persistent HBsAg, especially those in a group at high risk
(598).
Liver biopsy remains the only definitive test to assess the
grade (necroinflammatory activity) and stage (degree of
fibrosis) of liver disease. The rate of progression of chronic
hepatitis B disease among patients with HIV-1 co-infection
has not been studied, and the optimal indications for liver
biopsy are not known; however, because fibrosis grade and
stage are the most reliable means to assess prognosis and
provide information for decisions about the need for initiation
of therapy (598), in the absence of a contraindication, the
majority of specialists recommend a liver biopsy for all
HIV-1–infected persons with chronic HBV co-infection who
are candidates for antiviral therapy. Certain HIV specialists
would initiate therapy for chronic hepatitis B without a
pretreatment liver biopsy.
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Treatment Recommendations
All patients with chronic hepatitis B disease should be
advised to avoid or limit alcohol consumption because of the
effects of alcohol on the liver (AIII). In addition, they should
be counseled about the risk for household, sexual, and needle-
sharing transmission and the need for such contacts to receive
hepatitis B vaccine.
Because fulminant hepatic failure from HAV infection
occurs at increased frequency among persons with chronic
liver disease, persons susceptible to HAV should receive 2 doses
of hepatitis A vaccine (BIII). HAV vaccine should be
administered before the CD4+ T lymphocyte count declines
to <200 cells/µL because the response is likely to be better
(90,600).
The goals of anti-HBV therapy are to reduce HBV-related
morbidity and mortality. Surrogate endpoints include
sustained suppression of HBV DNA, prevention of liver disease
progression, and clearance of HBeAg; treated patients rarely
become HBsAg-negative as HBV reservoirs generally are not
sufficiently reduced by available anti-HBV therapy. Limited
data indicates that any treatment reduces the risk for HCC.
Antiviral treatment is recommended for patients who have
actively replicating virus in blood (as defined by a positive
HBeAg or HBV DNA levels >105 copies/mL) and liver disease
as indicated by either an elevated serum ALT (at least 2 times
the upper limit of normal) or histopathologic evidence of
moderate liver disease activity and/or fibrosis on liver biopsy.
The response to therapy is poor for those with a pre-treatment
ALT level <2 times the upper limit of normal and therapy
should generally be deferred for such patients (DIII). However,
ALT levels fluctuate widely in persons with chronic hepatitis
B, and the long-term pattern is more useful than an isolated
value in patient management. Certain specialists recommend
treatment of those with advanced fibrosis or cirrhosis on liver
biopsy with any detectable HBV DNA level provided other
causes for chronic liver disease have been eliminated.
No preferred treatment can be uniformly recommended for
all HIV-1 co-infected persons with chronic hepatitis B.
Therapy should be individualized, taking into account patient-
specific considerations. Because of limited data about the safety
and efficacy of chronic hepatitis B treatment among
HIV-1–infected persons, patients should be encouraged to
enroll in clinical trials.
IFN-alfa 2a and 2b, administered in subcutaneous doses of
5 MU daily or 10 MU 3 times per week, are approved for the
treatment of chronic hepatitis B disease among
HIV-uninfected persons but not among HIV-1–infected
patients. Approximately one third of HIV-seronegative patients
will clear HBeAg with either of these IFN regimens (598,601),
and the response is durable among 80%–90% of persons
followed for 4–8 years (602). Among HIV-infected persons
with chronic hepatitis B, PEG IFN alfa 2a appears to be
superior to standard interferon (603). If either standard or
pegylated interferon is used for treatment among HBeAg-
positive patients, 16–24 weeks of therapy is recommended
(BII); for HBeAg negative patients, who respond less well, a
minimum of 12 months and possibly longer is recommended
(604) (BIII). Patients who have a substantial decrease (certain
specialists suggest >2 log10 copies/mL) or clearance of HBV
DNA in response to IFN-alfa 2a or 2b at week 16 but have
persistent HBeAg also might be candidates for longer term
treatment of 12 months or longer (605); however, data are
insufficient to make a firm recommendation in
HIV-1–infected patients (601,606–608).
Certain specialists recommend that IFN alfa be used in
HIV-1 co-infected patients who are candidates for treatment
of chronic hepatitis B disease but not HIV-1 (CIII). This
strategy preserves lamivudine or tenofovir for later treatment
of HIV-1 and avoids certain potential complications of ART.
IFN-alfa should not be used among patients with
decompensated liver disease (EII). Studies of PEG IFN-alfa
among HIV-uninfected patients with chronic hepatitis B are
in progress, and it will probably become the preferred IFN
formulation.
For HIV-1–infected persons who are ART-naïve and require
ART, lamivudine 150 mg twice daily is commonly used for
treatment of chronic hepatitis B, because of its relative safety,
anti-HIV activity, wealth of data about its use among
HIV-1–infected persons, and the potential toxicity associated
with IFN-alfa (BIII). Lamivudine should be used together
with other antiretroviral drugs in a fully suppressive ART
regimen. Because of the high rate of development of HBV
resistance to lamivudine monotherapy, certain specialists
further recommend the use of lamivudine in combination with
either adefovir or tenofovir, although data are limited to
support this approach (CIII).
Seroconversion of HBeAg (loss of HBeAg, accompanied by
development of HBe antibody) occurs in 22% of HBeAg-
positive HIV-1–infected patients with chronic hepatitis B who
are treated with lamivudine for 1 year (609). In
HIV-seronegative patients, HBeAg seroconversions are
sustained among approximately 80% of patients if lamivudine
is continued several months after seroconversion. On the basis
of limited data on the duration of treatment, HBeAg-positive,
HIV-1/HBV co-infected patients who become HBeAg-
negative and anti-e–positive on lamivudine therapy should
be treated for a minimum of 1 year or at least 6 months beyond
HBeAg seroconversion (BIII). Among HIV-seronegative,
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HBeAg-negative patients with chronic hepatitis B who are
treated with lamivudine, ALT and HBV DNA levels might
decline, but high rates of relapse have been reported when
therapy is stopped (610). Therefore, the optimal duration of
treatment of HBeAg-negative patients, whether HIV-1 infected
or not, is unknown (CIII). The combination of lamivudine
and IFN does not appear to be superior to either medication
alone (611,612), and is not recommended (DII).
Adefovir dipivoxil, 10 mg daily, has no anti-HIV activity
and is unlikely to select for HIV-1 resistance; therefore, it is
an appropriate alternative to IFN-alfa for co-infected patients
who require treatment for chronic hepatitis B but do not yet
require ART (CIII). However, the long-term safety of adefovir
has not been established in HIV-1-infected persons.
Tenofovir, 300 mg daily, has similar in vitro anti-HBV
activity to adefovir, and expanding human data indicate it is
also active against lamivudine-resistant and wild-type HBV.
Although tenofovir is not approved for use in the treatment
of HBV infection and data are sparse in HIV-1/HBV
co-infected patients, certain specialists consider tenofovir to
be the optimal choice for persons who need treatment for
both HIV-1 infection and chronic hepatitis B (in conjunction
with a fully suppressive ART regimen) (CIII). Until long-term
data are available that demonstrate the absence of HBV
resistance to tenofovir, it might be prudent to use tenofovir in
combination with lamivudine (CIII). Tenofovir, if used for
treatment of HBV in patients receiving ART, should be added
as a single agent for this purpose only if plasma HIV-1 RNA
levels are undetectable to avoid selection pressure that
engenders drug resistance (CIII). If therapy is indicated for
HIV-1 infection but not for chronic hepatitis B, certain
specialists would withhold tenofovir, if possible, to allow for
its future use for treatment of chronic hepatitis B (CIII).
Emtricitabine (200 mg once daily) is also active against HBV
replication and could potentially be substituted for lamivudine;
however, data are limited for its use for this indication. It is
not active against lamivudine resistant HBV. Famciclovir is
less active than lamivudine against HBV and is not active in
lamivudine-resistant HBV; therefore, its use is not
recommended (613–615) (DII). For HBV treatment-naïve
patients who require treatment of both HIV-1 infection and
chronic hepatitis B, many specialists would recommend use
of an ART regimen that includes either lamivudine or
emtricitabine along with either adefovir or tenofovir. However,
combination therapy for treatment of HBV in this population
is not yet supported by data (CIII).
Among patients infected with HBV, HCV, and HIV-1,
consideration of the need for ART should be the first priority.
If ART is not required, the treatment of HCV should be
considered before HBV treatment because IFN therapies for
HCV also might treat HBV (CIII). If IFN-based therapy for
HCV has failed, treatment of chronic hepatitis B with
nucleoside or nucleotide analogs can be considered (CIII).
Monitoring and Adverse Events
A virologic response is defined as a substantial (certain
specialists recommend >2 log10 copies/mL) decrease in HBV
DNA and loss of HBeAg at the end of treatment. A sustained
virologic response is defined as suppression of HBV DNA
(level not defined) and loss of HBeAg sustained for >6–12
months after the end of treatment. Among HIV-uninfected
persons, the response rates to IFN-alfa or lamivudine-
containing regimens are >50% in patients with ALT levels >5
times the upper limit of normal and 20%–35% among patients
with ALT levels between 2–5 times the upper limit of normal.
Patients for whom therapy is not initiated should be monitored
regularly for changes in ALT levels (e.g., every 4–6 months).
Other markers of treatment success include improvement
in liver histology, normalization of hepatic transaminases, and
in those with loss of HBeAg, the development of HBe antibody.
Sustained loss of HBsAg is considered by some to be a complete
response (604). Although a decline in HBV viral load correlates
with response, no threshold HBV viral load has been
established that clearly defines a virological response.
Side effects of IFN-alfa include influenza-like symptoms and
fatigue, which can be reduced by premedication with
acetaminophen or a nonsteroidal medication. Other common
side effects include weight loss, alopecia, thrombocytopenia,
anemia, leukopenia (decreased total CD4+ T lymphocyte
count but not percentage), depression, and autoimmune
disorders. Hypo- or hyperthyroidism, which is often
irreversible, might occur 3–6 months after initiation of therapy
with IFN-alfa. As a result, serum TSH level should be
monitored at baseline and periodically (e.g., every 3 months)
for the duration of treatment.
Adefovir causes renal tubular disease and renal excretion of
carnitine in a substantial proportion of patients at higher doses,
but these side effects are uncommon at the 10 mg/day dose.
Substantial renal toxicity with tenofovir has not been reported,
although isolated cases of increased serum creatinine or renal
tubular dysfunction have been observed. Because of the
potential for overlapping toxicities and their similar structure,
tenofovir and adefovir should not be used in combination.
When anti-HBV therapy with lamivudine, adefovir, or
tenofovir is initiated, whether for the purpose of treating
chronic hepatitis B or for the treatment of HIV-1 infection,
discontinuation is associated with a flare of liver disease in
approximately 15% of cases, with loss of the benefit accrued
from previous anti-HBV treatment (616). Certain specialists
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recommend that when anti-HBV therapies are initiated, they
should be continued unless contraindicated or unless the
patient has been treated for >6 months beyond loss of HBeAg
positivity. However, the risks and benefits of this practice are
unknown. If anti-HBV therapy is discontinued and a flare
occurs, reinstitution of anti-HBV therapy is appropriate
because it can be potentially life saving (BIII).
Management of Treatment Failure
The rate of development of lamivudine resistance is
approximately 20% per year among HIV-1/HBV co-infected
persons treated with lamivudine (617). Among
HIV-1–infected patients who have been on lamivudine and
are candidates for treatment of chronic hepatitis B, certain
specialists recommend use of adefovir or tenofovir (CIII). How
long lamivudine should be continued beyond initiation of a
new treatment is unknown (617–621).
For HIV-1–infected persons previously treated with a
lamivudine-containing ART regimen, uncontrolled data
indicate that the combination of adefovir with continued
lamivudine has substantial antiviral effect even in the presence
of lamivudine-resistant HBV (622). Certain specialists use
adefovir to treat chronic hepatitis B among HIV-1–infected
patients who have had an inadequate response to a course of
lamivudine therapy as evidenced by high plasma HBV DNA
levels or persistent serum HBeAg (CIII). Whether lamivudine
should be continued (or restarted) if not needed as part of the
antiretroviral regimen is unknown.
Although data are sparse and the drug is not approved for
this indication, certain specialists would recommend tenofovir
to treat chronic hepatitis B among HIV-1–infected patients
who require ART and remain HBeAg-positive or have high
levels of circulating HBV DNA despite >12 months of
lamivudine (CIII). Whether lamivudine should be used (or
restarted) in such patients is unknown.
Flares of liver disease have been reported with development
of resistance to lamivudine. If this occurs, addition of tenofovir
or adefovir might be life-saving (CIII). HBV DNA testing
might be useful in this setting because increasing levels are
associated with emergence of lamivudine resistance or relapse,
and stable levels should suggest an alternative cause of acute
deterioration.
ESLD among HBV and HIV-1 co-infected patients is
managed as it is in HIV-seronegative patients. IFN is
contraindicated in ESLD, but limited data indicate that
lamivudine and adefovir (and probably tenofovir) can be safely
used (617–619). Liver transplantation has been performed
with limited success among selected patients with HBV and
HIV-1 infection. If a patient is thought to be a candidate for
liver transplantation, early consultation with a transplant center
should be obtained because transplantation does not cure HBV
infection and adequate post-transplant treatment is required
(BIII).
Prevention of Relapse and Recurrence
Among HIV-seronegative, HBeAg-negative patients with
chronic hepatitis B who are treated with lamivudine, ALT,
and HBV DNA levels might decline, but high rates of relapse
have been reported when therapy is stopped (610). Therefore,
the optimal duration of treatment of HBeAg-negative patients,
whether HIV-1 infected or not, is unknown (CIII). No known
effective means exist to prevent recurrence or flares of chronic
hepatitis B.
Special Considerations During Pregnancy
All pregnant women should be screened for HBsAg.
Treatment of symptomatic acute HBV infection during
pregnancy should be supportive with special attention given
to maintaining blood glucose levels and normal clotting status.
Risk for preterm labor and delivery might be increased with
acute HBV infection. Treatment of chronic HBV infection is
generally not indicated in pregnancy (DIII). If antiretrovirals
are administered to the mother to prevent HIV transmission,
caution should be used in selecting agents like lamivudine or
tenofovir that also suppress HBV and may cause hepatitis flare
when discontinued. Hepatitis A vaccination, indicated for
persons with chronic hepatitis B, can be given during
pregnancy.
Infants born to HBsAg-positive women should receive
hepatitis B immune globulin and hepatitis B vaccine within
12 hours of birth. The second and third doses of vaccine should
be administered at 1 and 6 months of age, respectively (AI).
This regimen is >95% effective in preventing HBV infection
in these infants. Postvaccination testing for anti-HBs and
HBsAg should be performed at age 9–15 months because of
the infant’s on-going exposure to HBV.
If treatment for chronic hepatitis B disease is necessary,
lamivudine is the preferred agent because it is not teratogenic
in animals or based on human experience including >1,000
first trimester exposures reported to the Antiretroviral
Pregnancy Registry (621–623). Lamivudine should only be
used in HIV-1–infected pregnant women as part of a fully
suppressive ART regimen.
Limited information is available about adefovir. It is
embryotoxic in mice and caused neonatal thymic lymphoid
tissue destruction with use in later pregnancy in mice. No reports
of its use in human pregnancy are available. Cases of exposure
during pregnancy should be reported to the Antiretroviral
Pregnancy Registry (800-258-4263; email: registry@pharma
research.com or http://www.apregistry.com).
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Limited information is available about tenofovir. No birth
defects have been seen in studies of rats, rabbits, and monkeys.
Decreased fetal weights and increased bone porosity were seen
in monkeys after high dose exposure in utero. Nineteen cases
of first trimester exposure in humans without birth defects
have been reported (621). Cases of exposure during pregnancy
should be reported to the Antiretroviral Pregnancy Registry
(800-258-4263; email: registry@pharmaresearch.com or http://
www.apregistry.com).




Penicilliosis is caused by the dimorphic fungus, Penicillium
marneffei, which is endemic in Southeast Asia (especially
Northern Thailand and Southern China) (624–626).
Disseminated penicilliosis is the clinical manifestation for 14%
of patients with AIDS in northern Thailand (625).
International travel requires increased awareness and
recognition of penicilliosis and its treatment.
The majority of cases of penicilliosis are observed in patients
with low CD4+ T lymphocyte counts, usually <50 cells/µL
(625). The infection is associated with a high mortality rate if
timely treatment with appropriate antifungal drugs is not
administered.
Clinical Manifestations
Penicilliosis is a systemic disease that commonly occurs with
fever, skin lesions, weight loss, and bone marrow, lymph node,
and hepatic involvement. The skin lesions consist of a
generalized papular rash; some of the papules might have
central umbilication resembling molluscum contagiosum.
Cutaneous penicilliosis lesions commonly appear on the face,
ears, extremities, and occasionally the genitalia. Patients with
hepatic penicilliosis have fever, abdominal pain, hepatomegaly,
and a marked increase in serum alkaline phosphatase levels.
Diagnosis
The diagnosis is based on isolation of the fungus from blood
or other clinical specimens or by histopathologic
demonstration of organisms in biopsy material. Fungal cultures
demonstrate characteristic features that include a flat green
surface and underlying deep red coloring.
An early presumptive diagnosis can be made several days
before the results of fungal cultures are available by microscopic
examination of Wright stained samples of skin scrapings, bone
marrow aspirate, or lymph-node biopsy specimens. Many
intracellular and extracellular basophilic, spherical, oval and
elliptical yeast-like organisms can be seen, some with clear
central septation, which is a characteristic feature of P.marneffei.
Treatment Recommendations
The recommended treatment is amphotericin B in a dose
of 0.6 mg/kg body weight/day administered intravenously for
2 weeks, followed by oral itraconazole solution in a dose of
400 mg/day for a subsequent duration of 10 weeks (627) (AII).
ART should be administered in accordance with standards of
care in the community; consideration should be given to
simultaneous administration of treatment for penicilliosis and
initiation of ART to improve outcome (CIII).
Management of Treatment Failure
Alternative treatment options for penicilliosis are not
available. For those who fail initial therapy, the approach to
treatment should consist of re-initiating parenteral
amphotericin B followed by another course of oral itraconazole,
coupled with optimizing ART, addressing obstacles to
adherence, avoiding adverse drug interactions, and ensuring
that adequate absorption and serum concentrations of
itraconazole are achieved (AIII).
Prevention of Recurrence
Relapse is common in the absence of chronic suppressive
therapy. All patients who successfully complete treatment for
penicilliosis should be administered secondary prophylaxis
(chronic maintenance therapy) with oral itraconazole in a dose
of 200 mg/day (628) (AI).
Special Considerations During Pregnancy
Invasive fungal disease should be treated the same in
pregnancy as in the nonpregnant adult with the exception
that amphotericin B is the preferred agent in the first trimester
because of the potential teratogenic effects of azoles.
Leishmaniasis
Epidemiology
Leishmaniasis is caused by Leishmania spp., obligate
intracellular protozoa. The organisms survive and replicate in
intracellular vacuoles within macrophages. The Leishmania
genus has traditionally been differentiated into multiple
species, which cause cutaneous, mucosal, or visceral diseases
(629,630).
Leishmaniasis is endemic in 88 countries in the world. An
estimated 12 million cases have been reported worldwide with
an incidence of 1.5–2.0 million new cases annually.
Co-infection with Leishmania and HIV-1 has been reported
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in at least 28 countries. Leishmaniasis among persons with
HIV/AIDS has been reported primarily from Spain, Italy,
France, Portugal, and other countries bordering the
Mediterranean, and Central and South America, and South
India, although the overall incidence has decreased
substantially in developed countries with the introduction of
ART (631,632).
Disease occurs primarily among those with advanced
immunosuppression with low CD4+ T lymphocyte counts,
usually <100 cells/µL (629,630). Evidence indicates that after
primary infection, Leishmania remain viable among healthy
persons for long periods, leading to a susceptible population
when immunosuppression intervenes. Primary leishmaniasis
is spread almost exclusively by sand flies of the genus
Phlebotomus or Lutzomyia; however, in the Mediterranean basin
and in Southern Europe, HIV-1 and Leishmania co-infections
have been reported predominantly in males and in association
with injection-drug use, suggesting that Leishmania might also
be acquired by needle sharing.
Clinical Manifestations
Depending on the persons infected and the species of
Leishmania, leishmaniasis can occur in four different
syndromes: localized cutaneous, diffuse cutaneous, mucosal,
and visceral disease. The most common clinical presentation
of leishmaniasis in persons with AIDS is a disseminated visceral
disease syndrome (70%). In Mediterranean countries, visceral
leishmaniasis among HIV-1–infected patients is in general
similar to that observed among non-HIV–infected populations
(633). The most common clinical and laboratory findings are
fever (80%), splenomegaly (65%), hepatomegaly (63%), and
pancytopenia (73%). Splenomegaly is less frequent among
HIV-1–infected patients (633). Among those with more
profound immunosuppression, atypical manifestations, with
involvement of the upper and lower gastrointestinal tract, lung,
pleural and peritoneal cavities and skin is common (633–635).
In geographic locations other than the Mediterranean basin,
clinical manifestations might include unusual nonulcerative
cutaneous lesions that mimic Kaposi sarcoma or the more
common nodular diffuse form of leishmaniasis. Disfiguring
mucosal lesions that are associated with anergy to Leishmania
antigens and a negative leishmanin skin test reaction have been
observed among persons with AIDS, unlike mucosal lesions
in immunocompetent persons that are associated with strong
DTH responses (635).
Diagnosis
Demonstration of characteristic amastigote forms of
Leishmania in tissue biopsy specimens (e.g., scrapings,
aspirates, other specimens by histopathology, cultures, and
smears) from cutaneous or mucosal lesions is the standard for
diagnosis of cutaneous leishmaniasis among HIV-1 co-infected
patients (630). The diagnosis of visceral leishmaniasis among
patients with hepatosplenomegaly is also made by the
demonstration of amastigote forms in buffy-coat smear
preparations, cultures from the peripheral blood, and smears
or cultures from bone marrow or spleen aspirates. Other
methods useful for demonstrating Leishmania in the blood of
co-infected patients include detection of Leishmania nucleic
acid by PCR amplification and xenodiagnosis using colonized
sand flies (636–638).
Antileishmanial antibodies against Leishmania antigens are
of high diagnostic value among immunocompetent patients
and can be detected by various serological methods (630).
However, among HIV-1 co-infected patients, serologic tests
are often negative. The use of recombinant antigen (e.g., rK39)
in ELISA assays might increase sensitivity. Also, immuno-
blotting with Leishmania infantum soluble antigen has been
successful in detecting specific antileishmanial antibodies in
up to 70% of European patients. Negative DTH responses to
leishmanin skin tests are frequently observed in persons with
HIV-1/Leishmania co infection, particularly in those with
profound immunosuppression and cutaneous anergy to other
antigens.
Treatment Recommendations
Pentavalent antimony, 20 mg/kg body weight/day,
administered by intravenous or intramuscular routes, is the
initial treatment of choice for leishmaniasis both for cutaneous
or visceral disease in many parts of the world (639,640) (AII).
The duration of treatment ranges from 3–4 weeks depending
on the initial response (633,639–641) (CIII). Antimonials
suppress Leishmania infection by decreasing the parasite
burden in infected macrophages but do not eradicate infection,
and relapses commonly follow cessation of therapy among
immunosuppressed patients with AIDS. Patients with visceral
leishmaniasis might have severe neutropenia and might benefit
from a short course of recombinant human (rHu) granulocyte
macrophage colony stimulating factor (GM-CSF) 5 mg/kg
body weight/day administered subcutaneously during the
initial 5 days of treatment (642) (CII).
Amphotericin B is an effective but less extensively evaluated
alternative treatment for leishmaniasis (639, 643–645) (AII).
Both the conventional and lipid complex or liposomal
encapsulated formulations of amphotericin B appear to have
similar efficacy compared with pentavalent antimonials
(639,640,643–645) (AII). The lipid complex or liposomal
preparations are generally better tolerated, and might be
preferable to conventional amphotericin B in this setting
(644–646) (BII).
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The optimal amphotericin B dosage has not been
determined. Reported regimens include amphotericin B
0.5–1.0 mg/kg body weight/day IV (maximum: 50 mg/day)
to achieve a total dose of 1.5–2.0 g (639,641,643) (BII) or
lipid complex or liposomal preparations 2–5 mg/kg body
weight/day over 10 consecutive days (640,644–646) (BII). If
lipid complex or liposomal preparations are used, a higher
daily dosage is recommended (639,644,645) (BII).
Pentamidine isethionate, 3–4 mg/kg body weight/day
administered as a single IV dose infused over at least 60
minutes, at intervals of three times per week for 3–4 four weeks,
is a second-line alternative for treatment of leishmaniasis
(641,643) (BII). The following regimens have also been
reported to have activity in the treatment of visceral
leishmaniasis: allopurinol 20 mg/M2 in three doses, alone or
combined with pentavalent antimony or imidazoles (CIII),
imidazoles such as ketoconazole (400–600 mg/day) or
itraconazole (400 mg/day) (CIII); and IFN-gamma as
adjunctive therapy for severe or refractory cases of visceral
leishmaniasis (647) (CIII).
Evidence indicates that HIV-1 co-infection alters T helper
cytokine responses to Leishmania (630,633). Poor clinical
response to antileishmanial chemotherapy has been reported
among co-infected patients who have high plasma HIV-1 RNA
levels. Data further indicate that patients receiving ART who
present with visceral leishmaniasis have better outcomes than
those not receiving ART (631). As such, strong consideration
should be given to initiation or optimization of ART among
patients who present with leishmaniasis (CIII).
Monitoring and Adverse Events
 Patients receiving pentavalent antimonials should be
monitored closely for adverse reactions, which are frequent
and vary from mild phlebitis to death. Overall, at a dose of 20
mg/kg bodyweight/day, >60% of patients might have one or
more of the following reactions: local pain at the site of
injection, thrombophlebitis, anorexia, myalgia, arthralgia,
abdominal pain, elevation of liver transaminases, amylase or
lipase, and in some patients, clinical pancreatitis. Occasional
electrocardiographic changes might be observed (e.g.,
prolonged QT intervals and T wave inversion). Rarely,
arrhythmias and sudden death have occurred (639,640).
Patients treated with amphotericin B should be monitored
for dose-dependent nephrotoxicity, electrolyte disturbances,
and infusion-related adverse reactions, which might be
ameliorated by pre-treatment with acetaminophen,
diphenhydramine, or limited doses of corticosteroids (CIII).
Previous fluid expansion with colloidal fluids might help
reduce the risk for nephrotoxicity during treatment (CIII).
Management of Treatment Failure
 For patients who fail to respond to initial therapy or
experience a relapse after initial treatment, a repeat course of
the initial regimen or use of one or more of the recommended
alternatives for initial therapy as outlined above should be
considered (CIII). The response rate for retreatment appears
to be similar to that for initial therapy although certain patients
might evolve to a chronic disease state with serial relapses
despite aggressive acute and maintenance therapies (CIII).
Although data to support its use among HIV-1–infected
persons are limited, miltefosine might be an alternative oral
agent for use as salvage therapy in countries outside the United
States (CIII). The drug is approved and available in India and
registration in Europe is pending. The adult dose is 100 mg
daily for 4 weeks. Cure rates in HIV-seronegative patients are
reported at approximately 95%. A phase II trial from India
indicated that miltefosine was as effective as amphotericin B
for the treatment of visceral leishmaniasis in HIV-seronegative
patients (648). Gastrointestinal side effects are the most
common adverse effects but rarely limit treatment.
Prevention of Recurrence
Among patients with visceral leishmaniasis who are not
receiving or responding to ART, the risk for relapse at 6 and
12 months, in the absence of secondary prophylaxis (chronic
maintenance therapy), is 60% and 90%, respectively (630,
649). Therefore, secondary prophylaxis with pentavalent
antimony, amphotericin B, or pentamidine, administered at
least every 2–4 weeks, is recommended, particularly for those
with CD4+ T lymphocyte counts <200 cell/µL (630,633,
646,649–651) (AII).
Relapse after discontinuation of secondary prophylaxis or
maintenance therapy for leishmaniasis is uncommon among
patients who respond to ART and maintain a CD4+
T-lymphocyte count >200 cells/µL (652), although relapse
might be more common among those with visceral
leishmaniasis, even with CD4+ T lymphocyte counts >200
cells/µL and undetectable plasma HIV-1 RNA (653). Although
data are insufficient to provide a recommendation,
discontinuation of secondary prophylaxis after successful
treatment of leishmaniasis might be considered after a sustained
(i.e., >3–6 months) increase in the CD4+ lymphocyte count
to levels >350 cells/µL after initiation of ART (652,653) (CIII).
Daily allopurinol, in a dose of 300 mg three times daily, used
for maintenance therapy is less effective than monthly
pentavalent antimony and is not recommended (649) (DIII).
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Special Considerations During Pregnancy
Diagnostic considerations are the same among pregnant
women as in nonpregnant adults. Labeling for pentavalent
antimony compounds (sodium stibogluconate available in the
United States through CDC and meglumine antimoniate)
states that they are contraindicated among pregnant women,
although various compounds were not teratogenic among
chickens, rats, or sheep (654–656). A single case report of use
of meglumine antimoniate in the second trimester of human
pregnancy reported a good outcome for mother and infant
(657,658). Because of concerns about toxicity and lack of
experience with use of pentavalent antimony compounds in
human pregnancy, amphotericin B would be the first choice
for therapy of visceral leishmaniasis in pregnancy if the
Leishmania species causing infection is expected to be
responsive to amphotericin B (658) (AIII). Pentamidine would
be the second choice, and antimony compounds reserved for
infections not responsive to the other two agents (AIII).
Perinatal transmission of Leishmania spp. occurs rarely; eight
documented cases have been reported (659). No data on the
risk for transmission of Leishmania spp. among
HIV-1–infected pregnant women are available.
Paracoccidioidomycosis
Epidemiology
Paracoccidioidomycosis is caused by Paracoccidioides
brasiliensis, a dimorphic fungus that exists in a mycelial phase
in the soil and as budding yeast in infected tissue.
Paracoccidioidomycosis is the most prevalent endemic mycosis
in Central and South America. An estimated 10 million
persons are infected. Infection of the susceptible host is
presumed to occur after inhalation of the fungus in the mycelial
phase (660–663).
Relatively few cases of paracoccidioidomycosis in association
with HIV-1 infection have been reported. One reason for this
is that TMP-SMX prophylaxis for P. jiroveci pneumonia also
appears to be effective in preventing clinical disease caused by
P. brasiliensis (660–663). However, other factors, such as lack
of intersection of the HIV-1 epidemic with areas where the
disease is endemic for P. brasiliensis, confusion of the diagnosis
with P. jiroveci pneumonia, and use of azole antifungals for
oropharyngeal candidiasis, also might have reduced the
apparent number of cases.
Clinical Manifestations
On the basis of a retrospective review of 27 cases, the
manifestations of paracoccidioidomycosis among patients with
HIV-1 infection are protean (661). Skin lesions, adenopathy,
mucosal lesions, and pulmonary infiltrates, all associated with
fever and other constitutional symptoms, are frequent.
Diagnosis
The diagnosis is based on histological identification of the
organism or its growth from involved tissue. Yeast forms in
tissue typically form a wheel-house pattern because of the radial
budding of daughter yeast forms from a mother cell.
Paracoccidioidal serology might be useful, although it appears
to be positive less frequently among HIV-1–infected persons
than among immunocompetent patients. Newer assays (e.g.,
genomic identification using PCR and antigen detection) are
promising.
Treatment Recommendations
No published randomized clinical trials for the treatment
of paracoccidioidomycosis exist. The majority of specialists
recommend amphotericin B for initial therapy in severe cases
(BII), but the efficacy of other agents (e.g., TMP-SMX and
azole antifungals) might be comparable. In particular, single-
arm studies of itraconazole, 100–200 mg daily, ketoconazole
200–400 mg, and sulfonamides have demonstrated activity
in immunocompetent hosts (BII). Fluconazole is associated
with a higher failure rate even at doses up to 600 mg daily and
is not recommended (662,663). Potent ART should be
administered in accordance with standards of care in the
community (AIII).
Management of Treatment Failure
In the absence of any clinical trials to indicate approaches
to the treatment of patients who fail to respond or who relapse
after initial treatment, consideration should be given to
retreatment with amphotericin B or to the use of azole
antifungals (CIII).
Prevention of Recurrence
Secondary prophylaxis (i.e., chronic maintenance therapy)
to prevent relapse should be considered for patients with AIDS
and CD4+ T lymphocyte counts of <200 cells/µL, although
no data indicate appropriate regimens in this setting. ART
should be optimized.
Special Considerations During Pregnancy
Invasive fungal infections should be treated the same in
pregnancy as among the nonpregnant woman. Amphotericin
B is the preferred agent in the first trimester because of the
potential teratogenic risks for the azoles, if efficacy of
amphotericin is expected to be similar to that of azoles (BIII).
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Isosporiasis
Epidemiology
Isosporiasis is caused by Isospora belli, a protozoan belonging
to the family Apicomplexa, commonly referred to as coccidia.
Infection results from the ingestion of sporulated oocysts in
contaminated food or water. Infection occurs worldwide, but
the prevalence of infection is higher in tropical and subtropical
regions. Infection can occur in both immunocompetent and
immunocompromised hosts. Isospora belli infections have been
observed among different immunocompromised patients and
among patients with AIDS (664–666).
Clinical Manifestations
The most common clinical manifestation of disease is
diarrhea, which in patients with AIDS can be similar to that
observed with cholera and associated with severe dehydration.
Blood is not present in the feces. Systemic symptoms of fever,
headache, malaise, abdominal pain, vomiting, and weight loss
are also common. Infection primarily involves the small
intestine. Colitis is not generally observed.
Diagnosis
The diagnosis of isosporiasis can be made by stool
examination for ova and parasites. Oocysts are ovoid in shape
and are 23–36 by 12–17 mM in size. Isospora oocysts
autofluoresce a blue-green color under an epifluorescence
microscope, enhancing their detection in wet mount
preparations. The organisms also stain red with the same
modified acid-fast technique used for diagnosis of
cryptosporidiosis. No commercial antigen-detection systems
have been developed.
Schizonts, merozoites, macrogamonts, microgamonts,
microgametes, and oocysts can be demonstrated in enterocytes
in biopsies of the small or large intestine. Extraintestinal
infections with tissue cyst-like stages have been demonstrated
in lymph nodes adjacent to the intestine in patients with AIDS.
Treatment Recommendations
Fluid support should be offered if the diarrhea has resulted
in dehydration (AIII). Malnutrition and wasting should be
treated with nutritional supplementation (AIII). The drug of
choice for therapy is trimethoprim (160 mg) and
sulfamethoxazole (800 mg) administered four times a day for
10 days (665) (AII). Doses of oral trimethoprim (320 mg)
plus sulfamethoxazole (1,600 mg) taken twice a day for 10–
14 days is as effective and might be associated with improved
adherence and tolerability (AIII). Treatment with TMP-SMX
results in clearance of parasites, decreased volume of diarrhea,
and decreased abdominal pain within a mean of 2.5 days after
initiation of treatment.
No effective alternative treatment is available for patients
unable to tolerate sulfonamides. Several agents have been used
with anecdotal success. Pyrimethamine used alone in doses of
50–75 mg/day appears comparable to treatment with
trimethoprim and sulfamethoxazole (666) (BII). When
pyrimethamine is used, it should be administered with folinic
acid (5–10 mg/day) to prevent bone marrow suppression (BII).
Ciprofloxacin and other fluoroquinolones have demonstrated
activity against other Apicomplexa in animal studies and might
be second-line alternatives for treatment of isosporiasis (BII).
In a limited, randomized clinical trial comparing ciprofloxacin
with TMP-SMX among HIV-1–infected patients with
isosporiasis, all patients treated with TMP-SMX cleared the
organism and had cessation of diarrhea within a median of 2
days; ciprofloxacin was effective in 83% of patients with a
median time to cessation of diarrhea of 4.5 days (667).
Treatment with other anti-protozoal agents (e.g.,
metronidazole, tinidazole, quinacrine, and furazolidone) is
probably of limited value and is not recommended (DIII).
Immune restoration after of ART among patients with AIDS
is associated with more rapid resolution of symptoms and fewer
relapses. Therefore, ART is recommended as part of the
treatment for patients with isosporiasis (AIII).
Management of Treatment Failure
Treatment failure is defined as persistence or worsening of
diarrhea and systemic symptoms after 5–7 days of appropriate
treatment. Retreatment with a second-line alternative agent
might result in improvement in those who fail initial therapy
(BIII).
Macrolide antibiotics have marginal efficacy in treating
I. belli enteritis (CII). Spiramycin (1.5 g twice daily) and
roxithromycin (2.5 mg/kg body weight every 12 hours) have
been effective in a limited number of patients with AIDS and
chronic refractory isosporiasis (668,669). Diclazuril (200–300
mg/day for 7 days), nitazoxanide (500 mg twice a day for
7–10 days), and albendazole coupled with ornidazole were
effective in limited numbers of patients with AIDS and I. belli
diarrhea and might be tried among patients unresponsive to
(or intolerant of ) TMP-SMX (670–672) (CII).
Prevention of Recurrence
Infections tend to be chronic and relapsing, particularly in
patients with AIDS and advanced immunosuppression.
Treatment is usually effective in controlling symptoms, but
recurrences are common after treatment is stopped, probably
because the agents used to treat the infection are not active
against the extra-intestinal tissue cyst stage of the parasite.
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Patients with CD4+ T lymphocyte counts <200/mL should
receive secondary prophylaxis (chronic maintenance therapy)
with trimethoprim (320 mg) and sulfamethoxazole (1,600 mg)
once daily or three times a week (AII). Pyrimethamine, 25
mg per day, also has been used successfully for secondary
prophylaxis following primary isosporiasis (BII).
Although not evaluated in any clinical trial or observational
cohort setting, it is likely, as with other similar opportunistic
infections, that secondary prophylaxis can be safely
discontinued after an increase in CD4+ T lymphocyte counts
to levels >200 cells/µL sustained for at least 3–6 months
following initiation of ART (BIII).
Special Considerations During Pregnancy
The incidence, clinical manifestations, and course of I. belli
infection do not appear to differ with pregnancy. Diagnosis




American trypanosomiasis, or Chagas disease, is an
anthropozoonosis caused by Trypanosoma cruzi, a flagellated
protozoan transmitted to humans and mammals by a group
of haematophagous reduviid insects. T. cruzi causes a lifelong
chronic bloodstream infection in vertebrate hosts, including
humans (675–678).
Chagas disease vectors have been reported in the Americas
from 42ºN to 46ºS, and the disease is distributed from the
southern United States to the southern regions of Argentina
and Chile. When reduviid insects bite the vertebrate host’s
skin to take a blood meal, T. cruzi parasites are deposited with
the insect’s feces and penetrate through the skin defect into
the host. Humans also might acquire trypanosomiasis by blood
transfusion, transplacentally, from an infected transplanted
organ, or from laboratory accidents (675–678).
In 1990, Chagas disease affected 16–18 million persons.
Approximately 45,000 deaths annually were attributed to
Chagas’ disease in the Americas, and approximately 7.2% of
the population of Argentina was chronically infected, 22% of
Bolivia, 4.3% of Brazil, and 10% of Chile. Since then, the
Southern Cone Initiative to interrupt transmission of Chagas
disease has reduced the incidence of the disease by 70% in the
Southern Cone countries. An estimated 50,000–100,000
persons in the United States are infected with T. cruzi.
In humans, T. cruzi infection is followed by an acute illness
with moderate to high levels of parasitemia which, after a
period of a few months, is followed by a lifelong chronic
infection, characterized by low-grade and intermittent
parasitemia in which tissue parasites are scarce and difficult to
demonstrate. All patients with chronic infection are potentially
able to transmit Chagas disease through triatomid insect bites,
pregnancy, blood transfusion, or organ donation.
Among patients with HIV-1 infection, reactivation of
chronic, latent T. cruzi infection can be triggered by profound
immunosuppression (679–682). The epidemiology of T. cruzi
infection among persons co-infected with HIV-1 in areas where
the disease is endemic has not been well-characterized.
Clinical Manifestations
Chagas disease can be divided into two stages: acute and
chronic. The acute phase of Chagas disease, usually observed
among children, begins shortly after infection and lasts 1–2
months. This stage of the disease is often asymptomatic,
although fever,  malaise, anorexia, induration, and
lymphadenitis around the inoculation site (chagoma) or
periocular edema (Romaña sign) might be observed.
Generalized lymphadenopathy and splenomegaly also might
occur. Severe illness with cardiac failure or meningoencephalitis
occurs in a limited proportion of patients. Acute infection is
characterized by relatively high level parasitemia.
The acute illness of Chagas disease usually resolves
spontaneously, and although the infection does not resolve
spontaneously, the patient enters an asymptomatic
indeterminate phase of the illness. After one or two decades,
10%–30% of infected patients experience chronic cardiac
and/or digestive tract disease.
The clinical features of immunosuppression-induced
reactivation of Chagas disease among patients with HIV-1
infection differ from that of chronic infection among
immunocompetent patients, with the most overt difference
being the high frequency of CNS involvement, with attendant
high morbidity and mortality. Neurological signs and
symptoms are the predominant clinical findings among HIV-
1–infected patients with reactivation of T. cruzi infection
(679–682). The most common presentation of this form of
disease is a severe multifocal or diffuse acute
meningoencephalitis with necrosis and hemorrhage associated
with a substantial number of amastigotes in tissue. Although
most patients have a single supratentorial lesion, some
demonstrate multiple lesions in both supratentorial and
infratentorial regions. Many of these patients also have
detectable peripheral parasitemia.
The clinical manifestations of perinatally acquired T. cruzi
in HIV-1 co-infected infants have not been well described.
Of those reported, the majority have had serious
meningoencephalitis syndromes (683,684).
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Diagnosis
Chagas disease should be considered in the differential
diagnosis of CNS mass lesions and cardiac disease (arrhythmias
or heart failure) among patients with HIV-1 infection in areas
where the disease is endemic. The imaging pattern of brain
chagoma is similar to that of cerebral toxoplasmosis although
chagomas tend to be larger than Toxoplasma lesions. MRI and
CT imaging indicate hypodense lesions, which enhance with
gadolinium.
A definitive diagnosis is established by brain biopsy or
identification of the parasite (or its products) in tissue or blood.
Preliminary results of tests to identify T. cruzi using a PCR
amplification assay of DNA are promising. Direct tests for
identifying T. cruzi microscopically are useful during the acute
stage and in reactivation of chronic infection (e.g., in the setting
of HIV-1 infection) because in these phases, relatively large
numbers of parasites circulate in the bloodstream. Blood
concentration techniques, such as capillary centrifugation
(microhematocrit test) can improve sensitivity (685,686). In
blood, T. cruzi sediments are seen just above the buffy coat.
Centrifugation of CSF also can be employed among patients
with suspected CNS Chagas disease. Parasites also might be
observed in lymph nodes, bone marrow, pericardial fluid, and
CNS mass lesions.
Indirect tests such as xenodiagnosis (recovering the organism
after inoculation of laboratory-raised insect vectors) (686) or
hemoculture (culture in liquid medium) are somewhat more
sensitive than the direct methods, but might take 2–8 weeks
to become positive. They are useful in the chronic stages of
T. cruzi infection, when the level of parasitemia is low.
Serological tests to detect the IgG antibody responses to
T. cruzi infection are useful for diagnosis of disease in
chronically infected patients, to screen blood donors, and for
seroepidemiological studies. The techniques used are indirect
hemagglutination, direct agglutination, complement fixation,
indirect immunofluorescence, and ELISA (687). In the United
States, multiple serologic tests are licensed for diagnosis, but
no test is licensed for screening blood donors. Detection of
IgM antibodies is not sensitive, even during the acute stage of
infection.
A serologic diagnosis of Chagas disease should not be relied
on unless at least two different types of serological tests for
T. cruzi antibodies are positive. Although all of these tests are
reasonably sensitive and specific, both false-positive and false-
negative reactions have been reported. For that reason, the
diagnosis of Chagas disease should not be discarded based on
negative serologic tests if the patient comes from a region where
the disease is endemic and has clinical findings compatible
with Chagas disease. In this instance, direct parasitologic
testing (e.g., microscopic examination of brain tissue and/or
demonstration of parasitemia) is the best diagnostic strategy.
Neonates born to mothers with chronic T. cruzi infection will
have positive antibody tests yet might not be infected;
parasitologic tests and repeat antibody testing at 6 and 12
months are recommended in this instance (683).
Treatment Recommendations
Treatment for Chagas disease is uniformly effective among
patients with chronic stage disease; however, the available
agents are toxic, and consultation with a specialist should be
sought. Benznidazole, 5–8 mg/kg body weight/day for
30–60 days, is the initial treatment most commonly
recommended (AIII). Nifurtimox, 10mg/kg body weight/day,
is an alternative (BIII). Limited data are available evaluating
the efficacy of these agents among HIV-1–infected patients
with Chagas disease. Neither drug is licensed in the United
States; however, nifurtimox is available from CDC under an
investigational protocol. Although no data are available
specifically to address this question, treatment of acute Chagas’
disease is likely to be more effective than treatment of patients
with late-stage complications.
The potential impact of immune reconstitution caused by
ART on HIV-1-related Chagas disease remains to be
established; however, it seems likely that maintaining normal
immune function will decrease the frequency of reactivation
of T. cruzi, as it has with other OIs. As such, initiation or
optimization of ART should be considered for patients
undergoing treatment for Chagas disease, but information is
limited about drug interactions between agents used to treat
Chagas disease and available antiretroviral agents (CIII).
<Monitoring and Adverse Effects
Patients undergoing treatment should be closely monitored
because both benznidazole and nifurtimox are toxic.
Benznidazole causes peripheral neuropathy, rash, and
granulocytopenia. Nifurtimox causes anorexia, nausea,
vomiting, abdominal pain and weight loss, restlessness,
seizures, and peripheral neuropathy. The adverse effects of both
drugs wane when the drugs are discontinued.
Management of Treatment Failure
Although no data are available among HIV-1–infected
persons, certain specialists recommend retreatment with
benznidazole or nifurtimox for patients who fail to respond
or relapse following initial therapy (CIII).
Prevention of Recurrence
Patients with HIV-1-infection are potentially at risk for
recurrent or relapsing clinical manifestations because of
intermittent reactivation of chronic infection. The drugs are
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only partially effective in the chronic stage of disease, are
suppressive rather than curative, and probably require lifelong
administration to prevent relapse in the setting of continued
immunosuppression. Precise doses and regimens have not been
described (CIII). Whether secondary prophylaxis or chronic
maintenance therapy should be used routinely among
HIV-1–infected patients with latent Chagas disease is unclear.
Whether chronic maintenance therapy can be safely
discontinued for persons on ART who have a sustained increase
in CD4+ T lymphocyte count to levels >200 cells/µL is
uncertain.
Special Considerations During Pregnancy
The seroprevalence of T. cruzi infection among pregnant
women in areas where the disease is endemic in Latin America
ranges from as high as 50% in urban areas to 81% in rural
areas (687). In the United States, seroprevalence data are
limited, but one study of 3,765 pregnant women in Houston,
Texas, confirmed antibody to T. cruzi in 0.4% of Hispanic
women and 0.1% of non-Hispanic women (688). No data
are available on the prevalence of T. cruzi antibodies among
HIV-1–infected pregnant women in the United States.
Congenital infection with T. cruzi might increase the risk
for spontaneous abortion, stillbirth, and low birthweight
(689,690). Congenital Chagas disease in newborn infants
ranges from subclinical to life-threatening with severe
neurological and cardiac disease. No data are available to
evaluate whether the combination of HIV-1 infection and
T. cruzi infection increases the risk for adverse pregnancy
outcomes. Diagnosis is the same in pregnancy as among
nonpregnant adults.
Both benznidazole and nifurtimox are associated with
substantial toxicity in chronic T. cruzi infection. Minimal data
are available on potential reproductive toxicity of these drugs,
although both drugs have been associated with increased
detection of chromosomal aberrations in children being treated
for Chagas disease (691–692). Benznidazole crosses the
placenta in rats and covalently binds to fetal proteins (693).
Because of the toxicity and limited experience with use of these
drugs in pregnancy, treatment of acute T. cruzi infection among
pregnant women should only be undertaken in consultation
with a specialist in this area, and treatment of chronic disease
should be considered after completion of the pregnancy. For
HIV-1–infected pregnant women with symptomatic
reactivation of T. cruzi infection, maximization of the immune
response with ART should be the primary approach to therapy
(AIII).
Perinatal transmission of T. cruzi might occur with acute
infection during pregnancy, which has been described rarely,
or more often, with reactivation of chronic infection. Perinatal
transmission rates among general populations of pregnant
women seropositive for antibodies to T. cruzi range from
2%–10% (689,690).
The effect of concurrent HIV-1 infection in the mother on
risk for perinatal transmission of T. cruzi is not well defined,
but the risk for reactivation and transmission might be
increased among women with advanced immunosuppression.
Infants co-infected with HIV-1 and T. cruzi might be more
likely to have symptoms, especially neurologic symptoms
(686).
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Chest radiograph, two views with shielding 0.00002–0.00007
Abdominal film, single 0.1
Hip film 0.2
Intravenous pyelogram 1.0–1.4
Upper gasterointestinal series 0.056
Barium enema or small bowel series 2.0–4.0
Computerized tomography (CT) scan of
head or chest <1
CT scan of abdomen and lumbar spine 2.6–3.5
Upper or lower extremity 0.001
Technetium lung scan 0.12–0.15
Technetium renal scan 0.1–0.33
Technetium bone scan 0.18–0.45
Technetium bleeding scan 0.2–0.47




Iodine (131I), at fetal thyroid 590.0

































































Impaired fertility, fetal death,
growth retardation in rats at high
doses. No teratogenicity in mice,
rats, rabbits at human levels
Embryotoxic in mice, caused
thymic lymphoid tissue destruction
later in the neonate with use in
later pregnancy in mice
Teratogenic (skeletal malforma-
tions) in rats and rabbits but not
in mice
Not teratogenic in mice, rats, or
rabbits
No effect on fertility, no
teratogenicity in rats or rabbits
Antimony not teratogenic in rats,
chicks, or sheep
Not teratogenic in rats or rabbits
No effect on fertility, no
teratogenicity in rodents
No specific studies of
teratogenicity
Possible increase in skeletal
variants in rats
Incomplete ossification in rats and
rabbits at similar to human doses




ties) in rats and rabbits
Arthropathy in immature animals;
not embryotoxic or teratogenic in
mice, rats, rabbits, or monkeys
Teratogenic in one strain of rats
(cardiovascular defects) and mice
(cleft palate); not teratogenic in
rabbits or monkeys; intrauterine
growth retardation in monkeys
Concerns about human pregnancy
Large experience in pregnancy
(>700 first-trimester exposures
reported to registry); well-tolerated
No experience with human use
No experience; animal data concerning
Theoretical risk for ototoxicty in fetus;
reported with streptomycin but not
amikacin
No studies. No evidence of teratogenicity;
might be preferred over fluconazole in
first trimester
One case report of use in human
pregnancy in second trimester with
good outcome. Labeled as
contraindicated in pregnancy
Limited experience
Moderate experience with use for
treatment of Chlamydia trachomatis in
pregnancy
Increase chromosomal aberrations in
children receiving treatment; uncertain
significance. No human pregnancy data
Limited experience in human pregnancy;
theoretical risk for fetal ototoxicity
No experience with human use
No evidence of teratogenicity in humans
Unknown risk; animal studies concerning
Because of cartilage changes in immature
animals, use in pregnant women and
children aged <18 years not recom-
mended; no increase in anomalies with
>200 first trimester exposures
Animal data concerning; limited human
experience. No increase in anomalies in
156 infants with first trimester exposure




Treatment of frequent or severe
symptomatic herpes outbreaks or
varicella; use for prevention of
recurrences at term investigational
Not recommended; report
exposures during pregnancy to
Antiretroviral Pregnancy Registry
(800-258-4263)
Consider in second and third







Therapy of visceral leishmaniasis




Preferred agent for Mycobacte-
rium avium complex (MAC)
prophylaxis or treatment (with
ethambutol); chlamydia
trachomatis infection
Not indicated in chronic infections;
seek expert consultation if acute
infection or symptomatic
reactivation of T. cruzi diagnosed
in pregnancy
Drug resistant tuberculosis
Invasive Candida or Aspergillus




Alternate treatment or secondary
prophylaxis of life-threatening or
sight-threatening cytomegalovirus
infections
Severe MAC infections; multidrug
resistant tuberculosis (Anthrax)
Treatment or secondary MAC
prophylaxis if other choices
exhausted
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No effect on fertility; no
teratogenicity in rodents
Not teratogenic in mice, rats, or
rabbits
No data available
No animal studies of teratogenicity
Increased fetal death in rats at
extremely high doses; no
teratogenicity
Incorporated into fetal bones,
teeth with staining; no birth
defects in mice, rats, or rabbits
No evidence of teratogenicity
Teratogenic, at high doses, in
mice (cleft palate, exencephaly,
vertebral abnormalities), rats
(vertebral abnormalities), and
rabbits (monophthalmia, cleft lip,
palate)
Increased rate of defects
(omphalocele, exencephaly, cleft
palate) in rats, mice, and rabbits
with high doses; not seen with
usual human doses
No evidence of teratogenicity in
rats or rabbits
Abnormal ossification, structural
defects in rats, and mice at high
doses
Facial clefts and skeletal
abnormalities in rats; no defects
in mice or rabbits
No animal studies
Teratogenic (skeletal abnormali-
ties) in rats and rabbits
Caused complete litter destruction
or growth retardation in rats,
depending on when administered
No concerns specific to pregnancy
Limited experience reported (19 cases);
no anomalies noted but red-brown skin
discoloration reported in several infants
exposed throughout pregnancy
No data available
Limited human experience does not
suggest teratogenicity; might displace
bound bilirubin in the neonate, increasing
the risk for kernicterus
Limited data do not indicate teratogenicity
Risk for hepatic toxicity increased with
tetracyclines in pregnancy; bone and
tooth changes contraindicate use in
pregnancy
Hepatotoxicity with erythromycin estolate
in pregnancy; other forms acceptable; no
evidence of teratogenicity
No evidence of teratogenicity in 320
cases of human use for treatment of
tuberculosis; avoid in first trimester if
possible
Limited human data; avoid in first
trimester if possible
Limited human experience; report
exposures during pregnancy to Registry
(888-669-6682)
Case reports of rare pattern of craniofa-
cial, skeletal abnormalities in four infants
born to three women with prolonged
exposure during pregnancy; no increase
in defects seen in several series after
single dose treatment
No reports of use in first trimester of
human pregnancy; might be metabolized
to 5-fluorouracil, which is teratogenic in
animals and possibly in humans
No data in human pregnancy
No data in human pregnancy
No data in human pregnancy
Treatment of anaerobic bacterial





Alternate choice for primary or
secondary Pneumocytis jiroveci
pneumonia (PCP) prophylaxis
Symptomatic treatment of diarrhea
None
Bacterial and chlamydial infections
Active tuberculosis and MAC
treatment
Active tuberculosis
Recurrent genital herpes and
primary varicella infection
Only for documented systemic
disease, not prophylaxis; not for
treatment of vaginal or oral
Candida; consider use of
amphotericin B in first trimester




safe in pregnancy at minimal
systemic levels
Treatment or secondary
prophylaxis of life-threatening or
sight-threatening CMV infection
Topical solution might be used for
ocular infections
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Embryotoxic in rabbits and mice;




Not teratogenic in rats and rabbits
No teratogenicity in rats and
rabbits
Abortifacient at high doses in
monkeys, mice; not teratogenic
in monkeys, mice, rats, or rabbits
Not teratogenic in rodents and
rabbits
Teratogenic in rats (skeletal
defects) and mice (encephalocele,
macroglossia) at high doses
Club feet in mice; no defects in
rats, rabbits and monkeys except
inner ear changes in multiple
species
Teratogenic (VSD, cleft palate) in
rats; increased fetal death in mice
and rabbits
No evidence of teratogenicity in
multiple species
Not teratogenic in rats and rabbits
Embryotoxic in rats and rabbits;
complete embryolethality in
rabbits at doses of 6 mg/kg
body weight/day
Multiple studies do not indicate
teratogenesis; one study with
positive findings in rodents and
guinea pigs
Case reports of safe use in human
pregnancy after transplants
Case reports of use in human pregnancy
without adverse effects
No experience with use in human
pregnancy
Approximately 30 cases of use of
interferon-alfa in pregnancy reported; 14
in first trimester without increase in
anomalies; possible increased risk for
intrauterine growth retardation
Possible increased risk for hepatotoxicity
during pregnancy; prophylactic
pyridoxine, 50 mg/day, should be given to
prevent neurotoxicity; prophylactic vitamin
K recommended at birth to prevent
hemorrhagic disease
Case reports of craniofacial, skeletal
abnormalities in humans with prolonged
fluconazole exposure during pregnancy;
no increase in defect rate noted among
156 infants born after first trimester
itraconazole exposure
Hearing loss in 2.3% of 391 children after
long term in utero therapy
Inhibits androgen and corticosteroid
synthesis; might impact fetal male genital
development; case reports of craniofacial,
skeletal abnormalities in humans with
prolonged fluconazole exposure during
pregnancy
No evidence of teratogenicity with
approximately 1,000 first-trimester
exposures to antiretroviral doses
No increase in birth defects among infants
born to 89 women with first trimester
exposure
No experience with human use
Studies in several hundred women with
first trimester exposure do not indicate
increase in birth defects
Treatment or secondary
prophylaxis of life-threatening or
sight-threatening CMV infection.
Preferred agent for therapy in
children
Treatment of leuckopenia
Because of lack of experience,
other treatment modalities such as
cryotherapy or trichloroacetic acid
recommended for wart treatment
during pregnancy
Treatment of hepatitis C should be
delayed until after delivery if
possible
Active tuberculosis; prophylaxis
for exposure or skin test
conversion
Only for documented systemic
fungal disease, not prophylaxis
Drug resistant tuberculosis
None
Hepatitis B therapy, only as part of
a combination antiretroviral
regimen


























































90 MMWR December 17, 2004



























































Not teratogenic in mice and rats
No data
Not teratogenic in rats and rabbits
Occipital bone defects in one
study in rats; not teratogenic in
rabbits.
Not teratogenic in mice and
rabbits
Not teratogenic in multiple animal
species
Embryocidal but not teratogenic in
rats and rabbits with systemic use
Increased embryonic and fetal
deaths in rats and mice but not
teratogenic
Dose dependent increased risk for
cleft palate in mice, rabbits, and
hamsters; dose dependent
increase in genital anomalies in
mice
Not available
Not teratogenic in mice
Teratogenic in mice, rats, and
hamsters (cleft palate, neural tube
defects, and limb anomalies)
Dose dependent risk for multiple
defects (craniofacial, CNS,
skeletal, anophthalmia) in rats,
mice, and hamsters starting at
doses below those used in
humans
Not teratogenic in rats and rabbits
Teratogenic in mice (cleft palate)
and rats (spina bifida) but not in
rabbits
No teratogenicity in mice, rats,
and guinea pigs
Increase chromosomal aberrations in
children receiving treatment; uncertain
significance; no experience in human
pregnancy
No experience in human pregnancy
Four case reports with use in early
pregnancy and normal outcomes
Possible increase in limb, ear anomalies
in one study with 143 first trimester
exposures; no specific pattern of defects
noted, several studies did not find
increased risk
Poor oral absorption makes toxicity,
teratogenicity unlikely.
Vast experience with use in human
pregnancy does not suggest
teratogenicity
Limited systemic absorption with aerosol
use; limited experience with systemic use
in pregnancy
Case reports of maternal and fetal deaths
after use of podophyllin resin in
pregnancy are concerning; no clear
increase in birth defects with first trimester
exposure
Human data inconsistent in finding
increased risk for cleft palate; risk for
growth retardation; low birthweight might
be increased with chronic use; monitor
blood sugars with use in third trimester
Limited experience with use in human
pregnancy; theoretical risk for hemolytic
anemia if fetus has G6PD deficiency
Limited experience with use in human
pregnancy
Limited human data have not suggested
an increased risk for birth defects; folate
antagonist, use with leucovorin
Reports of treatment during second half of
pregnancy among nine women without
incident; contraindicated in first trimester
because of consistent teratogenicity in
animals
No specific concerns for pregnancy
No clear teratogenicity in humans;
vitamin K recommended at birth to
prevent hemorrhagic disease of the
newborn
Possible increased risk for deafness and
VIII nerve damage; no evidence of other
defects
Not indicated in chronic infection;
seek expert consultation if acute
infection or symptomatic













Because alternative treatments for
genital warts in pregnancy are
available, use not recommended;
inadvertent use in early pregnancy
is not indication for abortion
Adjunctive therapy for severe
Pneumocystis pneumonia;










pregnancy; no clear indications in
pregnancy
Treatment or prophylaxis of MAC,
active tuberculosis
Active tuberculosis
Alternate therapy for active
tuberculosis
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Sulfonamides teratogenic in some
animal studies
No evidence of birth defects in
rats, rabbits, or monkeys at high
doses; decreased fetal weights
and increased bone porosity were
observed in monkeys with long
term exposure in utero to doses
25 times usual human dose;
chronic administration in immature
animals of multiple species at
6–50 times human doses have led
to dose-specific bone changes
ranging from decreased mineral
density to severe osteomalacia
and fractures
Teratogenic in rats and mice (cleft
palate)
Teratogenic in rats and rabbits
(visceral, ocular, skeletal,
cardiovascular, CNS defects) at
low doses
Not teratogenic in mice, rats, and
rabbits
Embryotoxic in rats, rabbits.
Teratogenic in rats (cleft palate,
hydronephrosis, ossification
defects)
No clear teratogenicity among humans;
potential for increased jaundice,
kernicterus if used near delivery
No experience with human use
Possible increase in congenital cardiac
defects, facial clefts with first trimester
use. Potential for increased jaundice,
kernicterus if used near delivery
Similar drugs, methotrexate and
aminopterin, are abortifacient and
associated with embryopathy including
“clover-leaf skull, limb defects, develop-
mental delay, sometimes with neural tube
defects; frequency might increase with
increasing maternal dose
Experience with valacyclovir in pregnancy
limited; prodrug of acyclovir, which is
considered safe for use in pregnancy




exposures during pregnancy to
Antiretroviral Pregnancy Registry
(800-258-4263)
Treatment and prophylaxis of
Pneumocystis pneumonia
Use in pregnancy should be
avoided if possible; might be used
for Pneumocystis pneumonia if
refractory/intolerant to TMP/SMX
and pentamidine
Alternate agent for herpes simplex




























Drug category maternal ratio) Animal reproduction studies Concerns about human pregnancy use during pregnancy
TABLE 3. Cytology and histology terms for Papanicolou smears and cervical, vaginal, and anal tissue samples
Tissue histology Tissue histology
Cytology (Bethesda System 2001) (Dysplasia system) (Intraepithelial neoplasia system)
Negative for intraepithelial lesion or malignancy Normal Normal
Unsatisfactory Unsatisfactory Unsatisfactory
Atypical squamous cells—undetermined significance No term No term
Atypical squamous cells- cannot exclude high-grade squamous No term No term
  intraepithelial lesion (HSIL)
Low-grade squamous intraepithelial lesion Mild CIN I
HSIL Moderate CIN II
Severe CIN III
CIS (carcinoma in situ) CIN III
Carcinoma Carcinoma Carcinoma
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TABLE 4. Treatment of anal intraepithelial neoplasia (AIN)*
Lesion location
AIN-1 (anal condolymata) AIN-2 or AIN-3
Lesion size Perianal Intra-anal Perianal Intra-anal
Discrete, <1 cm2 at base A,B,C,D,E A,B,E,F,G,H A,B,E,F A,B,E,F,G
Discrete lesion >1 cm2 at base, not circumferential A,B,C,D,E,F,G,H E,F,G,H E,F,G E,F,G
Diffuse or circumferential lesions C,D,E,F,G,H H E,F,G,H H
Key:






G Surgical cold scalpel excision
H Observation only
* Recommendations based on clinical experience (CIII) and not randomized clinical trials.
TABLE 5. Recommended dose adjustments when patients are administered rifabutin concurrently with antiretroviral drugs
Antiretroviral regimen Rifabutin Dose* Antiretroviral dose adjustment
Protease inhibitors (PI) regimens
Nelfinavir, indinavir, amprenavir, or Decrease daily dose to 150 mg; use 300 mg Nelfinavir: use 1,250 mg every 12 hours
fosamprenavir (plus two nucleoside for three times weekly therapy Indinavir: consider increase to 1,000 mg every 8 hours
reverse transciptase inhibitors [NRTIs]) Amprenavir or fosamprenavir: no change
Ritonavir (plus two NRTIs, other PIs, Decrease to 150 mg twice or three times weekly† None
and/or non-NRTIs [NNRTIs])
Lopinavir/ritonavir (Kaletra) (plus two Decrease to 150 mg twice or three times weekly† None
NRTIs and/or a NNRTI)
Atazanavir (plus two NRTIs) Decrease to 150 mg twice or three times weekly† None
NNRTI regimens
Efavirenz (plus two NRTIs) Increase to 450 QD or 600 mg twice or three None
times weekly
Nevirapine (plus two NRTIs) 300 mg daily or three times weekly None
NRTI regimens
Triple regimen (e.g., zidovudine, 300 mg daily or three times weekly None
lamivudine, and abacavir)§
PI plus NNRTI regimens
Efavirenz or nevirapine and protease 300 mg daily or three times weekly Consider increasing dose of indinavir to 1,000 mg
inhibitor (except ritonavir) every 8 hours
* Avoid twice-weekly rifabutin therapy among patients with CD4+ T-cell count <100 cells/µL at the time of tuberculosis diagnosis.
† When the dose of rifabutin is decreased, adherence with ritonavir, Kaletra, or atazanavir should be monitored because discontinuation of these drugs might
result in underdosing with rifabutin.
§ Rifampin increases concentrations of zidovudine and probably abacavir. Although the clinical significance of these changes is not clear, using rifabutin with
triple NRTIs is prudent.
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Preferred therapy and duration
Acute therapy
• Trimethoprim-Sulfamethoxazole (TMP/SMX):
[15–20 mg TMP and 75–100 mg SMX]/kg body
weight/day IV administered q6h or q8h (AI); or
• Same daily dose of TMP/SMX PO in 3 divided doses
(AI); or
• TMP-SMX DS 2 tablets 3 times a day (AI)




• Trimethoprim-sulfamethoxazole (TMP-SMX) 1 double-
strength tablet (DS) PO QD (AI); or
• TMP-SMX 1 single-strength tablet (SS) PO QD (AI)
Alternatives
• Dapsone 50 mg PO twice daily or 100 mg PO daily
(BI); or
• Dapsone 50 mg PO daily plus pyrimethamine 50 mg
PO weekly plus leucovorin 25 mg PO weekly (BI); or
• Dapsone 200 mg PO plus pyrimethamine 75 mg PO
plus leucovorin 25 mg PO weekly (BI); aerosolized
pentamidine 300 mg every month via Respirgard
nebulizer (manufactured by Marquest, Englewood,
Colorado) (BI); or
• Atovaquone 1,500 mg PO QD (BI); or
• TMP-SMX 1 DS PO TIW (CI)
Acute therapy
Pyrimethamine 200 mg POx1, then 50 mg (<60 kg body
weight) to 75 mg (>60 kg) PO QD and sulfadiazine
1,000 (<60 kg) to 1,500 mg (>60 kg) PO q6h
plus leucovorin 10–20 mg PO QD (can increase
>50 mg) (AI)




• Sulfadiazine 500–1,000 mg PO QID plus
pyrimethamine 25–50 mg PO QD plus leucovorin
10–25 mg by mouth daily (AI)
Second choice
• Clindamycin 300–450 mg PO every 6–8 hours plus
pyrimethamine 25–50 mg PO QD plus leucovorin
10–25 PO QD (BI); or
• Atovaquone 750 mg PO every 6–12 hours with or
without pyrimethamine 25 mg PO QD plus leucovorin
10 mg PO QD (CIII)
Symptomatic treatment of diarrhea (AIII)
Effective ART (to increase CD4+ count to >100 cells/µL)
can result in complete, sustained clinical,




• Pentamidine 4 mg/kg IV QD infused
over at least 60 minutes (AI), some
specialists reduce dose to 3 mg/kg
IV QD because of toxicities (BI)
For mild-to-moderate PCP:
• Dapsone 100mg PO QD and TMP
15 mg/kg/day PO (3 divided dose)
(BI); or
• Primaquine 15–30mg (base) PO QD
and Clindamycin 600–900 mg IV q6h
to q8h or Clindamycin 300–450 mg
PO q6h to q8h (BI); or
• Atovaquone 750 mg PO BID with
food (BI); or
• Trimetrexate 45mg/m2 or 1.2 mg/kg
IV QD with leucovorin 20 mg/m2 or
0.5 mg/kg IV or PO q6h (leucovorin
must be continued for 3 days after
the last trimetrexate dose) (B1);
addition of dapsone or
sulfamethoxazole or sulfadiazine
might improve efficacy (CIII)
• Pyrimethamine (leucovorin)* and
clindamycin 600 mg IV or PO q6h
(AI); or
• TMP-SMX (5 mg/kg TMP and 25
mg/kg SMX) IV or PO BID (BI); or
• Atovaquone 1,500 mg PO BID with
meals (or nutritional supplement)
and pyrimethamine (leucovorin)*
(BII); or
• Atovaquone 1,500 mg PO BID with
meals (or nutritional supplement)
and sulfadiazine 1,000–1,500 mg PO
q6h (BII); or
• Atovaquone 1,500 mg PO BID with
meals (BII); or
• Pyrimethamine (leucovorin)* and
azithromycin 900–1200 mg PO QD
(BII)
For severely ill patients who cannot
take oral medications
TMP-SMX IV and Pyrimethamine
PO (CIII)
For other regimens with limited
experience (CIII), see text.
Nitazoxanide 500 mg PO BID
Paromomycin 25–35 mg/kg body
weight PO in 2 to 4 divided doses
Other options/issues
Indications for corticosteroids (AI):
PaO2 <70 mm/Hg at room air; or
alveolar-arterial O2 gradient
>35 mm/Hg
Prednisone doses (beginning as
early as possible and within 72 hours
of PCP therapy) (AI):
40 mg BID days 1–5, 40mg QD days
6–10, then 20 mg QD days 11–21
IV methylprednisolone can be
administered as 75% of prednisone
dose
Chronic Maintenance Therapy
(Secondary prophylaxis) should be
discontinued if CD4+ T lymphocyte
count increases in response to ART




administered when clinically indicated
for treatment of mass effect attributed
to focal lesions or associated edema
(BIII) and discontinued as soon as
clinically feasible
Anticonvulsants should be
administered to patients with a history
of seizures (AIII)
Secondary prophylaxis may be
discontinued if
• Free of TE signs and symptoms;
and sustained CD4+ T lymphocyte
count of >200 cells/µL for
>6 months of ART (CIII)
Supportive care including hydration,
nutritional support
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TABLE 6. (Continued) Treatment of AIDS-associated opportunistic infections among adults
Opportunitstic




Initiate or optimize ART with immune reconstitution to
CD4+ >100 cells/µL (AII)
For disseminated (not ocular) and intestinal infection
attributed to microsporidia other than Enterocytozoon
bienuesi
• Albendazole 400 mg PO BID (AII), continue until
CD4+ >200 cells/µL (AIII)
For ocular infection
• Fumidil B 3 mg/mL in saline (final concentration is
fumagillin 70 µg/mL) eye drops continued indefinitely
(not available in U.S.) (BII) and Albendazole 400 mg
PO BID for management of systemic infection (BIII)
For gastrointestinal infections caused by
Enterocytozoon bienuesi
• Fumagillin 60 mg PO QD (not available in U.S.) (BII)
For drug-sensitive MTB
Initial phase (8 weeks) (AI)
Isoniazid (INH) 5 mg/kg body weight (max: 300 mg) PO
QD and rifampin 10 mg/kg (max: 600 mg) PO QD or
rifabutin 300 mg PO QD (or dose adjusted based on
concomitant meds†) and pyrazinamide (PZA) (dose
based on weight§) PO QD and ethambutol (EMB) (dose
based on weight¶) PO QD
Continuation phase (18 weeks) (AI)
• INH 5mg/kg (max: 300 mg) PO QD and [Rifampin
10 mg/kg (max: 600 mg) or Rifabutin 300 mg PO QD];
              or
• INH15 mg/kg (max: 900 mg) PO BIW or TIW plus
[Rifampin 10 mg/kg (max: 600 mg) or Rifabutin 300
mg PO TIW]
In patients with delayed clinical or microbiological
response to initial therapy (e.g., sputum culture (+) after
2 months or if cavitary pulmonary lesions are present),
total duration up to 9 months (BII)
Disseminated disease
Itraconazole 400 mg PO QD and
albendazole for disseminated disease
attributed to Trachipleistophora or
Brachiola (CIII)
Treatment for drug-resistant MTB:
Resistant to INH
• Discontinue INH (and streptomycin,
if used)
• Rifamycin, PZA, and EMB for
6 months (BII); or
Rifamycin and EMB for 12 months
(preferably with PZA during at least
first 2 months) (BII)
Resistant to Rifamycin
• INH and PZA and EMB and a
fluorquinolone (e.g., levofloxacin
500 mg/day) for 2 months, followed
by 10–16 additional months with INH
and EMB and fluoroquinolone (BIII)
Multidrug resistant (MDR) TB – both
INH and rifamycin resistant
• Therapy should be individualized
based on resistance pattern and with
close consultation with experienced
specialist (AIII)
TB treatment in patients with liver
disease
If AST >3 times normal before
treatment initiation
• Standard therapy with frequent
monitoring; or
• Rifamycin and EMB and PZA for 6
months
• INH and rifamycin and EMB for 2
months, then INH and rifamycin for 7
months (BII)
For patients with severe liver disease
• Rifamycin and EMB for 12 months
(preferably with another agent such
as fluoroquinolone for first 2 months)
(CII)
Fluid support among patients with
diarrhea resulting in severe
dehydration (AIII)
Nutritional supplement for patients
with severe malnutrition and wasting
(AIII)
Treatment for ocular infection should
be continued indefinitely (BIII); with
immune reconstitution, it is possible
that this treatment might be
discontinued (CIII)
Chronic maintenance therapy may be
discontinued if patients (CIII):
• remain asymptomatic with regards
to signs and symptoms of
microsporidiosis;
• sustained CD4+ T-lymphocyte
counts >200 cells/µL for >6 months
on ART
Treatment by directly observed
therapy (DOT) is strongly
recommended for all HIV patients (AII)
Rifabutin has less drug interaction
potential and can be used in place of
rifampin
Rifapentine administered once weekly
can result in development of
resistance; it is not recommended
among HIV patients (EI)
Twice weekly intermittent regimen
containing rifamycin might lead to
rifamycin resistance, particularly
among advanced HIV patients with
CD4+ T-cell count <100 cells/µL; in
this situation, therapy must be
administered as daily or three times
weekly
For paradoxical reaction that is not
severe, may be treated with
nonsteroidal anti-inflammatory drugs
(NSAIDs) without change in TB or HIV
medications (BIII)
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TABLE 6. (Continued) Treatment of AIDS-associated opportunistic infections among adults
Opportunitstic







At least 2 drugs as initial therapy
Clarithromycin 500 mg PO BID (AI) and ethambutol
15 mg/kg body weight PO QD (AI)
Consider adding third drug for patients with advanced
immunosuppression (CD4+ <50), high mycobacterial
loads, or in the absence of effective ART; rifabutin
300 mg PO QD (AI) (dosage may be adjusted based
on drug-drug interactions) (CIII)
Duration (Chronic Maintenance Therapy): Lifelong
therapy unless in patients with sustained immune




• Clarithromycin 500 mg PO BID (AI) plus ethambutol
15 mg/kg PO daily (AII); with or without rifabutin
300 mg PO QD (CI)
Second choice
• Azithromycin 500 mg PO QD (AII) plus ethambutol
15 mg/kg PO QD (AII); with or without rifabtuin
300 mg PO QD (CI)
Empiric therapy (targeting towards Streptococcus
pneumoniae and Hemophilus influenzae)
• Extended spectrum cephalosporin (e.g., cefotaxime,
or ceftriaxone) (AIII); or
• Fluoroquinolone with enhanced activity against
pneumococcus (e,g, gatifloxacin, levofloxacin, or
moxifloxacin) (AIII)
Empiric therapy in patients with severe illness
• Extended-spectrum cephalosporin and a macrolide or
quinolone (AIII)
Salmonella gastroenteritis
• Ciprofloxacin 500 mg–750 mg PO BID (or 400 mg
IV BID) (AIII)
Duration
• Mild gastroenteritis without bacteremia, 7–14 days
(BIII)
• Advanced HIV (CD4+ <200) and/or bacteremia,
at least 4–6 weeks (BIII)
Chronic Suppressive Therapy
• For patients with Salmonella bacteremia, ciprofloxacin
500 mg PO BID (BII)
Alternative to Clarithromycin
Azithromycin 500–600 mg PO QD (AII)
Alternative third or fourth drug for
patients with more severe symptoms or
disseminated disease (CIII)
• Ciprofloxacin 500–750 mg PO BID;
or
• Levofloxacin 500 mg PO QD; or
• Amikacin 10–15 mg/kg IV QD
For high-level penicillin-resistant
isolates (MIC >4.0 µg/mL)
• Consider adding vancomycin or a
fluoroquinolone (CIII); therapy
should be guided by susceptibility
results
• Empiric therapy in patients with
severe immunodeficiency (CD4+
T-cell count <100 cells/µL), a known
history of previous pseudomonas
infection, bronchiectasis, or relative
or absolute neutropenia) (BIII)
Broaden empiric coverage to include
antimicrobials with activities against
P. aeruginosa and other gram-
negative bacilli (e.g. ceftazidime,
cefepime, piperacillin-tazobactam,
a carbepenem, or high-dose
ciprofloxacin or levofloxacin)
• If ceftazidime or ciprofloxacin is
used, addition of another
antibacterial with optimal coverage
for gram-positive infection is
recommended
• TMP-SMX PO or IV (BIII)
• Third generation cephalosporin such
as ceftriaxone (IV) or cefotaxime (IV)
(BIII)
NSAIDs may be used for patients
who experience moderate to severe
symptoms attributed to ART-
associated immune reconstitution
syndrome (CIII)
If symptoms persist, short term
(4–8 weeks) of systemic
corticosteroid (20–40 mg of
prednisone QD) can be used (CIII).
Maintenance therapy can be
discontinued in patients who (BII)
• completed >12 months therapy,
and
• remain asymptomatic, and
• have sustained (>6 months) CD4+
count >100 cells/µL
Patients with CD4+ T-cell count of
>200 cells/µL should receive a single
dose of 23-valent polysaccharide
pneumococcal vaccine (if not received
during the preceding 5 years) (BII)
Yearly influenza vaccine might be
useful in preventing pneumococcal
superinfection after influenza
respiratory infection (BII)
Antibiotic prophylaxis may be
considered among patients with
frequent recurrences (CIII); caution
should be taken for the risks for
developing drug resistance and drug
toxicities
Treatment is recommended among
HIV patients because of high risk for




moxifloxacin) might also be effective
(BIII)
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For mild disease – might withhold therapy unless
symptoms persist for several days
Optimal therapy – not well defined; options include
• ciprofloxacin 500 mg PO BID (BIII); or
• azithromycin 500 mg PO QD (BIII); or
• consider addition of an aminoglycoside in bacteremic
patients (CIII)
Duration
• Mild to moderate disease, 7 days
• Bacteremia: at least 2 weeks
Fluoroquinolone IV or PO for 3–7 days (AIII)
Duration for bacteremia, 14 days (AIII)
Non-CNS infections
• Erythromycin 500 mg PO QID (or IV at same dose if
unable to take PO) (AII); or
• Doxycycline 100 mg PO or IV q12h (AII)
CNS infections
• Doxycycline 100 mg PO or IV q12h (AIII)
Duration
At least 3 months (AII)
Long-term suppression with crythromycin or doxycycline
may be considered in patients with relapse or
re-infection (CIII)
Early stage (primary, secondary, and early latent
syphilis)
• Benzathine penicillin G 2.4 MU IM for 1 (AII)
Late-latent disease (>1yr or of unknown duration,
without CNS involvement)
• Benzathine penicillin G 2.4 MU IM weekly for 3 weeks
(AIII)
Late-stage (aortitis and gummata)
• Infectious diseases consultation (AIII)
Neurosyphilis (CNS involvement including otic and
ocular disease)
• Aqueous crystalline penicillin G 3–4 MU IV q4h or
total dose by continuous IV infusion for 10–14 days
(AII) and/or benzathine penicillin G 2.4 MU IM weekly
for 3 weeks after completion of IV therapy (CIII)
• TMP-SMX DS 1 tablet PO BID for
3–7 days; or (BIII)
• Azithromycin 500 mg PO on day 1,
then 250 mg PO QD for 4 days (BIII)
Duration for bacteremia, 14 days (AIII)
• Azithromycin 600 mg PO QD (BII)
• Clarithromycin 500 mg PO BID (BII)
• Fluoroquinolones have variable
activity in case reports and in vitro;
may be considered as alternative
(CIII)
Early stage (primary, secondary, and
early latent syphilis)—treatment with
close clinical monitoring (BIII)
• Doxycycline 100 mg PO BID for
14 days; or
• Ceftriaxone 1 g IM or IV QD for
8–10 days; or
• Azithromycin 2 g PO for 1 dose
Late-latent disease (without CNS
involvement)
• Doxycycline 100 mg PO BID for
28 days (BIII)
Neurosyphilis
• Procaine penicillin 2.4 MU IM QD
and probenecid 500 mg PO QID for
10–14 days (BII) and/or benzathine
penicillin G 2.4 MU IM weekly for
3 weeks after completion of above
(CIII); or
• For penicillin-allergic patients
Ceftriaxone 2 g IM or IV QD for
10–14 days (CIII)
An increasing rate of quinolone
resistance is observed
Antimicrobial therapy should be
modified based on susceptibility
reports
Role of aminoglycoside is unclear
Therapy is indicated both to shorten
the duration of illness and to prevent
spread of infection (AIII)
Shigella infections acquired outside of
United States have high rates of
TMP-SMX resistance
Desensitization to penicillin might be a
better option than ceftriaxone among
penicillin-allergic patients with
neurosyphilis (BIII)
Combination of procaine penicillin and
probenecid is not recommended for
patients with history of sulfa allergy
because these patients might be at
risk for hypersensitivity reactions to
probenecid
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Initial episodes (7–14 day treatment)
• Fluconazole 100mg PO QD (AI); or
• Itraconazole oral solution 200 mg PO QD (AI); or
• Clotrimazole troches 10 mg PO 5 times daily (BII); or
• Nystatin suspension 4–6 mL QID or 1–2 flavored
pastilles 4–5 times daily (BII)
Esophageal candidiasis (14–21 days)
• Fluconazole 100 mg (up to 400 mg) PO or IV QD (AI);
or
• Itraconazole oral solution 200 mg PO QD (AI)
• Voriconazole 200 mg PO BID (AII)
• Caspofungin 50 mg IV QD (AII)
Vulvovaginitis
• Topical azoles (clotrimazole, butoconazole,
miconazole, ticonazole, or terconazole) for 3–7 days
(AII)
• Topical nystatin 100,000 units/day as vaginal tablet
for 14 days (AII)
• Oral Itraconazole 200 mg BID for 1 day or 200 mg QD
for 3 days (AII)
• Oral Fluconazole 150 mg for 1 dose (AII)
Acute infection (induction therapy)
• Amphotericin B deoxycholate 0.7 mg/kg body weight
IV QD and/or flucytosine 25 mg/kg PO QID for 2
weeks (AI); or
• Liposomal Amphotericin B 4 mg/kg IV QD and/or
flucytosine 25 mg/kg PO QID for 2 weeks (AI)
Consolidation therapy
• Fluconazole 400 mg PO QD for 8 weeks or until CSF
cultures are sterile (AI)
Chronic maintenance therapy
(Secondary Prophylaxis)
• Fluconazole 200 mg PO QD (AI);
Severe disseminated
Acute phase (3–10 days or until clinically improved)
• Amphotericin B deoxycholate 0.7 mg/kg body weight
IV QD (AI); or
• Liposomal amphotericin B 4 mg/kg IV QD (AI)
Continuation phase (12 weeks)
• Itraconazole 200 mg capsule PO BID (AII)
Less severe disseminated
• Itraconazole 200 mg capsule PO TID for 3 days,
then 200 mg PO BID for 12 weeks (AII)
Meningitis
• Amphotericin B deoxycholate or liposomal for
12–16 weeks (AII)
Chronic maintenance therapy (secondary prophylaxis)
• Itraconazole capsule 200 mg PO QD (AI)
Fluconazole-refractory oropharyngeal
candidiasis
• Itraconazole oral solution >200 mg
PO QD (BII); or
• Amphotericin B suspension
100 mg/mL (not available in U.S.) –
1 mL PO QID (CII); or
• Amphotericin B deoxycholate
0.3 mg/kg IV QD (BII)
Fluconazole-refractory esophageal
candidiasis
• Caspofungin 50 mg IV QD (BIII); or
• Voriconazole 200 mg PO or IV BID
(AII)
• Amphotericin B 0.3–0.7 mg/kg IV QD
(BII); or
• Amphotericin liposomal or lipid
complex 3–5 mg/kg IV QD (CIII)
Induction therapy (alternative)
• Amphotericin B 0.7 mg/kg/day IV for
2 weeks (BI); or
• Fluconazole 400–800 mg/day (PO or
IV) for less severe disease
• Fluconazole 400–800 mg/day (PO or
IV) and flucytosine 25 mg/kg PO QID
for 4–6 weeks (BII)
Consolidation therapy (alternative)
• Itraconazole 200 mg PO BID (BI)
Chronic maintenance therapy
(alternative)
• Itraconazole 200mg PO QD — for




•  Itraconazole 400 mg IV QD (BIII)
Continuation phase alternatives
• Itraconazole oral solution 200 mg
PO BID (BIII)
• Fluconazole 800 mg PO QD (CII)
Mild disseminated
• Fluconazole 800 mg PO QD (CII)
Suppressive therapy — generally not
recommended (DIII) unless patients
have frequent or severe recurrences
• Oropharyngeal candidiasis
fluconazole or itraconazole oral
solution may be considered (CI).
• Vulvovaginal candidiasis – daily
topical azole for recurrent cases
(CII)
• Esophageal candidiasis
fluconazole 100–200 mg QD (BI).
Chronic or prolonged use of azoles
might promote development of
resistance
Repeated lumbar puncture might be
indicated as adjunctive therapy among
patients with increased intracranial
pressure (AII).
Discontinuation of antifungal therapy
can be considered among patients
who remain asymptomatic, with
CD4+ T-lymphocyte count >100–200
cells/µL for >6months (CIII)





among HIV-1–infected patients with
CD4+ T-lymphocyte count >500
cells/µL might require no therapy
(AIII).
Insufficient data to recommend
discontinuation of chronic
maintenance therapy.
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Acute phase (diffuse pulmonary or disseminated
disease)
• Amphotericin B deoxycholate 0.5–1.0 mg/kg body
weight IV QD continue until clinical improvement,
usually 500–1,000 mg total dose (AII)
Acute phase (milder disease)
• Fluconazole 400–800 mg PO QD (BIII); or
• Itraconazole 200 mg PO BID (BIII)
Meningeal Infections
• Fluconazole 400–800 mg IV or PO QD (AII)
Chronic Maintenance Therapy
(Secondary prophylaxis)
• Fluconazole 400 mg PO QD (AII); or
• Itraconazole 200 mg capsule PO BID (AII)
Voriconazole 400 mg IV or PO q12h for 2 days, then
200 mg q12h (AIII)
Duration of therapy
Based on clinical response
CMV Retinitis
For immediate sight-threatening lesions
Ganciclovir (GCV) intraocular implant and valganciclovir
900 mg PO QD (AI)
For peripheral lesions
Valganciclovir 900 mg PO BID for 14–21 days, then




• Valganciclovir 900 mg PO QD (BI)
• Foscarnet 90–120 mg/kg body weight IV QD (AI)
CMV esophagitis or colitis
• Ganciclovir IV or Foscarnet IV for 21–28 days or until
signs and symptoms have resolved (BII); oral
valganciclovir may be used if symptoms are not
severe enough to interfere with oral absorption (BII)
• Maintenance therapy is generally not necessary, but
should be considered after relapses (BII)
CMV pneumonitis
• Treatment should be considered in patients with
histologic evidence of CMV pneumonitis and who do
not respond to treatment of other pathogens (AIII)
• The role of maintenance therapy is not yet
established (CIII)
CMV neurological disease
• GCV IV and Foscarnet IV continue until symptomatic
improvement (BII)
• Maintenance therapy should be continued for life (AI)
Nonmeningeal infection
Acute phase (diffuse pulmonary or
disseminated disease)
• Some specialists add azole to
amphotericin B therapy (BIII)
Meningeal infections
• Intrathecal Amphoterin B (CIII)
• Amphotericin B deoxycholate
1 mg/kg body weight/day IV (AIII); or
• Lipid formulations of amphotericin B
5 mg/kg/day IV (AIII)
CMV Retinitis
• Ganciclovir 5 mg/kg IV q12h for
14–21 days, then 5 mg/kg IV QD
(AI); or
• Ganciclovir 5 mg/kg IV q12h for
14–21 days, then Valganciclovir
900 mg PO QD (AI); or
• Foscarnet 60 mg/kg IV q8h or
90 mg/kg IV q12h for 14–21 days,
then 90–120 mg/kg IV q24h (AI); or
• Cidofovir 5 mg/kg IV for 2 weeks,
then 5 mg/kg every other weeks;
each dose should be administered
with IV saline hydration and oral
probenecid (AI); or
• Repeated intravitreal injections with
fomivirsen (for relapses only, not as
initial therapy) (AI)
Chronic maintenance therapy
• Cidofovir 5 mg/kg IV every other
week with probenecid 2 g PO 3
hours before the dose followed by 1
g PO 2 hours after the dose, and 1 g
by mouth 8 hours after the dose
(total of 4 g) (AI); or
• Fomivirsen 1 vial (330 mg) injected
into the vitreous, then repeated
every 2–4 weeks (AI)
Insufficient data to recommend
discontinuation of chronic
maintenance therapy
Not enough data to recommend
chronic suppression or maintenance
therapy (CIII)
Choice of initial therapy for CMV
retinitis should be individualized on
the basis of location and severity of
the lesion(s), level of immuno-
suppression, and other factors such
as concomitant medications and
ability to adhere to treatment (AIII)
Initial therapy among patients with
CMV retinitis, esophagitis, colitis,
and pneumonitis should include
optimization of ART (BIII)
Some specialists recommend delaying
ART among patients with CMV
neurological disease because of
concerns about worsening of condition
as a result of immune recovery
inflammatory reaction (CIII)
Pre-emptive treatment of patients with
CMV viremia without evidence of
organ involvement is generally not
recommended (DIII).
Maintenance therapy for CMV retinitis
can be safely discontinued among
patients with inactive disease and
sustained CD4+ T lymphocyte
(>100–150 cells/mm3 for >6 months);
consultation with ophthalmologist is
advised (BII)
Patients with CMV retinitis who
discontinued maintenance therapy
should undergo regular eye
examination for early detection of
relapse (AIII).
Ganciclovir intraocular implants might
need to be replaced every 6–8 months
for patients who remain
immunosuppressed with CD4+ T
lymphocyte counts <100–150 cells/µL
Immune recovery uveitis (IRU) might
develop in the setting of immune
reconstitution; treatment of IRU;
periocular corticosteroid or short
courses of systemic steroid.
Because of its poor oral bioavailability
and with the availability of
valganciclovir, oral ganciclovir should
not be used (DIII)
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Orolabial lesions and Initial or recurrent genital HSV
Famciclovir 500 mg PO BID or valaciclovir 1 g PO BID
or acyclovir 400 mg PO TID for 7–14 days (AII)
Moderate-to-severe mucocutaneous HSV infections
• Initial therapy acyclovir 5 mg/kg body weight IV q8h
(AII)
• After lesions began to regress, change to famciclovir
500 mg PO BID or valacyclovir 1 g PO BID or
acyclovir 400 mg PO TID (AII); continue therapy until
lesions have completely healed
HSV keratitis
• Trifluridine 1% ophthalmic solution, one drop onto the
cornea every 2 hours, not to exceed 9 drops per day,
for no longer than 21 days (AII)
HSV encephalitis
• Acyclovir 10 mg/kg IV q8h for 14–21 days (AII)
Primary VZV infection (chickenpox)
• Acyclovir 10 mg/kg body weight IV q8h for 7–10 days
(AIII)
• Switch to oral therapy (acyclovir 800 mg PO QID or
valacyclovir 1g TID or famciclovir 500 mg TID) after
defervescence if no evidence of visceral involvement
exists (AII)
Local dermatomal herpes zoster
• Famciclovir 500 mg or valacyclovir 1 g PO TID for
7–10 days (AII)
Extensive cutaneous lesion or visceral involvement
• Acyclovir 10 mg/kg IV q8h, continue until cutaneous
and visceral disease clearly resolved (AII)
Progressive outer retinal necrosis (PORN)
• Acyclovir IV 10mg/kg q8h and foscarnet 60 mg/kg IV
q8h (AIII)
Patient-applied treatment
Podofilox 0.5% solution or 0.5% gel – apply to all
lesions BID x 3 consecutive days, repeat weekly for up
to 4 weeks (BIII)
or
Imiquimod 5% cream – apply to lesion at bedtime and
remove in the morning on 3 nonconsecutive nights
weekly for up to 16 weeks (BII)
Acyclovir-resistant HSV
• Foscarnet 120–200 mg/kg/day IV in
2–3 divided doses until clinical
response (AI)
• Cidofovir 5 mg/kg IV weekly until
clinical response (AII)
Alternative for acyclovir-resistant HSV
infections
• Topical trifluridine (CIII)
• Topical cidofovir (CIII)
Note: Neither of these topical
preparations are commercially
available; extemporaneous
compounding of these topical products
can be prepared using trifluridine
ophthalmic solution and cidofovir
for intravenous administration
Provider-applied treatment
• Liquid nitrogen cryotherapy – apply
until each lesion is thoroughly
frozen, repeat every 1–2 weeks for
up to 3–4 times (BIII)
• Trichloroacetic acid or bicloroacetic
acid cauterization 80%–95%
aqueous solution, apply to each
lesion, repeat weekly for 3–6 weeks
(BIII)
• Surgical excision (BIII) or laser
surgery (CIII)
• Cidofovir topical (CIII) – not
commercially available
• Podophyllin resin 10%–25%
suspension in tincture of benzoin –
apply to area and wash off in a few
hours, repeat weekly for up to 3–6
weeks (CIII)
Chronic suppressive therapy with
oral acyclovir, famciclovir, or
valacyclovir might be indicated
among patients with frequent or
severe recurrences (CIII)
Corticosteroids for dermatomal
zoster are not recommended (DIII)
Intralesional interferon-alfa generally
not recommended because of high
cost, difficult administration, and
potential for systemic side effects
(DIII)
The rate of recurrence of genital warts
is high despite treatment
Data are limited on the responses to
treatment among HIV-1–infected
patients
Treatment of condyloma acuminata (genital warts)
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CIN 1
• Pap smears and/or colposcopy every 4–6 months
CIN 2 or 3
• Loop electrosurgical excision procedure (LEEP) (BIII)
AIN
• Insufficient data to recommend specific treatment;
treatment decision based on size, location of lesion
and grade of histology (CIII)
Combination therapy (AI)
Peginterferon alfa-2b (1.5 mcg/kg body weight) SQ
weekly; or Peginterferon alfa-2a (180 mcg) SQ weekly
and
Ribavirin PO (weight-based dosing: if <75 mg, 400 mg
in a.m. and 600 mg in p.m.; if >75 kg, 600 mg BID)
Duration of therapy
For genotype 1
• 48 weeks — for patients who demonstrate an early
virologic response (>2 log decrease in HCV viral load
at 12 weeks) (AI)
• 12 weeks — For patients who failed to achieve early
virologic response at 12 weeks (BI); therapy beyond
12 weeks is almost always futile for achieving
virologic cure
For genotype 2 or 3
• 24 weeks — based on data in non-HIV-1–infected
patients (BII)
• Some specialists recommend 48 weeks (CIII)
Because of the lack of controlled trial data on the use of
antiviral agents against HBV in HIV/HBV co-infected
patients, none of the current therapy can be
recommended as preferred regimen
In patients with HIV/HBV/HCV co-infection,
consideration for antiretroviral therapy should be the
first priority; if antiretroviral therapy is not required, then
treatment for HCV should be considered before HBV,
as interferon treatment for HCV also might treat HBV
infection (CIII)
CIN 2 or 3
• Cryotherapy (BIII)
• Laser therapy (BIII)
• Cone biopsy (BIII)




Peginterferon alfa-2b 1.5 mcg/kg or




• Lamivudine 150 mg PO BID is
commonly used as part of an ART
regimen (BIII); some specialists
advise adding adefovir 10 mg/day or
tenofovir 300 mg/day to lamivudine
(or emtricitabine) (CIII); or
• Adefovir 10 mg/day in addition to
ART (BIII); or
• PEG IFN alfa 2a 180 mg SQ q week,
or
• Interferon-alfa 2a or 2b 5 million
units (MU) SQ QD or 10 MU SQ TIW
(CIII)**
Duration of interferon alfa therapy
HBeAg-positive patients – 16–24
weeks (BII)
HBeAg-negative patients – minimum
of 12 months (BIII)
Lamivudine-experienced patients
requiring ART
• Tenofovir 300 mg PO QD as part of
an ART regimen and/or lamivudine
or emtricitabine (CIII) or
• Adefovir 10 mg PO QD and/or
lamirudine or emtracitabine (CIII)
Lamivudine-naïve or lamivudine-
experienced patients in whom ART is
not indicated:
Adefovir 10 mg PO QD (CIII) or
PEG IFN alfa 2a 180 mcg SQ q week
(CIII)
Low-dose intravaginal 5-fluorouracil (2
g twice weekly for 6 months) for CIN
might reduce short-term risk for
recurrence (CIII)
Efficacy of treatment of AIN-2 or 3 in
preventing anal cancer is unknown
All patients should be counseled to
avoid alcohol consumption because of
increased risk for fibrosis progression
Preliminary data suggest that
responses to HCV therapy correlates
to CD4+ cell count
• Some suggest treating HCV before
CD4+ drops below 500 cells/µL
(BIII);
• Conversely, if patient has CD4+
<500 cells/µL, some suggest
initiating ARV before treatment of
HCV (BIII)
Patients should receive 2 doses of
hepatitis A vaccine, preferably before
CD4+ T-cell count drops below 200
cells/µL (BIII)
All patients should be advised to avoid
or limit alcohol consumption (AIII)
Patients should receive 2 doses of
hepatitis A vaccine, preferably before
CD4+ T-cell count drops below 200
cells/µL (BIII)
Interferon should not be used among
patients with decompensated liver
disease (EII)
Discontinuation of therapy for HBV
infection risks flare of liver disease in
approximately 15% of patients and
lost of anti-HBV benefit
HAART should always include HBV










Treatment of cervical intraepithelial neoplasia (CIN)
or anal intraepithelial neoplasia (AIN)
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Acute infection in severely ill patients
Amphotericin B 0.6 mg/kg body weight/day IV for
2 weeks; followed by itraconazole oral solution 400 mg
daily for 10 weeks (AII)
Chronic maintenance therapy
(Secondary prophylaxis)
Itraconazole 200 mg PO QD (AI)
Pentavalent antimony (or sodium stibogluconate)
= 20 mg/kg body weight IV or IM QD (AI) for
3–4 weeks; duration depends on initial response (CIII)
Chronic maintenance therapy
(Secondary prophylaxis)
Single dose of the initial therapy every 4 weeks,
especially in patients with CD4+ <200 cells/µL (AI)
Amphotericin B for severely ill (BII)
Itraconazole 100–200 mg PO QD for less ill (BII)
TMP 160 mg and SMX 800 mg PO (or IV) QID for
10 days (AII)
or




In patients with CD4+ <200, TMP 320 mg and SMX
1600 mg PO QD or TIW (AII)
Benznidazole 5–8 mg/kg body weight/day in 2 divided
doses for 30–60 days (AIII)
Chronic maintenance therapy
(secondary prophylaxis)
Lifelong prophylaxis is probably indicated at same
doses (CIII)
• Amphotericin B deoxycholate (AII)
0.5–1.0 mg/kg body weight IV QD
(maximum: 50 mg QD) for total dose
of 1.5–2.0 gm (BII); or
• Amphotericin B lipid formulation (AI)
2–5 mg/kg IV QD for 10 days (BII)
there is less experience with shorter
regimens; or
• Pentamidine isethionate 3–4 mg/kg
IV TIW for 3–4 weeks followed by
monthly maintenance therapy (BII)
Secondary prophylaxis
Single dose of the initial therapy every
4 weeks, especially in patients with
CD4+ <200 cells/µL (AI)
• Ketoconazole 200–400 mg PO QD
(BIII)
• Sulfonamide (BIII)
• Pyrimethamine 50–75 mg PO QD
and Leucovorin 5–10 mg PO QD
(BII); or
• Ciprofloxacin 500 mg PO BID (BII)
• Other fluoroquinolones (BII)
Alternative secondary prophylaxis
Pyrimethamine 25 mg PO QD and
leucovorin (BII)
Nifurtimox (not available) 10 mg/kg/day
(BIII). Lifelong secondary prophylaxis
probably indicated at same doses (CIII)
ART should be administered
according to standard of care in the
community (CIII)
Severely neutropenic patients with
visceral leishmaniasis might benefit
from short course of granulocyte
macrophage colony stimulating factor
(GM-CSF) 5 µg/kg body weight/day
SQ for 5 days (CII)
Alternative regimen for treatment
failure
• Miltefosine 100 mg PO QD for
4 weeks (CIII)
Strong consideration should be given
to initiation or optimization of ART
(CIII)
Potent ART should be initiated in
accordance with standards of care in
the community (AIII)
Fluid management among patients
with dehydration (AIII)
Nutritional supplementation for
malnutrition and wasting (AIII)
Immune reconstitution with ART might
result in fewer relapse (AIII)
Discontinuation of secondary
prophylaxis may be considered among
patients with sustained CD4+ T-cell
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ART = antiretroviral therapy; IM = intramuscular; IV = intravenous; PO = oral; SQ = subcutaneous; QD = daily; BID = twice a day; TID = three times daily; QID = four times a day;
TIW = three times weekly; q‘n’h = every ‘n’ hour.
* Pyrimethamine and leucovorin doses — same as in “preferred therapy” for toxoplasmosis.
† See Table 5 for rifabutin doses based on concomitant antiretroviral drug use.
§ Pyrazinamide dose: <55 kg = 1,000 mg; 56–75 mg = 1,500 mg; >76 kg = 2,000 mg.
¶ Ethambutol dose: <55 kg = 800 mg; 56–75 kg = 1,200 mg; >76 kg = 1,600 mg.
** Among HIV-HBV co-infected patients who do not need HIV therapy but who have HBeAg-positive chronic hepatitis B and ALT >2 times normal, certain authorities recommend
treating HBV with interferon-alfa provided no evidence of hepatic decompensation exists. This strategy spares the patient from developing HIV and HBV resistance to lamivudine
therapy and from the toxicity of ART.













































Nephrotoxicity, infusion-related reactions, electrolyte imbalances, anemia, thrombophlebitis, nausea,
and vomiting
Lipid formulation might have lower incidence of nephrotoxicity and infusion-related reactions
Headache, thrombophlebitis, facial flushing, erythema, skin rash, and infusion-realted reactions
Bone marrow suppression, diarrhea, nausea, and vomiting
Hepatotoxicity
Hepatotoxicity, congestive heart failure, edema, hypokalemia, nausea, vomiting, diarrhea, and
abdominal pain
Visual disturbances, photosensitivity, skin rash, hepatotoxicity, peripheral edema, headache, and
hallucination
Diarrhea, rash, nausea, vomiting, and headache
Diarrhea, pseudomembranous colitis, and rash
Methemoglobinemia and hemolytic anemia (especially for patients with G-6-PD deficiency),
neutropenia, rash, fever, hepatitis, hyperkalemia, and peripheral neuropathy
Nephrotoxicity, infusion-related hypotension and/or arrhythmias, pancreatitis, hypoglycemia, diabetes
mellitus, hepatitis, and electrolyte abnormalities
Methemoglobinemia and hemolytic anemia (especially in patients with G-6-PD deficiency), abdominal
cramps, nausea, and vomiting
Rash, Stevens-Johnson Syndrome, bone marrow suppression, hepatotoxicity, increased serum
creatinine, nausea, vomiting, and crystalluria
Bone marrow suppression, stomatitis, fever, rash, and hepatitis
Neutropenia, thrombocytopenia, megaloblastic anemia, and rash
Rash, Stevens-Johnson syndrome, bone marrow suppression, crystalluria, renal insufficiency,
nausea, and vomiting
Nephrotoxicity and ototoxicity
Hepatotoxicity, ototoxicity, skin rash, urticaria, pruritus, nausea, vomiting, abdominal pain, and
diarrhea
Hepatotoxicity, ototoxicity, headache, nausea, vomiting, abdominal cramps, diarrhea, and skin rash
Nausea, vomiting, abdominal pain, diarrhea, headache, dizziness, sleep disturbances, crystalluria,
renal impairment, tendonitis, photosensitivity, and neurotoxicity (especially with high dose or in
patients with renal dysfunction)
Neuropsychiatric toxicities (headache, somnolence, vertigo, tremor, dysarthria, irritability, confusion,
paranoia, and psychosis)
Optic neuritis, peripheral neuropathy, headache, nausea, vomiting, anorexia, hepatotoxicity, and
hyperuricemia
Hepatotoxicity, peripheral neuropathy, ataxia, and optic neuritis
Hepatotoxicity, hyperuricemia, and arthralgia
Hepatotoxicity, uveitis, neutropenia, red-orange discoloration of body fluids, and skin rash
Hepatotoxicity, red-orange discoloration of body fluids, thrombocytopenia, hemolytic anemia, and skin
rash
Nephrotoxicity and ototoxicity (especially vestibular toxicity)
TABLE 7. Common toxicities of systemic agents for treatment of opportunistic infections
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Crystalluria, nausea, vomiting, neurotoxicity (high doses, especially in patients with renal impairment;
agitation, confusion, hallucination, seizure, coma), nephrotoxicity (particularly after rapid IV infusion),
and thrombophlebitis at peripheral intravenous infusion site
Increase serum creatinine, nausea, vomiting, and asthenia
Nephrotoxicity, proteinuria, ocular hypotony, anterior uveitis/iritis, neutropenia, metabolic acidosis,
and asthenia
Side effects most likely related to co-administration of probenecid: skin rash, nausea, vomiting, and
anorexia
Headache, nausea, vomiting, and anorexia
Nephrotoxicity, electrolyte imbalances (hypocalcemia, hypomagnesemia, hypophosphatemia,
hyperphosphatemia, hypokalemia), penile ulceration, nausea, vomiting, anorexia, headache, and
seizure, thrombophlebitis, catheter-related infections
Neutropenia, thrombocytopenia, anemia, catheter-related infections
Oral ganciclovir: nausea, and vomiting
Influeza-like syndrome (fever, headache, fatigue, and myalgia), neuropsychiatric disorders
(depression and suicidal ideation), neutropenia, thrombocytopenia, thyroid dysfunction, injection site
reactions, alopecia, nausea, anorexia, diarrhea, weight loss, development or exacerbation of
autoimmune disorders, and ophthalmologic disorders (retinal hemorrhage, retinal artery or vein
obstructions, and cotton wool spots)
Nausea, vomiting, and pancreatitis in children
Hemolytic anemia, leukopenia, hyperbilirubinemia, nausea, vomiting, anorexia, dyspepsia, and skin
rash
Nausea, vomiting, and headache; at a high dose of 8 g/day: thrombotic thrombocytopenic purpura/
hemolytic uremic syndrome reported in advanced human immunodeficiency virus patients and in
transplant recipients
Neutropenia, thrombocytopenia, anemia, and nausea
Nausea, vomiting, hepatotoxicity, hypersensitivity, neutropenia, dizziness, and headache
Peripheral neuropathy, bone marrow suppression, and skin rash
Oral therapy: neutropenia, thrombocytopenia, vertigo, nausea, vomiting, diarrhea, anorexia, and
abdominal cramps
Ocular therapy: minimal systemic effect or local effect
Serum transaminase elevation, amylase, lipase elevations, pancreatitis, thrombophlebitis, prolonged
QT interval and T-wave inversion, and arrhythmias
Cholelithiasis, skin rash, bone marrow suppression, and injection site reactions (intramuscular
administration)
Photosensitivity reaction, nausea, vomiting, and esophageal ulceration
Nausea, vomiting, abdominal pain, hepatotoxicity, cholestatic jaundice, ototoxicity (hearing loss,
tinnitus), skin rash, and cardiac arrhythmia
All penicillin G preparations: hypersensitivity reactions (immediate or delayed reaction), bone marrow
suppression, and drug fever
Benzathine penicillin G: injection site reactions (pain and erythema)
Procaine penicillin G : injection site reactions (pain and erythema)
Aqueous crystalline penicillin G: thrombophlebitis and neurotoxicity at high doses (especially in
patients with renal dysfunction)
Drug class Drugs Toxicities
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Recommendations
No dosage adjustment; monitor for acyclovir toxicities
This combination should be avoided
This combination should be avoided
This combination should be avoided; interaction
study with doxycycline not available
No dosage adjustment recommended, monitor for
zidovudine toxicities
Manufacturer recommends considering increasing
maintenance dose of caspofungin to 70 mg/day
when co-administered with the interacting drugs
Caspofungin dose should be increased to 70 mg/day
Because of the infrequent dosing of probenecid when
used with cidofovir, no dosage adjustment is
necessary for interacting drugs; monitor for dose-
related toxicities
Administer didanosine buffered preparation at least 2
hours after or 6 hours before ciprofloxacin
No dosage adjustment necessary; monitor for
ciprofloxacin toxicities
Because of concerns about QT prolongation,
decrease clarithromycin dose 50% or use alternative
agent
No dosage adjustment recommended; might
consider clarithromycin dose adjustment in patients
with renal insufficiency; monitor for clarithromycin
toxicities; or switch to azithromycin
Significance unknown, no dosage adjustment
recommended; some clinicians recommend switching
to azithromycin
Monitor for toxicities of both itraconazole and
clarithromycin
No dosage change in patients with normal renal
function.
CrCl (mL/min) Clarithromycin
30–60 decrease dose 50%
<30 decrease dose 75%
Might need clarithromycin dose increase and
decrease rifabutin dose; might result in increased
rifabutin toxicities; some recommend use of
azithromycin in place of clarithromycin
This combination should be avoided; consider
switching to azithromycin
No dosage change in patients with normal renal
function.
CrCl (mL/min) Clarithromycin
30–60 decrease dose 50%
<30 decrease dose 75%
No formal study performed; avoid concomitant use or
monitor for trimetrexate toxicities
Reduced dapsone activities; might consider
increasing dapsone dose or use alternative agent







































Probenecid might decrease renal clearance of acyclovir
by 32%, increasing acyclovir area under the concentra-
tion curve (AUC)
Atovaquone concentration (conc.) decreases by 34%;
Rifabutin conc. Decreases by 19%
Atovaquone conc. decreases by 52%; Rifampin conc.
increases by 37%
Atovaquone conc. Decreases by 40%
Zidovudine AUC increases by 31%, possibly because
of atovaquone inhibition of zidovudine glucuronidation
Possible decreases in caspofungin conc. based on
regression analyses of patient pharmacokinetic data;
no formal pharmacokinetic study available at this time
Caspufungin conc. decreases by 30%
Probenecid might decrease renal clearance of these
drugs, increasing plasma conc.
Decreased ciprofloxacin absorption attributed to
chelation with magnesium-aluminum buffer
Probenecid might reduce renal clearance of
ciprofloxacin, increasing plasma conc.
Atazanavir minimum concentration (Cmin) increased
91%; Clarithromycin AUC increased 94%
Delavirdine AUC increased 44%;
clarithromycin AUC increased 100% and 14-OH
clarithromycin AUC decreased 75%
Clarithromycin AUC decreased 39%; 14-OH
clarithromycin AUC increased 34%
Possible bi-directional CYP 3A4 inhibition and
increased AUC of both drugs
Increased clarithromycin AUC and decrease in 14-OH
clarithromycin AUC
Clarithromycin AUC decreased by 44%; rifabutin AUC
increased 76%–99%
Decreased mean clarithromycin conc. by 87%
Clarithromycin AUC increased 77% and decrease in
14-OH clarithromycin AUC
Might increase trimetrexate AUC
Decreased dapsone level 7–10-fold and dapsone t1/2
decreased from 24 to 11 hours
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TABLE 8. (Continued) Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic
infections*
























(study with enteric coated











Tetracycline decreased atovaquone conc. 40%; effect
of doxycycline on atovaquone unknown
Decreased doxycycline absorption attributed to
chelation with magnesium-aluminum buffer
Decreased doxycycline clearance, decreased t1/2 and
AUC
Potential for bi-directional inhibition of hepatic
metabolism and increased serum conc. of both
Nevirapine conc. increased by 100% compared with
historic control
Might increase trimetrexate AUC
Rifabutin AUC increased 80%; no effect on fluconazole
levels
Fluconazole AUC decreased by 23%–56%; no change
in rifampin conc.
Might increase trimetrexate AUC
Fluconazole decreased glucuronidation of zidovudine;
fluconazole 400 mg/day results in increased zidovudine
AUC by 74%
Didanosine AUC increased 78% with IV ganciclovir and
increased 111% with oral ganciclovir
Probenecid might decrease ganciclovir clearance and
increase ganciclovir conc.
Potential for bi-directional inhibition of CYP3A4
metabolism with increased AUC of itraconazole and/or
interacting drug(s)
Potential for bi-directional inhibition of CYP3A4
metabolism with increased AUC of itraconazole and/or
delavirdine
Might decrease itraconazole oral absorption because
of increased gastric pH from antacid in the didanosine
preparation
No interaction study reported; potential induction or
inhibition of itraconazole metabolism with increase or
decrease in itraconazole AUC
Potential for bi-directional inhibition of CYP3A4
metabolism with increased AUC of itraconazole and/or
erythromycin
Potential for induction of itraconazole metabolism and
decrease in itraconazole conc.
Potential for bi-directional inhibition of CYP3A4
metabolism with increased AUC of itraconazole and/or
protease inhibitors
Decrease in itraconazole conc. by 70%; potential for
inhibition of rifabutin metabolism and increased
rifabutin conc.
Until doxycycline-atovaquone interaction data
become available, avoid this combination if possible
Separate doxycycline with didanosine by at least 2
hours or use didanosine enteric-coated capsule
Potential for decreased doxycycline efficacy; monitor
closely for therapeutic failure
Monitor for toxicities of both drugs
Recommended monitor for nevirapine toxicity
No formal study performed; avoid concomitant use or
monitor for trimetrexate toxicities
Monitor for rifabutin toxicity or might consider dose
reduction to 150 mg/day
May need to increase fluconazole dose
No formal study performed; avoid concomitant use or
monitor for trimetrexate toxicities
Monitor for zidovudine toxicities
Might consider reducing didanosine dose; monitor for
didanosine toxicities
Because of the infrequent dosing of probenecid when
used with cidofovir, no dosage adjustment is
necessary; monitor for dose-related toxicities
Monitor for toxicities of clarithromycin; monitor
itraconazole level and toxicities
Monitor for toxicities of delavirdine; monitor
itraconazole level and toxicities
Administer itraconazole at least 2–4 hours before
didanosine buffered tablets, use didanosine enteric
coated capsule, or take itraconazole with cola
beverage to decrease gastric pH
Monitor itraconazole level and adjust dose
accordingly
Monitor for toxicities of erythromycin; monitor
itraconazole level and toxicities
Monitor itraconazole level and adjust according;
monitor therapeutic efficacy
Monitor for toxicities of protease inhibitors; monitor
itraconazole level and toxicities (especially in patients
with ritonavir-boosted protease inhibitor regimens)
Avoid concomitant use if possible; if the combination
is to be used, monitor itraconazole level and adjust
dose accordingly; monitor for rifabutin toxicity
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TABLE 8. (Continued) Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic
infections*






































Itraconazole AUC decreased 64%–88%; no change in
rifampin conc.
Potential for substantial increase in itraconazole conc.
Itraconazole might substantially increase trimetrexate
level because of inhibition of CYP3A4 metabolism
Amprenavir AUC increased 31%; ketoconazole AUC
increased 44%
Delavirdine Cmin increased 50%
Might decrease oral absorption of ketonconazole
because of increased gastric pH from antacid in the
didanosine preparation
Indinavir AUC increased 68%; no substantial change in
ketocoazole conc.
Ketoconazole AUC increased threefold; no substantial
change in lopinavir pharmacokinetics
Ketoconazole AUC decreased 63%; nevirapine AUC
increased 15%–30%
Possible increase in rifabutin conc. and decrease in
ketoconazole conc.
Ketoconazole levels decreased 50%;
Ketoconazole AUC increased 3.4-fold
Ketoconazole might substantially increase trimetrexate
level because of inhibition of CYP3A4 metabolism
Decreased pyrazinamide conc. in one study
Increased intracellular levels of dideoxyadenosine
triphosphate (ddA-TP)
Decreased intracellular activities of zidovudine against
HIV in vitro
Rifabutin AUC increased 193%; no change in
amprenavir conc.
Rifabutin AUC increased 210%; Cmin increased 343%;
minimal change in atazanavir pharmacokinetics
Atovaquone conc. decreased 34%; rifabutin conc.
Decreased 19%
Rifabutin AUC increased 76% because of inhibition of
hepatic metabolism; clarithromycin AUC might be
reduced
Delavirdine AUC decreased 80%; rifabutin AUC
increased 100%
Decreased rifabutin oral absorption
Rifabutin AUC decreased 38%; no change in efavirenz
conc.
Avoid concomitant use if possible.
If the combination is to be used, monitor itraconazole
level and adjust dose accordingly; monitor therapeu-
tic response
Might require reduced itraconazole dose; monitor
itraconazole level and toxicities
Monitor for trimetrexate toxicities
Monitor for toxicities of each drug
Monitor for delavirdine toxicities
Space apart doses of ketoconazole and didanosine
by at least 2 hours or administer ketoconazole with
cola beverage to decrease pH
Decrease indinavir dose to 600 mg every 8 hours
Decrease ketoconazole dose and monitor for
toxicities
Consider alternative antifungal or monitor for
ketoconazole efficacy
Monitor for rifabutin toxicities and ketoconazole
efficacy
Avoid concomitant use if possible; consider
alternative antifungal and/or antimycobacterial
agent(s)
Ketoconazole dose >200 mg/day not recommended;
monitor for ketoconazole toxicities
Monitor for trimetrexate toxicities
Monitor therapeutic efficacy or consider monitoring
pyrazinamide level
This combination should be avoided; increased
didanosine (ddI)-associated mitochondrial toxicities;
if used together, monitor for toxicities (lactic acidosis,
pancreatitis, peripheral neuropathy)
Potential for worsening of HIV suppression;
monitoring HIV viral load
Decrease rifabutin dose by 50% (to 150 mg/day or
300 mg TIW)
Decrease rifabutin dose by 75% (to 150 mg every
other day or three times weekly)
This combination should be avoided
Consider reducing rifabutin dose; monitor for rifabutin
toxicities, or switching macrolide to azithromycin
This combination should be avoided
Space rifabutin and didanosine buffered formulation
apart by at least 2 hours or use enteric coated
didanosine capsule
Increase rifabutin dose to 450 mg/day or 600 mg two
to three times weekly; effect of efavirenz and
protease inhibitor(s) on rifabutin conc. has not been
studied
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infections*
































Rifabutin AUC increased 80% because of inhibition of
hepatic metabolism
No data of interactin between fosamprenavir and
rifabutin; interaction between amprenavir and rifabutin
suggests inhibition of rifabutin metabolism
Itraconazole conc. decreased by 70%; potential for
inhibition of rifabutin metabolism and increased
rifabutin conc.
Rifabutin AUC increased 204%; Indinavir AUC
decreased 32%
Possible increase in rifabutin conc. and decrease in
ketoconazole conc.
Rifabutin AUC increased 303%;
25-O-des-acetyl rifabutin AUC increased 47.5-fold
Rifabutin AUC increased 207%; insignificant change in
nelfinavir conc.
Rifabutin AUC increased 430%; no change in ritonavir
conc.
Saquinavir AUC decreased 43%; no change in
rifabutin conc.
Voriconazole AUC decreased 79%; rifabutin AUC
increased three-fold
Amprenavir AUC decreased 82%, Cmin decreased
92%; no change in Rifampin conc.
Pharmacokinetic study not available; expect rifampin
to decrease atazanavir concentrations substantially
(up to 90%), as seen with other protease inhibitors
Atovaquone conc. decreased 52%; rifampin conc.
increased 37%
Decreased mean clarithromycin conc. 87%
Dapsone half-life decreased from 24 to 11 hr; dapsone
conc. decreased 7–10 fold
Delavirdine AUC decreased 95%; no change in
rifampin conc.
Efavirenz AUC decreased 22%; no change in rifampin
conc.
Fluconazole AUC decreased by 23%–56%; no change
in rifampin conc.
No study done with fosamprenavir to date; amprenavir
AUC decreased 82%; Cmin decreased 92%
Indinavir AUC decreased 89%; rifampin conc. slightly
increased
Itraconazole AUC decreased 64%–88%; no change in
rifampin conc.
Ketoconazole levels decreased 50%
Consider reducing rifabutin dose or monitor for
rifabutin toxicities
Decrease rifabutin dose by 50% (to 150 mg/day or
300 mg TIW); if used with ritonavir/fosamprenavir
combination, dose reduction to 150 mg every other
day or three times weekly
Avoid concomitant use if possible; if the combination
is to be used, monitor itraconazole level and adjust
dose accordingly; monitor for rifabutin toxicity
Decrease rifabutin dose to 150 mg/day or 300 mg
TIW and increase unboosted indinavir dose to 1000
mg every 8 hours
Monitor for rifabutin toxicities and ketoconazole
efficacy
Decrease rifabutin dose to 150 mg every other day or
three times weekly
Decrease rifabutin dose to 150 mg/day or 300 mg TIW
Decrease rifabutin dose to 150 mg every other day or
three times weekly
This combination should be avoided; might consider
adding ritonavir to saquinavir or monitor saquinavir
conc.
This combination should be avoided
This combination should be avoided; effect of
rifampin on ritonavir and amprenavir has not been
studied
This combination should be avoided
This combination should be avoided
This combination should be avoided; consider
switching clarithromycin to azithromycin
Monitor for dapsone efficacy; consider alternative
therapy
This combination should be avoided
No dosage adjustment or consider increasing
efavirenz dose to 800 mg/day
Might need to increase fluconazole dose
This combination should be avoided
This combination should be avoided
Avoid concomitant use if possible; if the combination
is to be used, monitor itraconazole level and adjust
dose accordingly; monitor therapeutic response
Avoid concomitant use if possible; consider
alternative antifungal and/or antimycobacterial
agent(s)
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TABLE 8. (Continued) Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic
infections*












Didanosine (buffered and enteric
coated preparations)

















Lopinavir AUC decreased 75% and Cmin decreased
99%; Rifampin AUC might be increased
Nelfinavir AUC decreased 82%; no change in rifampin
conc.
Nevirapine maximum concentration (Cmax) and AUC
decreased by >50%; no change in rifampin conc.
Ritonavir AUC decreased 35%; no change in rifampin
conc.
Saquinavir AUC decreased 84%; no change in
rifampin conc.
Might increase trimetrexate metabolism and decrease
trimetrexate conc.
Voriconazole AUC decreased 96%
Rifampin increased zidovudine glucuronidation,
decreasing zidouvdine AUC 47%
Potential for compete active tubular secretion of these
drugs
Atazanavir Cmin decreased 40%; mechanism
unknown
Increased didanosine AUC by 44%–60%; no change in
tenofovir AUC
Might increase trimetrexate concentration
Might decrease trimetrexate concentration
Probenecid might decrease ganciclovir renal clearance
and increase ganciclovir conc.
Oral ganciclovir increased didanosine AUC 111%
Potential bi-directional inhibition of metabolism,
increasing conc. of both drugs
Voriconazole Cmax decreased 61%; AUC decreased
77%; efavirenz Cmax increased 38% and AUC
increased 44%
Potential induction of voriconazole metabolism,
decreasing voriconazole conc.
Potential bi-directional inhibition of metabolism,
increasing conc. of both drugs; Indinavir and
voriconazole lead to no substantial interaction
Voriconazole AUC decreased 79%; Rifabutin AUC
increased three-fold
Voriconazole AUC decreased 96%
Ritonavir, at a dose of 400 mg twice a day, decreased
voriconazole Cmax 66% and AUC 82%; effect of lower
ritonavir doses (100–400 mg/day) on variconazole
pharmacokinetics unknown
This combination should be avoided
This combination should be avoided
This combination should be avoided
Monitor for antiretroviral activity of ritonavir
This combination should be avoided; use only in the
presence of ritonavir, consider monitoring saquinavir
concentration
Monitor for trimetrexate efficacy
This combination should be avoided
Monitor for zidovudine efficacy
Monitor for toxicities of these drugs and tenofovir
Co-administer with ritonavir at a dose of ritonavir
100 mg daily plus atazanavir 300 mg daily
Reduce didanosine dose (from 400 mg to 250 mg
in patients weighing >60 mg); monitor for didanosine-
associated toxicities; discontinue didanosine if
serious toxicity occurs
Monitor for trimetrexate toxicities
Monitor for trimetrexate efficacy
Because of the infrequent dosing of probenecid when
used with cidofovir, no dosage adjustment is
necessary; monitor for dose-related toxicities
Monitor for didanosine toxicities; study with
valganciclovir and didanosine enteric coated
formuation has not been done
No formal interaction studies; monitor for toxicities
This combination should be avoided
No formal interaction studies; monitor for therapeutic
failure of voriconazole
No formal interaction studies except for indinavir and
ritonavir; monitor for toxicities
This combination should be avoided
This combination should be avoided
Use with ritonavir 400 mg twice a day should be
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Saquinavir (as sole PI)
Voriconazole
Efavirenz
Ritonavir 400 mg twice
a day
Increased intracellular levels of ddA-TP, increase in ddI-associated mitochondrial toxicities (e.g., lactic
acidosis, pancreatitis, and peripheral neuropathy)
Atovaquone concentration (conc.) decreased 34%; rifabutin conc. decreased 19%
Delavirdine area under the concentration curve (AUC) decreased 90%; rifabutin AUC increased 100%
Itraconazole conc. decreased 70%; potential for inhibition of rifabutin metabolism and increased rifabutin
conc.
Saquinavir AUC decreased 43%; if used, consider addition of ritonavir and/or monitor saquinavir
concentration; no change in rifabutin conc.
Voriconazole AUC decreased 79%; rifabutin AUC increased three-fold
Amprenavir AUC decreased 82%, minimum concentration (Cmin) decreased 92%; no change in rifampin
conc.
Pharmacokinetic study not available; expect rifampin to decrease atazanavir concentrations substantially
(up to 90%), as seen with other protease inhibitors
Atovaquone conc. decreased 52%; rifampin conc. increased 37%
Decreased mean clarithromycin conc. 87%
Delavirdine AUC decreased 95%; no change in rifampin conc.
No study done with fosamprenavir; amprenavir AUC decreased 82%; Cmin decreased 92%
Indinavir AUC decreased 89%; rifampin conc. slightly increased
Itraconazole AUC decreased 64%–88%; no change in rifampin conc.
Ketoconazole levels decreased 50%; rifampin maximum concentration (Cmax) decreased 40%–50%
probably because of impaired rifampin oral absorption
Lopinavir AUC decreased 75% and Cmin decreased 99%; rifampin AUC might be increased
Nelfinavir AUC decreased 82%; no change in rifampin conc.
Nevirapine Cmax and AUC decreased 50%; no change in rifampin concentration
Saquinavir AUC decreased 82%; no change in rifampin concentration
Voriconazole AUC decreased 96%
Voriconazole Cmax decreased 61%; AUC decreased 77%; efavirenz Cmax increased 38% and AUC
increased 44%
Voriconazole Cmax decreased 66%; AUC decreased 82%
First drug Second drug Reason
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TABLE 10. Dosage adjustment in renal insufficiency
Dosage adjustment in renal insufficiency














IV dose for serious HSV/VZV
infections:
  10 mg/kg body weight q8h
PO dose for Herpes zoster:




5 mg/kg IV two times each
week, then every 2 wks (with
probenecid and hydration)
500 mg PO BID
500 mg PO BID
15 mg/kg q24h PO
200-800 mg PO or IV QD
25 mg/kg PO Q6H
120-180 mg/kg/day
Induction therapy:
5 mg/kg IV q12h
Maintenance Therapy
5 mg/kg IV q24h
For HIV/HBV co-infected
Patients – 150 mg BID or 300
mg QD






If increased 0.3–0.4 mg/dL >baseline



























<5 or on hemodialysis
20–49
10–19
Hemodialysis or continuous ambulatory
peritoneal dialysis





No dosage adjustment necessary;
alternative amphotericin B preparation or
other antifungals might be considered if
renal insufficiency occurs during therapy
3 mg/kg per dose
d/c therapy
250 mg q12hr
250 mg q18h (or 375 mg q24h)
250 mg q24hr (given after dialysis)
250 mg BID or 500 mg QD
15 mg/kg q24-36h
15 mg/kg q48h
15 mg/kg TIW after hemodialysis
Full dose
50% of full dose
full dose after dialysis
25 mg/kg q12h
25 mg/kg q24h








0.625 mg/kg tiw after dialysis
150 mg QD
150 mg x 1, then 100 mg QD
150 mg x 1, then 50 mg QD




Dosage adjustment according to calculated CrCl/kg; consult package labeling for dosing
table
Dosage adjustment based on serum levels
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Dosage adjustment in renal insufficiency












Neurosyphilis or Ocular Syphilis
3-4 million units (MU) IV q4h
1,000–1,200 mg/day (based on
weight)
300 mg daily (or adjustment
based on drug-drug interaction)
1 g IM or IV q24h
15–20 mg/kg/day (of TMP)
IV or PO in 3–4 divided doses
For HIV (in HBV patients)
300 mg PO QD
For Herpes Zoster
1 g PO TID
900 mg PO BID (induction)
900 mg PO QD (maintenance)
IV dose: 6 mg/kg
body weight g12h as loading






























1 g q72–96 h
Supplemental 500 mg after hemodialysis
(unless 1 g dose is scheduled around the
same time)
5 mg/kg q6-8h x 48 hr,
then 3.5-5 mg/kg q12h
7–10 mg/kg/day in 1–2 divided doses
7–10 mg/kg after dialysis
300 mg q48h
300 mg twice weekly
300 mg once weekly
1 g PO q12h
1 g PO q24h
500 mg PO q24h
500 mg PO q24h, schedule timing of dose
after dialysis
Induction Maintenance
450 mg BID 450 mg QD
450 mg QD 450 mg QOD
450 mg QOD 450 mg BIW
Not recommended Not recommended
Consider switching to PO dosing; SBECD
vehicle might accumulate in patients with
renal insufficiency
IV = intravenous; PO = oral; QD = daily; BID = twice a day; TID = three times daily; TIW = three times weekly; g‘n’h = every ‘n’ hour.
* To prevent underdosing, some specialists prefer to use standard dose and measure drug levels.
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This report summarizes West Nile virus (WNV) surveillance
data reported to CDC through ArboNET and by states and
other jurisdictions as of August 7, 2002.
United StatesDuring the reporting period of July 31–August 7, a total of
68 laboratory-positive human cases of WNV-associated ill-
ness were reported from Louisiana (n=40), Mississippi (n=23),
Texas (n=four), and Illinois (n=one). During the same
period, WNV infections were reported in 447 dead crows,
263 other dead birds, 42 horses, and 183 mosquito pools.
During 2002, a total of 112 human cases with laboratory
evidence of recent WNV infection have been reported from
Louisiana (n=71), Mississippi (n=28), Texas (n=12), and Illi-
nois (n=one). Five deaths have been reported, all from Louisi-
ana. Among the 98 cases with available data, 59 (60%)
occurred among men; the median age was 55 years (range:
3–88 years), and the dates of illness onset ranged from June 10
to July 29.In addition, 1,076 dead crows and 827 other dead birds
with WNV infection were reported from 34 states, New York
City, and the District of Columbia (Figure 1); 87 WNV
infections in horses have been reported from 12 states
(Alabama, Florida, Georgia, Illinois, Kentucky, Louisiana,
Minnesota, Mississippi, North Dakota, South Dakota, Ten-
nessee, and Texas). During 2002, WNV seroconversions have
been reported in 52 sentinel chicken flocks from Florida,
Nebraska, and Pennsylvania; and 425 WNV-positive mos-
quito pools have been reported from 12 states (Alabama, Geor-
gia, Illinois, Indiana, Massachusetts, Mississippi, New Jersey,
Ohio, Pennsylvania, South Dakota, Texas, and Virginia), New
York City, and the District of Columbia.
West Nile Virus Activity — United States, July 31–August 7, 2002,
and Louisiana, January 1–August 7, 2002
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FIGURE 1. Areas reporting West Nile virus (WNV) activity —
United States, 2002*
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1. Regarding which of the following opportunistic infections does the
potential benefit warrant immediate initiation of potent combination
antiretroviral therapy concurrently with treatment for the opportunistic
pathogen/disease?




2. The preferred drug for treating Pneumocystis jiroveci (formerly carinii)
pneumonia among HIV-infected adults and adolescents is . . .
A. trimethoprim-sulfamethoxazole (TMP-SMX), 15–20 mg/kg body
weight TMP and 75–100 mg/kg body weight SMX, administered
orally or intravenously 3–4 times/day.
B. TMP-SMX, 15–20 mg/kg body weight TMP and 75–100 mg/kg
body weight SMX administered orally once daily or 3 times/week.
C. atovaquone, 750 mg administered orally twice daily with food.
D. dapsone 100 mg administered orally once daily.
3. The preferred alternative regimen for treating Toxoplasma gondii
encephalitis among adults and adolescents intolerant of the
combination of pyrimethamine, sulfadiazine, and leukovorin is . . .
A. trimethoprim-sulfamethoxazole (TMP-SMX), 15–20 mg/kg body
weight TMP and 75–100 mg/kg body weight SMX, administered
orally or intravenously in 3–4 divided doses.
B. atovaquone, 750 mg administered orally twice daily with food, plus
sulfadiazine 1–1.5 gm administered orally every 6 hours, plus
leukovorin.
C. pyrimethamine 200 mg administered orally as a first dose followed by
50–75 mg/day administered orally, plus clindamycin 600 mg
administered orally or parenterally every 6 hours, plus leukovorin.
D. pyrimethamine plus azithromycin 900–1,200 mg administered orally
once daily, plus leukovorin.
4. Which of the following is true regarding Mycobacterium tuberculosis
(TB) disease among adults and adolescents with HIV-1 coinfection?
A. HIV-1–infected persons who have a positive (>5-mm induration)
tuberculin skin test have a yearly risk of developing active TB that is
similar to that for HIV-uninfected persons who have a positive
(>10-mm induration) tuberculin skin test.
B. Persons with HIV-1 coinfection and active TB have lower viral loads
than HIV-1–infected persons without active TB.
C. Extrapulmonary TB, with or without pulmonary involvement, is
more common among HIV-1–infected persons with more advanced
immunosuppression (i.e., CD4+ T-cell counts <100 cells/µL.
D. The yield of mycobacterial stain and culture of specimens from
extrapulmonary sites is lower for HIV-1–infected persons with
advanced immunosuppression than for HIV-uninfected persons with
extrapulmonary TB.
5. Which of the following is not recommended for treating active TB
among persons with HIV-1 infection?
A. A 6-month regimen including an initial phase of isoniazid (INH),
rifampin (RIF) or rifabutin, pyrazinamide (PZA), and ethambutol
(EMB) administered for 2 months, followed by INH and RIF (or
rifabutin) for 4 months, when the disease is caused by organisms
known or presumed to be susceptible to first-line anti-TB drugs.
Goal and Objectives
This MMWR provides evidence-based guidelines for treating opportunistic infections that are common among human immunodeficiency virus (HIV)-1-infected
adults and adolescents. These recommendations were developed by a panel of professionals in the management of opportunistic infections and HIV/acquired
immunodeficiency syndrome (AIDS), representing CDC, the National Institutes of Health, the Infectious Diseases Society of America, and other organizations. The
goal of this report is to provide guidelines for clinicians and health-care professionals regarding management of opportunistic infections among HIV-1-infected adults
and adolescents. Upon completion of this activity, the reader should be able to 1) describe the management of antiretroviral therapies while treating acute
opportunistic infections among HIV-1-infected adults and adolescents; 2) describe the clinical diagnosis of HIV-associated opportunistic infections among adults
and adolescents; 3) describe recommended treatments for HIV-1-related opportunistic infections among HIV-1-infected adults and adolescents; and 4) describe
chronic maintenance therapy for HIV-1-infected adults and adolescents after infection with HIV-1-associated opportunistic infections.
To receive continuing education credit, please answer all of the following questions.
B. When intermittent regimens are used, rifampin or rifabutin-based
regimens should be administered twice weekly for persons with TB
and advanced HIV-1 disease (CD4+ T-cell count <100 cells/µL).
C. Prolonged therapy, <9 months, is recommended for a delayed clinical
or bacteriological response to anti-TB therapy or possibly for persons
with cavitary disease visible on chest radiograph.
D. Directly observed therapy is strongly recommended for persons with
HIV-1–related TB.
6. Which of the following statements regarding Mycobacterium avium
complex (MAC) disease is false?
A. Immune reconstitution inflammatory syndrome associated with
Mycobacterium avium complex (MAC) disease requires discontinuation
of antiretroviral therapy and TB drugs.
B. Anemia and isolated elevation of alkaline phosphatase are non-
specific but are common laboratory abnormalities observed among
HIV-1–infected persons with disseminated MAC disease.
C. Treatment for disseminated MAC disease should include >2
antimycobacterial drugs, clarithromycin (or azithromycin), and
ethambutol to prevent or delay emergence of drug resistance.
D. Persons who have completed >12 months of anti-MAC therapy who
are asymptomatic with respect to MAC disease and who have sustained
a CD4+ T-cell count >100 cells/µL for >6 months on antiretroviral
therapy are at low risk for recurrence of MAC disease and can safely
discontinue chronic maintenance therapy.
7. Which of the following statements regarding bacterial infections
among persons with HIV-1 infection is true?
A. The strategy most effective in preventing bacterial pneumonia among
HIV-1–infected patients is to optimize antiretroviral therapy.
B. Adults and adolescents who have a CD4+ T lymphocyte count of
>200 cells/µL should not be administered 23-valent polysaccharide
pneumococcal vaccine.
C. The initial preferred treatment for Salmonella infection is trimethoprim-
sulfamethoxazole.
D. Chronic suppressive or maintenance therapy is recommended for
Campylobacter or Shigella infections among persons with HIV-1
infection.
8. Which of the following statements regarding cytomegalovirus (CMV)
disease among adults and adolescents is false?
A. End organ disease as a result of CMV occurs among persons with
advanced immunosuppression, typically those with CD4+ T lympho-
cyte counts <50 cells/µL.
B. The determination of serum antibodies to CMV is useful in diagnosing
CMV end organ disease.
C. For patients with peripheral CMV retinitis lesions that are not immediately
sight-threatening, oral valganciclovir is preferable to the ganciclovir intra-
ocular implant, intravenous ganciclovir or intravenous foscarnet.
D. Discontinuing secondary prophylaxis (chronic maintenance therapy)
should be considered for patients with a sustained (>6 months)
increase in CD4+ T lymphocyte count to >100–150 cells/µL in
response to antiretroviral therapy.




























































































































































































































































































































































































































































































































































































































































































































































































































9. Antiviral treatment for hepatitis C among HIV-1–infected adults and
adolescents should be considered . . .
A. only for HIV-1–infected persons with liver biopsy evidence of
bridging fibrosis and severe inflammation.
B. for HIV-1–infected persons with normal or minimally elevated ALT
levels (<2 times the upper limit of normal).
C. for HIV-1–infected persons with detectable HCV ribonucleic acid
(RNA) levels and liver biopsy findings of portal or bridging fibrosis and
moderate inflammation or necrosis.
D. for HIV-1-HCV coinfected persons with high levels of HCV RNA in
the plasma in the absence of liver biopsy findings of portal or bridging
fibrosis, liver inflammation or necrosis.
10. Treatment options for HIV-1–infected adults and adolescents with
chronic hepatitis B include all of the following except . . .
A. peginterferon alfa-2a. C. lamivudine.
B. adefovir. D. famciclovir.
11. Indicate your work setting.
A. State/local health department. D. Managed care organization.
B. Other public health setting. E. Academic institution.
C. Hospital clinic/private practice. F. Other.
12. Which best describes your professional activities?
A. Physician. D. Office staff.
B. Nurse. E. Other.
C. Health educator.
13. I plan to use these recommendations as the basis for . . . (Indicate all
that apply.)
A. health education materials. D. public policy.
B. insurance reimbursement policies. E. other.
C. local practice guidelines.
14. Each month, approximately how many adults or adolescents with HIV
infection do you treat?
A. None. D. 21–50.
B. 1–5. E. 51–100.
C. 6–20. F. >100.
15. How much time did you spend reading this report and completing the
exam?
A. <2.0 hours. C. >3.0 hours but <4.0.
B. >2.0 hours but <3.0 hours. D. >4.0 hours.
16. After reading this report, I am confident I can describe the management
of antiretroviral therapies while treating acute opportunistic infections
among HIV-1–infected adults and adolescents.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
17. After reading this report, I am confident I can describe the clinical
diagnosis of HIV-associated opportunistic infections among adults
and adolescents.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
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Correct answers for questions 1–10.
1. D; 2. A; 3. C; 4. C; 5. B; 6. D; 7. A; 8. B; 9. C; 10. D.
18. After reading this report, I am confident I can describe recommended
treatments for HIV-1–related opportunistic infections among
HIV-1–infected adults and adolescents.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
19. After reading this report, I am confident I can describe chronic
maintenance therapy for HIV-1–infected adults and adolescents after
infection with HIV-1–associated opportunistic infections.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
20. The objectives are relevant to the goal of this report.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
21. The teaching strategies used in this report (text, figures, and tables)
were useful.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
22. Overall, the presentation of the report enhanced my ability to
understand the material.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
23. These recommendations will affect my practice.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
24. The content of this activity was appropriate for my educational needs.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
25. The availability of continuing education credit influenced my
decision to read this report.
A. Strongly agree. D. Disagree.
B. Agree. E. Strongly disagree.
C. Neither agree nor disagree.
26. How did you learn about this continuing education activity?
A. Internet.
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